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Challenges in the assessment and prediction of safety 
pharmacology and drug toxicity in humans 
 





Despite ongoing efforts to better understand the mechanisms underlying safety and toxicity, 
approximately 30% of the attrition in drug discovery and development is still due to safety 
concerns.  Changes in current practice regarding the assessment of safety and toxicity are 
required to reduce late stage attrition and enable effective development of novel medicines.  
This review focuses on the implications of empirical evidence generation for the evaluation 
of safety and toxicity during drug development.  A shift in paradigm is proposed to 1) ensure 
that pharmacological concepts are incorporated into the evaluation of safety and toxicity; 2) 
facilitate the integration of historical evidence and thereby the translation of findings across 
species; and 3) promote the use of experimental protocols tailored to address specific safety 
and toxicity questions.  
Based on historical examples, we highlight the challenges for the early characterisation of 
the safety profile of a new molecule and discuss how model-based methodology can be 
applied for the design and analysis of experimental protocols.  Issues relative to the scientific 
rationale are categorised and presented as a hierarchical tree describing the decision making 
process. Focus is given to four different areas, namely, optimisation, translation, analytical 
construct, and decision criteria.  From a methodological perspective, nonlinear-mixed effects 
modelling is recommended as a tool to account for such requirements.  Its use in the 
evaluation of pharmacokinetics (PK) and pharmacokinetic-pharmacodynamic relationships 
(PKPD) has enabled the advance of quantitative approaches in pharmacological research in 







The assessment of the safety and toxicity profile of new chemical or biological entities is an 
integral part of drug development.  Despite ongoing efforts to better understand the 
mechanisms underlying safety and toxicity, approximately 30% of the attrition in drug 
discovery and development is still due to safety concerns (1,2).  Such a high attrition rate is 
further compounded by the empiricism and entrenched belief which prevails among 
industry scientists and regulators about the level of evidence and requirements for 
determining acceptable risk in humans.   
In addition to its contribution to the attrition rate, safety and toxicity findings have business, 
legal and societal consequences, which often lead to speculations and even more empiricism 
in the evaluation and interpretation of experimental data.  Whilst a positive benefit-risk ratio 
should be anticipated and subsequently demonstrated when administering new drugs to 
humans, the basis upon which inferences are made still lacks the scientific clarity and rigour 
one would endeavour.  The efficiency and value of current paradigm for the evaluation of 
safety and toxicity, which relies primarily on standard battery tests at supra-therapeutic 
exposure levels of the investigational drug, is not questioned by the scientific community. 
Rather, it is mandated by regulators as a mechanism to minimise liabilities.  
A shift in paradigm is required that 1 ) enables the introduction of pharmacological concepts 
to the evaluation of safety and toxicity; 2) facilitates the integration of historical evidence 
and thereby the translation of findings across species; and 3)  promotes the value of 
experimental protocols tailored to address specific safety and toxicity questions.  
In this review we will focus on the implications of current practice for drug development and 
consider the scientific and ethical requirements for the evaluation of safety and toxicity.  Of 
particular interest for us is to demonstrate that despite the assumption that preclinical 
safety testing, toxicity findings are generally seen as predictive of human toxicity (3), 
inefficiencies in the experimental design violate the principle of the 3 Rs (reduction, 
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refinement and replacement) (4).  Empirical evidence must be replaced by a model-based 
approach. 
Two recent examples can be used to illustrate the issues with the current paradigm for the 
evaluation of safety and toxicity, namely the serious adverse events observed with TGN1412 
and the increased incidence of myocardial infarction in patients who were prescribed 
rofecoxib. These two cases encompass most of the critical issues one attempts to address 
prior to making a commitment to clinical development and subsequently to regulatory 
submission and marketing of a medicinal product. Albeit neglected in the assessment of the 
clinical findings and in the subsequent reports in the published literature, the use of a 
mechanism-based approach in conjunction with some basic pharmacology concepts would 
be sufficient to predict the consequences of the treatment, whether given as single dose to 
healthy subjects or chronically to patients; i.e., both examples reflect the immediate 
consequences of target engagement and the corresponding changes due to the mechanism 
of action and  (patho)physiological pathways. Yet, the experimental evidence generated pre-
clinically for these two compounds does not take into account target engagement or 
exposure-response relationships as the basis for the interpretation of the findings. Instead, it 
is the characterisation of the maximum tolerated dose (MTD) and /or no-adverse effect level 
(NOAEL) that ultimately drives the design of safety pharmacology and toxicity experiments. 
The empirical evidence of MTD and NOAEL does not provide insight into the underlying 
mechanisms and often obscures the translation of findings across species.  
According to published reports, the serious adverse events observed after intravenous 
administration of TGN1412, a novel monoclonal T-cell agonist, could not have been 
“predicted” or inferred from non-clinical data.  The empiricism in the design of the 
experimental protocol and in the interpretation of the findings clearly shows the 
disconnection between pharmacology and toxicology, despite extremely high degree of 
selectivity and specificity of the biologicals.  The failure to predict a systemic inflammatory 
response by rapid induction of cytokines (a “cytokine storm”) with catastrophic multi-organ 
failure (5) is not surprising when structure homology, target occupancy and pharmacokinetic 
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principles are disregarded. Despite the availability of in vitro binding assays, there was no 
attempt to correlate or integrate the results from different experiments with each other.  
Most importantly, the effects observed with the proposed dosing regimen could have been 
anticipated even without any experimental data. Knowledge of receptor agonism theory and 
drug disposition properties would have been sufficient to make inferences about target 
activation and pharmacological effects. 
Tragedies like this provoke reactive measures from industry and regulator (6-11).  New 
guidelines for the assessment of preclinical data were released by regulatory authorities.  
However, none of them tackle the problem from a scientific, mechanistic perspective.  
Similarly, changes have been introduced to the design of first-in-man studies (6), which 
reflect mitigation measures for process-related consequences of safety and toxicity findings.  
A framework that ensures critical appraisal of the scientific rationale, based on 
pharmacological concepts and expected biological activity (i.e., target engagement) is still 
missing.   
Rofecoxib, a selective COX-2 inhibitor prescribed to more than 107 million patients in the US 
(12), is another example of withdrawal from the market because of so-called “unexpected” 
long-term safety findings. Despite the debate that followed the evidence from clinical trial 
data on the increased risk of myocardial infarction (13), little effort was made to incorporate 
very basic pharmacological concepts into the evaluation of the findings and provide a 
mechanism-based interpretation, which could easily disentangle the core issue: whether this 
is a class-effect or whether that was a compound specific toxicity.  Paracelsus highlighted the 
importance of the dose more than 500 years ago, and yet none of the published reports 
considered this critical question: were patients receiving the optimal dose and dosing 
regimen for the proposed indications? Clinical and scientific experts dwelled on the realm of 
toxicity as the result of an off-target event, without exploring in a systematic manner the 
(obvious) connection to dosing regimen, target exposure, the time course of 
pharmacological effect, the duration of treatment and physiological role of the substrates 
for COX2 in the heart and other tissues. Evidence of concentration-effect relationship was 
14 
 
not gathered, neither used as basis for interpreting those findings.  Instead, allegations of 
misconduct followed that overruled any comprehensive scientific debate (12).   
From a clinical pharmacology perspective, the aforementioned examples reflect the failure 
in exploring causality and anticipating the biological consequences of target engagement, 
i.e., in establishing the correlation between target-related events and drug exposure, as 
defined by the evidence of pharmacokinetic-pharmacodynamic relationships.  Post-market 
withdrawals are not an uncommon occurrence: between 1975 and early 2000 there have 
been 26 withdrawals from the US market due to safety issues (14).  In fact, the withdrawal of 
a medicinal product seems to have become the expected course of action for regulators and 
industry who are faced with ‘unexpected’ safety findings. Interestingly, dosage changes, due 
to safety occurred in approximately one out five drugs in the period from 1980 to 1999 
(15,16). On the other hand, from a clinical perspective, the aforementioned landscape 
appears to result from the lack of a formalised assessment of the benefit-risk ratio in which 
efficacy and safety are evaluated in an integrated manner.  Different stakeholders appraise 
the problem from a distinct point-of-view without acknowledging the intrinsic, albeit 
indirect, link between dosing regimen, exposure, target engagement and clinical events. 
The incorporation of model-based concepts and pharmacokinetic-pharmacodynamic 
relationships into the rationale for the design, analysis and interpretation of safety 
pharmacology and toxicology protocols is vital for the future of screening of novel 
compounds and for an effective shift in the assessment of safety and acceptable risk in drug 
discovery and development.  More than just enabling a framework for modernisation of 
outdated methods and techniques, a model-based approach challenges the mainstream 
scientific views about the role of experimental evidence as the sole basis for the assessment 
of non-clinical safety; it unravels the strength of inferential methods and evidence synthesis.   
In this review, we aim therefore at identifying the pitfalls in current approaches to 
estimating and predicting safety pharmacology and toxicity in humans.  Focus is given to the 
estimation of safety thresholds and decision making, with special emphasis on the 
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underlying methodological issues.  Our objectives may intersect with the message from 
other reviews of safety in humans (17,18). However, our concerns go beyond technical 
aspects of experimental and statistical methods; the objective of the larger research to be 
presented in this thesis, is to detail improved techniques for data analysis and study design, 
as well as to illustrate how a mechanism-based approach for risk assessment can formally be 
applied to support more accurate decision making. 
In the subsequent sections, we will cover a wide range of methodological and conceptual 
issues, starting with low level problems, which usually comprise experimental aspects or 
relate to the statistical methods.  Given their technical nature, implementation of the 
proposed recommendations requires little effort and can be relatively straightforward, as 
compared to higher level problems, which involve conceptual features and require a 
different attitude towards the generation, analysis and interpretation of experimental data 
regarding safety and toxicity. From a theoretical perspective, different facets of the same 
problem will be discussed, which relate to four seminal areas of scientific research: 1. 
optimisation (e.g., accuracy, precision), 2. translation (e.g., sensitivity, biological substrate, 
relevance), 3. analytical construct (e.g. choice of parameterisation) and 4. decision criteria 
(e.g., acceptable risk level).  Each of these points will be addressed separately.   
As shown in Figure 1, on the most basic level of the hierarchical tree is the choice of the 
measure of drug exposure and endpoint selected for the assessment of safety.  These issues 
are compounded by the use of point estimates and by statistical inferences regarding the 
reporting of safety thresholds. Experimental design considerations in relation to type I and II 
errors constitute the next level of attention.  The drawbacks of the use of empirical 
approaches as opposed to mechanism-based approaches will be covered. Empiricism here 
relates to data analysis methods which are primarily descriptive rather than explanatory of 
the observed phenomena. Of particular interest is the current dichotomisation of the 
problem using safety thresholds.  This will be followed by a critique of allometric scaling to 
predict exposure in humans and then more generally the manner in which risk is translated 
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Figure 1: A hierarchical tree describing the different levels and issues underpinning decision making 
during the assessment of safety and toxicity profile of a new chemical entity.   
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2. Nonclinical evaluation of safety and toxicity 
2.1. Defining variables of interest. 
The development of a pharmaceutical is a stepwise process involving an evaluation of both 
animal and human efficacy and safety information. The goals of the nonclinical safety 
evaluation generally include a characterisation of toxic effects with respect to target organs, 
dose dependence, relationship to exposure, and, when appropriate, potential reversibility. 
This information is used to estimate an initial safe starting dose and dose range for the 
human trials and to identify parameters for clinical monitoring for potential adverse effects.  
Toxicity occurs when the drug-induced alteration of biological function overcomes normal 
repair and homeostatic mechanisms. Toxicity can be measured by its effects on the target 
(organism, organ, tissue or cell) or indirectly by measuring altered biological function 
downstream after acute, sub-chronic or chronic exposure to a chemical or biological entity.  
Drug exposure is then used as a proxy or surrogate for the undesirable effects.  It should be 
noted that an adverse event is any undesirable experience associated with the use of a 
medical product, irrespective of the evidence of a causal relationship between drug and 
adverse event. However, from a drug development perspective, different aspects of safety 
and toxicity need to be evaluated experimentally, which encompass the expected 
therapeutic and supra-therapeutic dose levels.  Although different experimental protocols 
must be implemented during the development of a new compound, the evaluation of 
immunotoxicity, genotoxicity, carcinogenicity, phototoxicity, abuse liability and reproductive 
performance and developmental toxicity are beyond the scope of this review.  The 
nonclinical safety and toxicity studies should be adequate to characterise potential adverse 
effects that might occur under the conditions of the clinical trial to be supported. Serious 
nonclinical findings can influence the continuation of the development programme and of 
clinical trials. 
Despite the different protocols for the assessment of safety and toxicity and the myriad of 
adverse events one may come across, a common practice in this field of research is the 
assessment of empirical safety thresholds such as the no observed adverse effect level 
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(NOAEL), which are no more than qualitative indicators of acceptable risk.  Support for the 
existence of thresholds has been argued on biological grounds (19-21).  The argument is that 
although any exposure to a chemical will cause some change in the biological system, the 
change must override homeostatic mechanisms in order for it to be biologically significant.  
In contrast to the maximum tolerated dose (MTD), which remains the primary endpoint of 
choice in the evaluation of chronic toxicity, the NOAEL is one of the main indicators of risk in 
nonclinical safety assessment.  Definitions of the NOAEL vary from source to source, 
however the basis behind all of them is the estimation of “the highest experimental point, 
without biologically significant adverse effects that are above baseline” (22).  In fact, the 
experimental findings are used to reflect another threshold, i.e., the underlying no adverse 
event level (NAEL).  The calculation involves determination of the lowest observed adverse 
effect level (LOAEL) which is the lowest observed dosing level for which AEs are recorded.  
The NOAEL is the dosing level below this.  If no LOAEL is found, then the NOAEL cannot be 
determined.  In these cases the LOAEL/10 is sometimes used in place of the NOAEL.  
Drug exposure and risk can be represented by a variety of different experimental measures.  
Usually, in the NOAEL approach, the measures used are dosing level, area-under-
concentration-time-curve (AUC) and/or maximum concentration (CMAX). On the other 
hand, the benchmark dose (BMD) is an alternative to the NOAEL.  The method involves the 
construction of a model of the exposure-AE relationship to predict the dosing level that 
corresponds to the threshold between non-significant and significant risk of AEs.  The 
quantity is usually expressed as a dose level rather than an AUC or CMAX, but the BMD 
remains of limited use in Industry (23). 
Another common measure is the human equivalent dose (HED), which represents the 
estimated dose level in humans yielding equivalent drug exposure as observed in animals at 
the safety threshold (23).  In addition, recommendations have been made for the use of the 
maximum recommended starting dose (MRSD) for the selection of the starting doses in first-
in-human studies. The MRSD is believed to minimise the chance of serious adverse events in 
early clinical studies (7,23).  Recently, the minimum anticipated biological effect level 
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(MABEL) has also been introduced to assist in selection of doses for first in man studies and 
to supplement existing approaches.  MABEL describes the exposure that is anticipated, prior 
to clinical testing, to produce a minimum biological effect level (24,25).  
Given the empirical nature of such safety thresholds, errors in the prediction of safety may 
arise.  Despite the various options, there is still a real safety concern when using these 
thresholds to extrapolate drug exposure levels from animals to humans and to make 
inferences from short to long term effects.  Unfortunately, instead of pursuing a more 
mechanistic approach, empirical methods continue to be used. To cope with inaccuracy and 
poor precision, safety factors, also known as uncertainty factors, have been incorporated on 
the top of empirical thresholds.  Their application in drug development has become 
widespread (26) and is detailed within the regulatory guidelines.  The purpose of such safety 
factors is to account for variability potentially greater toxicity in humans than predicted by 
the HED using existing approaches.  This is to ensure that the safety threshold is beneath the 
true threshold.  The default safety factor is 10, but it can by modified by considering it as a 
product of more refined uncertainty factors. These comprise; interspecies uncertainty, UFA, 
interindividual uncertainty UFH, subchronic to chronic uncertainty, UFS, LOAEL to NOAEL 
uncertainty, UFL, and data adequacy UFD, for when chronic toxicity studies in at least two 
different species are unavailable (27,28).  There is also a modification factor where there is a 
perceived greater risk of toxicity in humans. 
It should be noted that even when safety factors are factored into the estimation of 
thresholds, the actual risk a treatment represents to humans can be overlooked.  Over-
conservative attitude may give the wrong perception of caution. Accurate assessment of risk 
can simply not be performed without some degree of understanding of target engagement 





2.2 Measures of drug exposure used as descriptors of acceptable risk 
A consequence of the use of safety thresholds is the estimation of drug exposure or dose 
levels that can be correlated with the adverse events observed beyond that specific 
threshold, for which the risk for humans is deemed unacceptable.  Numerous assumptions 
are however required to ensure accurate translation of such findings from animals to 
humans.  To be predictive, the exposure levels and the adverse events must reflect 
pathophysiological processes and pharmacokinetics in humans.  
Different measures of exposure are used in reports.  The most basic of these is dosing level, 
which is usually expressed in terms of daily dose (e.g., mg/day).  Dose, however may be a 
poor indicator of response since it does not account for confounders such as bioavailability, 
differences in metabolic capacity, or other pharmacokinetic processes that alter target 
exposure despite comparable dose.  For this reason, parameters derived from the 
assessment of systemic drug concentrations are preferred (e.g., AUC and CMAX).  The choice 
for those parameters relies on the assumption that rapid equilibration occurs between 
systemic circulating drug and the target tissue.  Given the fragmented process used for the 
evaluation of pharmacology and toxicology data, the validity of this assumption is 
questioned even when evidence from pharmacological and pharmacokinetic data indicates 
otherwise.  Nonlinearity in drug disposition is another important pharmacokinetic aspect 
which is not accurately captured by the use of dose as a measure of drug exposure.  
Differences in systemic and target exposure can be large in the case of metabolic saturation, 
when small increments in dose can produce disproportionately large increases in AUC.  This 
can lead to deceptively safe estimates even if the dose is divided by a safety factor.  
Conversely, the occurrence of metabolic induction may lead to overly conservative dose 
selection. 
In addition to the aforementioned points, it is also critical to understand the implications of 
the use of systemic levels as compared to target tissue or target organ exposure.  Time-
dependent processes take place which cannot be neglected or inferred from conventional 
measures of exposure. First, one should realise that given that pharmacokinetic equilibration 
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between plasma and tissue may not always be assumed.  Unbound drug concentrations are 
primarily distributed into tissues.  The extent and rate of distribution depend on 
physicochemical as well as receptor binding properties.  The implications of such processes 
are that irreversible binding, slowly reversible binding and tissue accumulation may not be 
easily correlated with circulating total concentrations.  From a pharmacodynamic 
perspective, the same considerations must be made when signal transduction and 
downstream mechanisms are rate limiting for the onset and maintenance of effects (i.e., 
adverse events).  Consequently, the use of AUC and CMAX, expressed over a single day may 
not accurately reflect the underlying relationship between exposure and adverse event.  The 
implicit assumption that there is a correlation between “daily” drug exposure and risk is 
suitable mainly for direct and reversible processes; however it is insufficient to account for 
the complex nature of indirect effects, slowly reversible and irreversible binding.  
These complexities can be illustrated by permetrexed-induced neutropenia. Absolute 
neutrophil count (ANC) is reduced by inhibition of thymidylate synthase, dihydrofolate 
reductase and glycinamide ribonucleotide formyltransferase  (29).  The trough of the ANC 
curve occurs between 8 and 9.6 days after dosing (30), and is followed by an overshoot 
effect once levels return to baseline (Figure 2).  Empirical approaches are in principle able to 
quantify the PK exposure associated with a particular ANC minimum, however this ignores 
the complexity of the ANC-curve.  The time below a threshold ANC may be a more relevant 
descriptor of risk and will require a different measure (i.e., parameterisation) of drug 
exposure.  Most importantly, in these circumstances the time course of drug effects (onset, 




Figure 2. Time course of predicted absolute neutrophil counts (PRED) following 500 mg/m2 
pemetrexed. Lines: Solid black curve the overall ‘‘typical’’ patient in the analysis dataset (i.e., median 
values for each of the covariates contained in the final PKPD model); gray shading predictions based 
on the population PKPD model for each of the patients in the analysis dataset, assuming a 500 mg/m2 
dose; dashed horizontal lines hematologic toxicity grades (grade 1 <2, grade 2 <1.5, grade 3 <1, grade 
4 <0.5) (30). 
 
 
Likewise, irreversible binding mechanisms cause drug accumulation at the effect site yielding 
adverse events that depend primarily on the treatment duration, rather than on daily 
exposure.  Measures that do not capture the cumulative nature of these processes may lead 
to poor correlation between species.  Measures such as cumulative AUC may provide better 
prediction than 24-hour AUC since the entire dosing history is used.  Figure 3 shows an 




Figure 3. Curve showing incidence of tardive dyskinesia given cumulative neuroleptic exposure. 
Patients with more than 30 days of neuroleptic use at baseline had a trend for a greater cumulative 
incidence of tardive dyskinesia than those with 0-30 days of neuroleptic use  (31). 
 
Although safety factors have been used to account for possible inaccuracies in the estimates 
of safety thresholds, there are translational aspects that cannot be factored in by such an 
empirical approach.  A systematic, rational translation of findings across species requires the 
use of mechanism-based approaches to assess the implications of differences in 
pharmacokinetics, pharmacodynamics as well as in pathophysiology.  Of particular 
importance is the fact that between species variability in metabolic rate and capacity can 
lead to completely different safety profiles across specie if metabolites are the moiety 
underlying adverse events.  Likewise, molecules that are substrate to active transporters, 
carrier-mediated processes and other distribution mechanisms with known species-specific 
differences will show discrepancies in safety profile.  
 
2.3 Statistical and biological limitations of point estimates 
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From a statistical perspective, safety thresholds are often presented as point estimates to 
describe the population.  This ignores variability which can be decomposed into two parts; 
variability associated with estimation methods and real variability in response between and 
within subjects.  There is also lack of best practice in statistical inference.  Risk is inferred 
from toxicology results using statistics that may be imprecise or inaccurate.  A statistic is a 
random variable which is typically a function of the experimental data (such as, e.g., a mean 
or an observed rate).  Statistics are intended to provide an estimate of underlying 
parameters reflecting physiological processes and/or pharmacokinetics.  The implications of 
such practice can be illustrated by the comparison between sample standard deviation and 
population standard deviation.  The former is a statistic and the latter is the inferred 
parameter.  The equivalent for NOAEL is the no adverse effect level (NAEL).  The term 
“NOAEL estimate” is a misnomer in that it is the NAEL, which is being estimated by the 
NOAEL (see figure 4).  Based on statistical concepts, it can be shown that meaningful and 
useful reporting of toxicology findings should be of the estimate of NAEL with its precision 
(standard errors).  However, an empirical approach prevents the estimation of uncertainty in 
the NAEL. 
 
The use of statistics, in place of model parameters for decision making can treat the estimate 
as if it were of sufficient precision to give sufficiently narrow confidence intervals.  This 
limitation is believed to be mitigated by the incorporation of safety factors, an assumption 
which we dispute. As can be seen in Table 1, the parameter precision for the probability of 
an AE varies from 1587 to 67%, depending on group size and risk.  The number of animals in 
a group exhibiting an adverse event is often reported however, the performance of this 
estimator is highly dependent on the underlying risk of the AE in question and the sample 




Figure 4. Relationship between MABEL and NOAEL/HED.  Shaded region indicates the expected 
therapeutic range. 
 
Table 1: Parameter precision for probability of adverse events 
Risk of AE n=4 n=8 n=10 n=16 n=20 
0.10% 1578.77% 1116.75% 998.08% 790.59% 707.92% 
1.00% 497.41% 351.67% 314.71% 248.64% 222.50% 
5.00% 217.98% 154.14% 137.83% 108.98% 97.46% 
10.00% 150.03% 106.07% 94.87% 74.99% 67.08% 
AEs were assumed to be independent binary events. The estimator is the number of animals as a percentage of 




The other aspect to missing variability is the real variability in the data.  Since sampling in 
toxicology is often very sparse, exposure levels are calculated from satellite groups which 
mirror dosing of the animals assigned to the primary treatment group.  This ignores real 
differences that may be present between the two groups.  It is equivalent to assuming that 
all animals have the same exposure and variability in exposure or the underlying 
physiological processes is not responsible for variability in response.  
Given that human variability is typically larger, it is important to understand the role of the 
different sources of variability.  Without quantification of variability and identification of 
covariates it becomes difficult to predict which groups are more prone to overexposure or 
more sensitive to adverse events.  Furthermore, depending on the actual distribution of drug 
exposure, the distribution of AEs in this group may not be representative of the risk posed to 
the overall target population.  This is not limited to pharmacokinetics, pharmacodynamic 
differences have the greater potential for harm and can be more variable than 
pharmacokinetic differences.  In this case, hypersensitive subpopulations can be completely 
missed.  This is the case of abacavir-induced rash and other dose-independent reactions 
associated with receptor or target polymorphism. 
Finally, it should be noted that empirical approaches remain prone to bias.  For example, the 
mean NOAEL is only unbiased if its underlying distribution is symmetrical.  This practice 
ignores that such a summary violates current understanding of pharmacokinetic processes, 
which are best described by lognormal distributions.  Without clear assumptions of the 
underlying distribution, the choice of measure for central tendency remains unjustifiable and 
may lead to bias. 
 
2.4 Mechanism-based assessment of safety, toxicity and risk 
Whilst the introduction of regulatory policies for the non-clinical evaluation of medicinal 
products in humans, at a time when understanding about receptor pharmacology and 
pathophysiology was very limited, partly explains the historical evolution of current 
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standards and practice in safety and toxicity research, its perpetuation is no longer 
justifiable.  It is evident that the concept of safety thresholds as well as the measures of 
exposure used as proxy for acceptable risk cannot be deemed absolute: they rely upon 
numerous assumptions, which may not hold true in a considerable number of cases. In 
principle, information regarding the causal chain between target engagement and adverse 
events should be used as basis for relevant measures of exposure and risk.  This concept can 
be implemented even in the absence of evidence for the actual target or mechanism 
underlying a given adverse event or undesirable effect. Sufficient evidence exists to support 
the use of concentration-effect relationships to identify the rate limiting step in the chain of 
events from dose to response. In conjunction with tailored experimental protocols and 
pharmacokinetic-pharmacodynamic modelling, a mechanism-based evaluation of safety 
findings provides the basis for characterising safety and toxicity.  Moreover, it should be 
noted that safety and toxicity findings may not solely depend on pharmacokinetic drug 
exposure, but also on the extent of target activation or inhibition, post-receptor 
amplification and signal transduction processes as well as homeostatic mechanisms. For 
instance, drug concentrations may be a poor predictor of risk relative to the relevant 
biomarker concentrations when signal transduction is the rate limiting step for a given 
response. It is unfortunate that despite the wide discussion regarding the use of biomarkers 
in the literature (32-35), the focus has primarily been on the assessment of efficacy, not 
safety. 
In addition, experimental protocols and data analysis have not advanced in the same way 
risk management concepts have evolved over the last decade.  Causality has become pivotal 
for the characterisation of adverse drug reactions, which in contrast to adverse events, are 
defined as any noxious unintended and undesired effects of a drug that occur at doses used 
for prevention, diagnosis or treatment.  This subtle difference in definition has major 
consequences for the evaluation of safety, toxicity and risk, including experimental protocol 
requirements.  Rawlins and Thompson devised a classification scheme in 1991, which 
continues to be the most frequently used in clinical research, which could be used as the 
basis for the assessment of nonclinical safety. Their scheme, shown in Table 2, defines 
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adverse drug reactions according to seven different categories, which account for the 
underlying chain of events.  The different categories nicely match the mechanistic 
classification of biomarkers proposed by Danhof et al., and could form the basis for a new 
paradigm for the evaluation of nonclinical safety and toxicity (34).  
 
Table 2. Classification of adverse drug reactions, as proposed by Rawlins and Thompson. 
Type “A”: Predictable, common and related to Pharmacological action of the drug 
Toxicity of overdose:   e.g.  hepatic failure  paracetamol 
Side effects:    e.g sedation Antihistaminergic drugs 
Secondary effects:  e.g. development of 
diarrhoea due to altered 
antibiotic therapy 
Drug interaction: e.g. Theophylline toxicity erythromycin therapy 
Type “B”: Unpredictable, uncommon, usually not directly related to the mechanism or  
pharmacological actions of the drug. 
Intolerance:  e.g. tinnitus Aspirin 
Hypersensitivity: e.g. anaphylaxis penicillin  
Pseudoallergic: (Non-Immunological) 
reaction 
radio contrast dye reaction 
Idiosyncratic reaction: e.g. anaemia due to glucose-
6 phosphate dehydrogenase 
anti-oxidant drugs  
Type “C”: These reactions are associated with long-term drug therapy e.g. Benzodiazepine 
dependence and Analgesic nephropathy. They are well known and can be anticipated. 
Type “D”: These reactions refer to carcinogenic and teratogenic effects. These reactions are 
delayed in onset and are very rare since extensive mutagenicity and carcinogenicity studies 
are done before drug is licensed. 
Type “E” : The end of treatment or rebound effects 
Type “F” : Failure of treatment 
Type “G” : due to genetic polymorphism, not immunologically mediated 
 
 
As it can be seen from Figure 5
reaction types in Rawlins and Thom
the causal chain of events to be 
in a quantitative manner. 
(mechanistic) interpretation of risk in humans. 
distant these concepts are from the approaches currently used in the assessment of 
nonclinical safety and toxicity. 
 
Figure 5.  Mechanistic classification of biomarkers.
 
 
2.5 Minimum Anticipated Biological Effective Level
A first attempt to implement mechanism
last decade, which relies on the assessment of the minimum anticipated
level (MABEL).  In the calculation of the MABEL any biomarker can be used, 
receptor occupancy or even downstream markers such as 
has the advantage of allowing measures that correlate 
including off-target or secondary target) when pharmacokinetic processes are not the rate 
limiting step.  The concept relies 
targets underlying the adverse event to accurately interpret (patho)physiological response 
and assess causality.  However, 
toxicity, it is not a measure of risk and 
therefore to use the NOAEL as a measure of risk to guide maximum d
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studies, but the maximum recommended starting dose in FTIH should now be no higher than 
both the MABEL and the NOAEL-derived MRSD. If the NOAEL with the addition a safety 
factors were indeed protective, such a measure would be an unnecessary.  Yet, one needs to 
acknowledge that the MABEL is simply a retrospective risk-mitigation measure that can 
account for some of the deficiencies of the NOAEL approach.   
 
2.6. Limitations in experimental design 
There are methodological aspects that need to be addressed to allow wider use of MABEL or 
any other mechanism-based measures of ‘acceptable risk’.  The predictive or prognostic 
value of statistical correlations depends on satisfying five important criteria, namely: 
selectivity, specificity, sensitivity, reproducibility and clinical relevance.  Currently, despite 
the characterisation of a correlation between biomarker and response, very little effort has 
been made to quantify estimators such as false positive and false negative rates.  For 
instance, liver enzyme levels provide an example of a biomarker which has high sensitivity 
but poor specificity.   Interestingly, despite the aforementioned limitations clinical scientists 
and pathologists will defend the value of ALT, AST and bilirubin as better predictors of risk, 
as compared to drug exposure. Another aspect of interest is the fact that according to 
current practice, if e.g., elevated liver enzymes are observed in one individual and acute liver 
failure in another, an empirical framework ignores the correlation between these adverse 
events. It may be treated as the same adverse event (i.e., 100% correlation), or a two 
different adverse events (i.e., uncorrelated).  The statistical methods and summary measures 
of toxicity are unable to account for partial correlation or interaction between events within 
or between individuals. 
So the question is why does one not go further along the causal chain of toxicity for all 
adverse events, instead of relying on measures of systemic exposure?  The answer probably 
lies in that pharmacokinetics is seen as the primary step along the way for most adverse 
drug reactions.  It is a simple, general purpose measure which fits the criterion of providing 
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predictive value for many adverse events, despite the exceptions, for which it will perform 
poorly, with low predictivity. 
From a theoretical point of view, it should be highlighted that empirical approaches perform 
poorly when incidence of a type of adverse event is low (Table 3).  This means that pooling 
data across different types of adverse events is necessary, and this is the root cause behind 
the choice for a single measure of exposure, rather than more predictive ones. 
 
Table 3: Probability of detection of adverse events with low incidence.  Summary data is reflect the 
occurrence of adverse events according to a Bernoulli random variable.  For different incidence rates, 
value depicts its probability of occurrence given an experimental group size of n. 
Risk of adverse 
events 
n=4 n=8 n=10 n=16 n=20 
0.10% 0.40% 0.80% 1.00% 1.59% 1.98% 
1.00% 3.94% 7.73% 9.56% 14.85% 18.21% 
5.00% 18.55% 33.66% 40.13% 55.99% 64.15% 
10.00% 34.39% 56.95% 65.13% 81.47% 87.84% 
 
 
As indicated previously, empirical data analysis does not provide uncertainty estimates to 
properly account for Type I (false positive) and Type II (false negative).  In addition, 
experimental findings are evaluated in an experiment by experiment basis. This leads to 
misrepresentation of the estimated population characteristics, which imposes the need for 
conservative safety factors to account for bias and uncertainty. An immediate consequence 
of this is illustrated by safety levels identified for tolcapone (36), cerevastin (37), and 
ximelagatran (38), which were deemed “well-tolerated” at the predefined dose levels, but 
were later shown to be unsafe (39).  It should therefore become clear that the use of the 
term tolerability ignores the high incidence of false negative results in standard designs.  
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Based on empirical methods, the absence of adverse events within the experimental group 
implies that risk is not present all.    
Another problem is the fixed design used for in the estimation of the safety thresholds, 
which relies on a set of arbitrary selection of the dose levels.  Consequently, the NOAEL is 
limited to one of the experimental dose levels.  This results in the dose selection having a 
heavy influence on the precision and accuracy of the NOAEL estimate.  Unfortunately, 
attempts to overcome the uncertainty and bias in the results may prove ineffective even if 
the number of animal is increased per group. In addition to the dose selection, the duration 
of the experiments also requires careful consideration and must be factored accordingly into 
the estimation of safety thresholds.  Current approaches consider treatment duration as a 
constant factor, irrespective of the nature of the underlying adverse event. In general, high 
doses administered over shorter periods of time are deemed comparable to therapeutic 
doses administered chronically.  This has little pharmacological foundation where time-to-
onset may bear little relationship to dose (e.g. neutropenia).  At high doses, effects may 
merely be due to secondary pharmacology. On the other hand, certain effects that can occur 
at therapeutic levels may be overlooked at higher exposures.  Furthermore, if toxicity is 
delayed, then the likelihood of false negatives will increase if recording of adverse events 
stops at the end of dosing.  A historical example is the case of methylmercury-induced 
dendritic degeneration in cats (40). Daily dosing for two months results in no differences 
from control groups, up to month five, when a significant difference becomes evident.  If 
observations had ceased at month two, this effect would have been missed. In brief, the 
experimental limitations of current approaches can be summarised not only in terms of 
imprecision and inaccuracy, but also in terms of the lack of integration of the information 
contained within and between experiments.   
From a statistical perspective, the occurrence of an adverse event can be viewed as a 
multidimensional random process over time, with one dimension for each type of adverse 
event.  In practice, these dimensionalities are reduced to binary processes, leading to loss of 
information for data arising from continuous processes.  Data loss also occurs when all these 
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binary processes are combined and reduced to a single binary number for each individual:  
the animal either had an adverse event or it didn’t.  Information about which adverse event 
occurred, the time-to-onset, duration, frequency and severity is all lost.  On top this a further 
reduction happens at group level whereby the binary numbers for each individual are 
combined and reduced to a single binary number: an adverse event occurs at a given dosing 
level, or it does not.  This approach prevents the use of quantitative methods, as it removes 
the evidence arising from the number of animals which exhibited adverse events.  Data are 
further reduced by the very definition of NOAEL, which requires only the lowest dose to be 
considered in the estimation of the NOAEL: the NOAEL is highest treatment level exhibiting 
no adverse events.  As a consequence of all the aforementioned steps, important 
information about the relationship between dose and exposure and adverse events may be 
lost.    
By contrast, an approach which involves longitudinal statistical modelling of continuous and 
categorical data has the potential use all information in the production of estimates without 
any loss in information.  However, an alternative to the NOAEL, the benchmark dose (BMD) 
approach has been proposed (41), which permits better use of experimental data.  The BMD 
yields evidence about the entire dose-response curve, rather than a single point.  Typically 
there are also large reductions at an individual and group level, but on a smaller scale.  
Relevant data across experimental groups are not collated and analysed together (42). 
 
2.7. Additional flaws in the empirical evaluation of safety and toxicity 
From a scientific and clinical point of view, one of the main disadvantages of empirical 
approaches is that extrapolation beyond experimental setting is often unreliable.  
Paradoxically, the ability to extrapolate or make inferences is central for the evaluation of 
safety and toxicity.  Nonclinical data are generated with the primary objective of data 
extrapolation in mind.   
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Another limitation which cannot be easily circumvented is the inability to parameterise risk 
in a systematic manner, accounting for what is observed and what can be inferred from an 
intervention, irrespectively of the experimental evidence.  Consequently, for instance, one 
fails to assess the implications of an adverse event arising from two different mechanisms of 
actions. To make accurate extrapolations, any relevant differences in the mechanism of 
action must be incorporated into the analysis and interpretation of the data.  A similar 
problem arises in the case of nonlinear kinetics, when extrapolation to dose ranges outside 
of experimental ranges can lead to very different exposure levels, as compared to those 
expected from linear kinetics.  Hence, it is evident that extrapolations derived from safety 
factors are doomed to remain inaccurate without further understanding of the mechanisms 
underlying the overt symptoms and signs.  
Lastly, it is important to bear in mind that empirical methods often do not lend themselves 
well to integrating data and combining results from multiple experiments.  This situation 
forces one to rely on clinical judgment to decide which findings can be deemed relevant.  
This inflexibility represents another inherent weakness of current approaches for the 
evaluation of safety, which clashes with one of the primary objectives of the drug 
development process, i.e., to reduce uncertainty about the safety and efficacy of a 
compound (43).  In theory, more information should to lead to improve precision rather 
bias.      
 
2.8. Safety threshold vs. risk or hazard surface 
Currently, the use of fixed thresholds as a metric of safety ignores the variable nature of 
continuous processes and potentially prevents accurate interpretation of the underlying 
phenomena. For example, gastric ulceration is dependent on membrane permeability.  
Interindividual differences in tissue permeability are perceived as interindividual differences 
in sensitivity to drug effects, i.e., in the exposure which is required to reach a threshold.  
Based on current practice, the factor driving such differences often remains obscure. More 
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sophisticated approaches have been proposed to incorporate toxicodynamic differences 
through use of a sensitivity parameter (44).  However, this suffers from the same weakness 
as the use of a threshold.  Furthermore, thresholds offer no mechanistic basis for 
extrapolation across species.  For example, there is no way to account for interspecies 
differences in membrane permeability.  As such, interspecies differences can only be 
handled by safety factors.  
Another immediate difficulty is the lack of consensus on what is defined as adverse events 
and how definitions vary across species.  These definitions lead to different safety levels, 
meaning that safety thresholds are sensitive to definitions of events as adverse or non-
adverse rather than the risk associated with them.  Therefore, it should be noted that even 
with agreed definitions, the relevance of a threshold for the assessment of risk is 
questionable since it mostly relates only to the presence of an adverse event, rather than its 
severity. In this context, the shape and slope of the exposure-risk relationship is an 
important consideration.  Yet, the use of thresholds incurs the danger that risk is treated and 
thought of as a binary endpoint.  Since the only way to truly eliminate risk is to cease the 
hazard-causing activity, this is at odds with the binary treatment of it.  Safety thresholds can 
also obfuscate more complicate U-shaped or bell-shaped relationships which may be 
relevant characteristics for consideration in a risk-benefit analysis. 
In summary, it should be clear that despite the dichotomous nature of thresholds, all 
(patho)physiological processes underlying an adverse event are continuous processes. In 
fact, increasing understanding of the mechanisms underlying drug-target interactions (e.g. 
receptor pharmacology theory) as well as the identification of downstream pathways (i.e., 
factors determining post-receptor events) imposes revisiting the utility and relevance of 
thresholds as basis for the evaluation of drug response, irrespective of whether it involves 
efficacy or safety.  The continuous nature of ligand-target relationships, based upon which 
target exposure must approach a certain order or magnitude in order to block or transducer 
a signal, offers the possibility of exploring signal using multidimensional response surfaces, 
rather than thresholds.  
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2.9. Translational toxicology: allometric scaling 
All the undertaking required to implementing experimental protocols in safety 
pharmacology and toxicity implies the validity of a set of assumptions regarding the 
correlation between findings in animals and humans.  Unfortunately, these assumptions do 
not take into account the prerequisite of construct validity to ensure direct comparability of 
the findings across species.  
As indicated previously, uncertainty about differences between species and lack of 
understanding about the relevance of certain effects in humans, have lead to the 
introduction of safety factors the estimation of safety thresholds.  Whilst many supporters of 
the approach envisage this as a plausible, cautionary measure, it cannot be ignored that in 
many cases over-conservatism will prevent the development of compounds that otherwise 
could be innocuous in humans.  The challenge is therefore to identify a mechanistic basis for 
translating nonclinical safety findings or at least making inferences about drug action based 
on the results in a different species or experimental system (e.g., in vitro or cell culture).  
Five different dimensions need to be considered for that purpose: 1) differences in 
pharmacokinetics (i.e., accounting for physiological processes determining drug absorption, 
distribution, metabolism and elimination); 2) differences in pharmacodynamics (i.e., 
accounting for variation or differences in receptor engagement, activation and downstream 
amplification of the biosignal); 3) differences in homeostasis (i.e., accounting for functional 
capacity and feedback mechanisms which may compensate for drug-induced changes in 
physiological processes); 4) differences in response during health vs. disease conditions and 
5) differences due to drug delivery properties. 
It can be anticipated that accurate assessment of causality is essential for making inferences 
from one species to another.  Furthermore, it is rather evident that in most cases all five 
dimensions need to be factored in the interpretation of nonclinical findings.  However, 
currently, more focus is given to differences in pharmacokinetics more than any other 
aspect.  As a matter of fact, extrapolation of findings between species often relies on the use 
of allometric scaling principles (45,46). Allometry requires assumptions about the 
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relationships between physiological function (e.g., metabolic capacity) and body size.  In 
principle, this concept can also be applied to differences in pharmacodynamics (46,47), but 
the use of this technique in drug development is usually restricted to pharmacokinetic 
parameters, and more specifically to volume of distribution and clearance.   
Despite its wide use in drug development, one needs to be aware of the limitations 
allometric methods represent to the prediction of pharmacokinetics and pharmacodynamics 
in humans. The first point relates to the unawareness of the underlying differences 
between-species.  For example, total clearance can result from multiple routes; metabolism 
by oxidation and glucuronidation, biliary excretion, and/or renal excretion.  The use of 
allometry assumes that when multiple physiological processes are involved, processes are 
scaled solely based on size differences and processes that do not scale well are considered 
clinically irrelevant (48).  Biliary excretion is known not to scale well due to the role of ABC 
transporters expression levels.  As such the decision to use scaling is dependent on an 
overall judgement of its ability to be scaled.  For volume of distribution, the assumption is 
that distribution of drug outside system circulation occurs primarily due to passive diffusion; 
active transport is not accounted for either.  Scaling via the more realistic physiologically 
based pharmacokinetic (PBPK) models (49), has been shown to account for both size-
dependent and size-independent differences. 
The second source of error in allometric scaling relate to the use of allometry as a monolithic 
extrapolation strategy:  allometric relationships, even if correct, only relate to size 
differences between species.  It is functionally equivalent to assuming that a human is a 
large rodent or another non-clinical species.  Furthermore, the scaling of parameters 
assumes that size-related factors influencing systemic exposure are the only important 
covariate relationships governing drug effects.  
Despite the clear flaw in this approach, the evaluation of alternative methods for scaling or 
translating pharmacokinetics and PKPD relationships remains limited.  In fact, size-
independent differences compose a much larger part of the differences in 
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pharmacodynamics and this is not accounted for with allometry.  Paradoxically, there is also 
support for the view that size-independent differences are usually small given that adverse 
events in humans are predictable in the majority of cases (75%) from information obtained 
from preclinical experiments (50).  This leads to the apparent conclusion that mechanisms of 
action in animals are similar to humans, however potentially serious differences may exist 
(51).  A related problem is that clinical outcome is dependent on the underlying disease 
process, which may be different between species.  Differences in baseline (physiological) 
response and in variability due to disease conditions in humans can confound the 
measurement of drug-induced effects, as compared to animals.  Likewise, differences in 
target distribution can also complicate the interpretation and translation of non-clinical 
findings.  For example,  anaphylaxis is observed in the intestine and liver of rats, but in 
humans these symptoms are primarily observed in the lungs and blood vessels (52).  The 
translational gap becomes even larger if one considers psychiatric or other neurological 
adverse events, which may not be detected in animals.  
 
2.10. Translation of Risk 
Translation of the risk associated with the experimental evidence observed in animals is the 
ultimate step triggering decisions related to nonclinical safety and toxicity of a novel 
molecule.  Thus far, expert judgment is used by decision makers, which ultimately consists in 
the use of qualitative criteria for the assessment of risk.  These criteria informally include 
some measure of overall uncertainty, but such an approach makes it difficult to understand 
the propagation of uncertainty. For instance, to infer that small physiological changes to the 
binding levels across species can lead to large changes the estimates of safe exposure.  
Clearly, accurate judgment is even more difficult when dependent on parameters for which 
uncertainty is unknown or not quantifiable.   
Whilst  the aforementioned issues have been recognised as important, regulators remain 
reluctant about the use of quantitative methods for risk assessment (53).  There are various 
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reasons why qualitative risk assessment has been advocated over quantitative methods.  
However, many of the argued limitations do not necessarily apply when more modern 
statistical techniques are considered.  We will address some of these points later in the next 
section, where model-based approaches are discussed.  
The danger with a qualitative analysis is that the extent of any overall benefit will be left to 
human intuition.  Informed decisions involve taking both benefits and risks of the drug into 
account.  Yet, the consideration of risks and benefits based on safety thresholds is 
dependent on the nature of the risks in question and as such do not account for the 
underlying mechanisms, which in turn could be used for subsequent clinical interpretation.  
An encompassing inferential method is needed which accounts for underlying mechanisms 
and balance them against benefits.  Most importantly, decision making regarding risk should 
include the contribution of historical data in a statistically and clinically formal manner.  
 
3. Non-linear mixed effects modelling 
 
The use of model-based methods has the ability to address many of the aforementioned 
criticisms pertinent to the design and analysis of safety pharmacology and toxicology 
protocols.  Nonlinear-mixed effects models are a particular class of models that allow one to 
handle a variety of parameterisations by integrating stochastic and deterministic 
components of a problem.  Although such models are often referred to as population 
models, they provide insight at the individual level, separating real variability from 
estimation uncertainty.  They contain the necessary complexities required to assess risk in a 
manner that translates into scientifically rigorous decisions. In pharmacokinetic-
pharmacodynamic data analysis, the use of a parametric approach based on nonlinear 
mixed-effects models provides a tool for handling repeated-measurement data in which the 
relationship between the explanatory variable and the response variable can be described 
by a single function, allowing model parameters to differ between subjects (54).  An 
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immediate advantage of the approach is that the within-subject variability for a given 
individual can be distinguished from the differences between subjects even in the absence 
of balanced or frequent sampling of the data.  
In hierarchical modelling, the term “mixed” refers to the use of both fixed effects 
(characterising the typical individual in the population) and random effects (describing the 
parameter distribution).  The latter are divided into two levels: the difference between the 
individual prediction and the observation (residual error) and the variability between 
subjects (BSV).  There may also be circumstances in which individual parameters vary 
longitudinally between occasions, randomly or due to some unknown physiological process.  
In such cases, a third level of variability can be introduced, i.e. the inter-occasion variability 
(IOV).   
The general structure of a hierarchical model is as follows: 
 = , 
 + , ~(0, )   Eq. 1 
where yijk is the j
th observation at occasion k in individual i. f( ) is typically a nonlinear 
function of individual parameter Pik and independent variables Xijk.  In PKPD modelling, f( ) is 
usually then individual prediction of the observation. Independent variables are usually time, 
dose or drug exposure and demographic covariates.  The εijk forms the residual variability 
with variance . When the variance is independent of , 
, the model is said to 
have additive variability. On the other hand, when  is proportional to f( ), we have a 
proportional error model (55).  
For the ith individual, the individual parameters Pik can by the expression: 

 =  ∙  ,			~(0,ω)	   Eq. 2 
This describes a log-normal variation of the individual parameter P, which has a typical value, 
Θ. The ηi and ki are the random effects describing the differences between the typical 
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(population) value and the individual parameter value.  ηi is assumed to be normally 
distributed with mean zero and variance ω. 
Among other applications, the use of hierarchical models is justified and appropriate when 
the data available per individual are sparse.  In addition, it is recognised as the most effective 
method to perform meta-analysis of data arising from different studies and to incorporate 
prior knowledge to the estimation of model parameters.  It allows one to adjust for different 
variances (e.g. presence of influential factor in a given subgroup in the population) and to 
explore confounding correlations, when the design of the study correlates with the outcome 
(e.g., effect of weight vs. sex).  
 
3.1. Estimation methods 
The field statistical modelling field has developed well-established parameter estimation 
methods which provide the means not only to estimate the most likely value of the 
parameters given the data, but also to quantify uncertainty and correlation in estimated 
parameters and model (mis)specification.  This ultimately provides us the opportunity to 
account for limited information and gaps in our knowledge.  For example, if there is little 
information on the relationship between level of target occupancy and target activation, the 
corresponding parameters will have an appropriately high uncertainty.  This feature is 
particularly relevant for the estimation and translation of risk as uncertainty can be 
propagated as high imprecision in exposure-risk relationships.  Moreover, the calculation of 
the propagation of model uncertainty to uncertainty in the risk-benefit profile offers the 
prospect of efficient data collection. 
The standard method for parameter estimation for nonlinear mixed effects models has been 
the maximum likelihood approach (56-59).  This is where parameters are treated as random 
variables with distribution governed by the likelihood function p(y|Θ), which represents the 
probability of the total data arising given the value of the parameters.  The reported value 
for each parameter is the parameter at the maximum of the distribution, and associated 
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uncertainty given by the variance of the distribution.  No data reduction is required; each 
raw data point directly informs parameter estimation thereby making maximal use of the 
available data.  When multiple studies have been performed in populations which share 
common physiological processes or treatments, datasets may be aggregated to support 
integrated analyses across these studies.  Furthermore, model-based analysis can handle 
multiple types of observations (e.g., pharmacokinetics and pharmacodynamics) as well as 
multiple data types (e.g., continuous and categorical). 
Of particular interest for the assessment of safety and toxicity is the possibility of applying 
extensions of the maximum likelihood, which enable mathematically rigorous incorporation 
of prior parameter information (e.g., receptor occupancy or blood to plasma binding ratio in 
vitro to describe in vivo data).  The two main methods for achieving this are the penalised 
likelihood method (49,60) and Bayesian estimation (61).  It should also be noted that the 
advent of exact likelihood methods such as expectation maximisation (EM) methods (62) has 
provided  increased reliability of PKPD analyses, especially in the presence of sparse data, 
often available from general toxicity protocols. 
We should also emphasise that in the context of safety pharmacology and toxicity studies, 
trial optimisation represents proper adherence to the three R’s (reduction, refinement and 
replacement).  When prior information is available for class-specific parameters, a model-
based analysis may benefit from this allowing for a reduction experimental cohort sizes or 
burden to animals.  This is possible because model-based analyses are inferential in nature. 
 
3.2. Model parameterisation: empirical vs. mechanistic models 
Despite the increasing number of modelling examples in biomedical and pharmaceutical 
research, the use of pharmacokinetic and pharmacokinetic-pharmacodynamic models has 
remained primarily descriptive.  However, the application of such models for the evaluation 
of safety requires further consideration of its biological plausibility and predictive or 
prognostic value. For example, instead of using a simple compartmental model to describe 
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the observed phases of drug elimination, one may need to consider a physiologically-based 
pharmacokinetic model (PBPK) (63).  Such models can be developed by integrating prior in 
vitro data and literature information.   
On the other hand, it is not unusual for components of PKPD models to be statistically 
correlated to some degree.  Therefore, it is important that when identifying at-risk 
subpopulations based on collected data, covariate selection is guided by a mechanistic or 
physiological evaluation.  There are several methods that allow such an approach (64-67).  
More recently, these methods have also been applied to describe disease processes (33).  
Statistically, these models include a response variable that characterises the disease status 
and its progression over time.  
 
3.3. Simulations, experimental design and optimisation 
Model predictions, simulated outside the experimental context are extrapolations subject to 
model specification bias.  Since our primary goal is to show the relevance of such models to 
analyse data arising from pre-clinical species and eventually from healthy subjects to assess 
safety and toxicity in patients who will be receiving these drugs, this point is of special 
importance.  In PKPD modelling, computer simulation involves using statistical models to 
predict the behaviour of the biological system described by the model (68).  Clinical trial 
simulations (CTS) i.e. computer simulation of trials, allows for the investigation of the impact 
of different design characteristics on the outcome of a trial.  It can also be used to 
investigate the implications of uncertainty and variability in pharmacokinetic and 
pharmacological processes for recruited individuals, thereby allowing the prior assessment 
of the robustness of the protocol to known uncertainty and variability (69).  More generally, 
in a CTS it is possible to test the influence of any modelling assumption and design factor 





Figure 6: The diagram depicts the major components of a clinical trial simulation (CTS).  In model-
based drug development, CTS can be used to characterise the interactions between drug and 
disease, enabling among other things the assessment of disease-modifying effects, dose selection 
and covariate effects.  In conjunction with a trial model, CTS allows the evaluation of such 
interactions, taking into account uncertainty and trial design factors, including the implications of 
different statistical methods for the analysis of the data. 
 
 
Trial design can also benefit from the use of optimal design methodology.  The goal of 
optimal design, specifically the procedure known as D-optimality, is to determine design 
variables (such as sampling times and dose selection) that optimise the expected 
information content (usually by maximising the determinant of the Fisher Information 
Matrix (FIM)) within the desired resource constraints.  A variety of software programs exist 
purpose built for the estimation of PK/PD models (70).  Optimal sampling schedules for 
toxicity experiments can help increase the precision by which drug specific parameters can 
be estimated and/or reduce the burden to animals by minimising the number of samples 
needed.  This is desirable from an ethical and scientific perspective, as poor experimental 
design is known to result in biased estimates.  Among other advantages, optimal sampling 
may facilitate the collection of biomarkers in conjunction with pharmacokinetic data when 






High attrition rates due to a poor safety profile combined with inability to correctly identify 
risk demand revisiting of concepts and modernisation of the approaches currently used for 
the assessment of toxicity.  Current practices fail to support decision making on multiple 
levels.  Firstly, the parameterisation of drug exposure and available metrics of risk are often 
justified by historical precedent rather than by an informed scientific rationale.  These 
measures are assumed to be predictive of drug effects in humans, despite the fact that in 
many cases known pharmacokinetic and pharmacological drug properties contradict such 
assumptions. Evidence clearly shows that empirical protocols remain primarily descriptive 
rather than explanatory of the observed phenomena and are therefore unsuitable for 
extrapolation, an important point to consider when analysing and interpreting safety 
pharmacology and toxicology data.  Moreover, statistically, the use of point estimates and 
thresholds prevents understanding of the consequences of between subject variability and 
identification of at-risk subpopulations.  Additionally, type I and II errors are also not 
accounted for in the design or analysis of toxicity data, both of which are critical informed 
decision making. 
In summary, our review has highlighted the implications of empirical data generation for the 
evaluation of safety and toxicity during drug development.  A shift in paradigm was 
proposed to ensure that pharmacological concepts are incorporated into the evaluation of 
safety and toxicity. Moreover, we indicate the urgent need to integrate historical evidence, 
so that findings across species can be effectively translated.  Based on historical examples, 
we have shown some important challenges for the early characterisation of the safety 
profile of a new molecule and discuss how model-based methodologies can be applied for 
better design and analysis of experimental protocols.  From a methodological perspective, 
nonlinear-mixed effects modelling is recommended as a tool to account for such 
requirements. Its use in the evaluation of pharmacokinetics (PK) and pharmacokinetic-
pharmacodynamic relationships (PKPD) has enabled the advance of quantitative approaches 
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in pharmacological research in recent decades.  Comparable benefits can be anticipated for 
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Scope and intent of investigation 
 
Historically, the evaluation of safety pharmacology and toxicity of drugs has largely relied on 
research in animal models, of which results have been used to extrapolate to potentially 
harmful events in humans. The research in these models has been developed to evaluate 
specific toxicological endpoints, (such as oral, dermal and ocular toxicity, immunotoxicity, 
genotoxicity, reproductive and developmental toxicity and carcinogenicity) rather than 
specifically designed to understand the exposure response relationships associated with the 
anticipated adverse event or toxicity (1). Furthermore, even if one considers the information 
obtained from these experiments useful, they are low throughput and inconsistently 
predictive of human pharmacology and pathophysiology. Some of these limitations persist in 
spite of the recognition of toxicokinetics as an important part of the safety assessment (2-3).  
More recently, several major new initiatives have begun to utilise in vitro methods and a 
variety of new technologies to develop in vitro signatures and computational models 
predictive of in vivo response. These initiatives provide insight and tools to identify a battery 
of in vitro assays to detect perturbations in cellular pathways that are expected to contribute 
to or result in adverse health effects (4,5). Furthermore, these initiatives represent a 
welcome movement away from traditional in vivo high-dose hazard studies (6,7).  
Despite such a continuing improvement in methods to characterise the safety and toxicity of 
novel medicines, uptake of these new approaches by regulatory agencies remains limited, 
with quantitative pharmacology concepts still being rarely applied to address clinical and 
regulatory questions on the safety pharmacology and toxicity of a novel compound. 
Evidence of the relevance of such concepts has been highlighted with the introduction of 
structure-activity relationships (SAR) in the absence of adequate toxicity data on the 
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chemical under certain circumstances, such as when the extent of exposure of humans is 
extremely low and toxicokinetic data cannot be easily generated (8). Clearly, the lack of a 
stronger pharmacological basis for the assessment of safety has prevented the 
implementation of a model-based approach aimed at the characterisation in a strict 
quantitative manner of the relationship between drug exposure and effects.  To date, efforts 
have been limited to physiologically-based pharmacokinetic modelling, but it is mostly 
applied to environmental toxicology, rather than to pharmaceutical R&D (9).  
Irrespective of the urgently needed changes in regulatory guidance, methodologies that 
support the translation and prediction of safety pharmacology and toxicity in humans are 
still required. To this purpose, more than novel experimental protocols and technologies are 
required. We strongly believe in integrative approaches that enable efficient use of available 
evidence and facilitate the assessment of pharmacokinetic-pharmacodynamic relationships. 
Of special importance is the possibility to evaluate and predict long term or rare adverse 
events, which continue to contribute to high attrition in drug discovery and development 
(10).  In light of the known limitations of current experimental protocols and the implications 
they represent for hazard characterisation in humans, a range of different approaches is 
necessary to ensure that the appropriate endpoint is detected and risk evaluated in a precise 
and accurate manner.  
The scientific and regulatory communities should acknowledge that most toxicity tests, as 
currently designed, are aimed solely at hazard identification at supratherapeutic levels. Data 
produced using current testing guidelines are not always suitable for robust mathematical 
exposure–response modelling. We recognise therefore that adequate characterisation of the 
exposure–response relationship requires a number of doses giving a range of different 
response levels. On the other hand, mathematical modelling of the exposure–response 
relationship would represent an important improvement to the risk assessment process.  
Here we tackle a number of issues that need to be considered during the course of drug 
discovery and development to ensure more efficient use of the evidence on safety 
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pharmacology and toxicity which is generated. Four central questions will form the basis for 
the work to be presented in the subsequent chapters in this thesis: 
1. Can current experimental protocols for safety pharmacology and toxicology evaluation be 
optimised to support the characterisation of pharmacokinetic-pharmacodynamic 
relationships? 
2. Does a meta-analytical approach based on nonlinear mixed effects modelling provide 
more precise and accurate estimates of safety thresholds than current methodologies? 
3. Can mechanism-based models be used for accurate inferences about safe drug exposure 
for low frequency, delayed (long term) or rare adverse events?   
4. Should biomarkers be used in conjunction with pharmacokinetic data to enable accurate 
estimation of the safe drug exposure (and consequently of safety thresholds) during chronic 
therapy? 
Our work is presented in a way that both conceptual and practical issues are addressed 
concurrently. After revisiting the requirements for the implementation of quantitative 
pharmacology concepts in the evaluation of safety pharmacology and toxicology, we 
highlight how existing protocols should be redesigned to obtain accurate results from the 
modelling and emphasise that an appropriate design might even result in a reduction in the 
total number of animals studied. Moreover, we show that biomarker data may allow 
translation of the external dose to an internal dose (or target-organ dose), as it reflects a 
compounds pharmacology. In fact, using naproxen as a paradigm compound for the acute 
and chronic effects of cyclo-oxygenase inhibition, we explore how biomarkers could be used 
to provide a full pharmacologically-based exposure-response model, i.e., a PBPKPD model.  
Our endeavour is complemented by further insight into the implications of modelling for risk 
prediction purposes, as described by logistic, hazard models. Clear recommendations are 
provided about the requirements for future refinements regarding the characterisation of 
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exposure–response relationships, which need to account for the extent of uncertainty and 
variability in modelling and simulation output.  
 
Section I: General introduction 
 
In Chapter 1, we have described the problems with existing practices from a methodological 
point of view and highlighted the value of mechanism-based PKPD modelling as a tool for 
the evaluation of safety pharmacology and toxicology.   From a methodological perspective, 
we show that the parameterisation of drug exposure and available metrics of risk are often 
justified by historical precedent rather than by an informed scientific rationale. These 
measures are assumed to be predictive of drug effects in humans, despite the fact that in 
many cases known pharmacokinetic and pharmacological drug properties contradict such 
assumptions. Evidence clearly shows that empirical protocols remain primarily descriptive 
rather than explanatory of the observed phenomena and are therefore unsuitable for 
extrapolation, which is an important point to consider when analysing and interpreting 
safety pharmacology and toxicology data. Moreover, statistically, the use of point estimates 
and thresholds prevents understanding of the consequences of between subject variability 
and identification of at-risk subpopulations. Additionally, type I and II errors are also not 
accounted for in the design or analysis of toxicity data, both of which are critical informed 
decision making. 
A shift in paradigm is proposed to 1) ensure that pharmacological concepts are incorporated 
into the evaluation of safety and toxicity; 2) facilitate the integration of historical evidence 
and thereby the translation of findings across species; and 3) promote the use of 
experimental protocols tailored to address specific safety and toxicity questions. Three 
important components have been identified, which will form the framework proposed 
throughout this thesis., namely, model based optimisation of experimental design, data 
integration, and incorporation of biomarkers as a way towards the implementation of a 
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pharmacology-based approach for the characterisation of safety and toxicity  in drug 
discovery and development. 
Of particular interest for us is to demonstrate that inefficiencies in the experimental design 
violate the principle of the 3 Rs (reduction, refinement and replacement) (11,12).  Optimality 
concepts are available that could be implemented even when terminal sampling procedures 
are used, as is the case of histopathological measures.  Using examples, we show that the 
poor predictive value of experimental data reflects the failure in anticipating the biological 
consequences of target engagement, i.e., in establishing the correlation between target-
related events and drug exposure, as defined by the evidence of pharmacokinetic-
pharmacodynamic (PKPD) relationships.   
Based on the requirements for the implementation of a pharmacology-based approach, 
specific issues have been identified which underpin the scope and intent of the 
investigations described here in Chapter 2. Nonlinear-mixed effects modelling will be 
recommended as a tool for protocol optimisation and knowledge integration (i.e., evidence 
synthesis). Its use in the evaluation of pharmacokinetics and pharmacokinetic-
pharmacodynamic relationships has enabled the advance of quantitative approaches in 
pharmacological research in recent decades.  As shown in the subsequent chapters of this 
thesis, comparable benefits can be anticipated for the assessment of safety and toxicity. 
The overall focus of the work presented in the following sections of this thesis is therefore to 
illustrate how the proposed methodology can be applied prospectively during the evaluation 
of a novel molecule in the early stages of development.  We also attempt to demonstrate 
the need and added value of an integrative approach to predict potential long term AEs with 
respect to performance metrics commonly used in safety pharmacology and toxicology 
experiments.  Where possible, proposals to amend study protocols are kept to a minimum to 




Section II: Conceptual framework 
 
In the section, different aspects, including advantages and limitations of a model-based 
approach are evaluated. Of interest is the fact that despite the increased attention to the 
importance of toxicokinetics, the extrapolation and prediction of a safe exposure range in 
humans from preclinical experiments continues to be based on the assessment of empirical 
safety thresholds, in particular the no observed adverse effect level (NOAEL), which is a 
qualitative indicator of acceptable risk.  In addition, pharmacokinetic data generated from 
different experiments are not evaluated in an integrated manner, whereby drug disposition 
(e.g., clearance) can be described mechanistically or at least compartmentally in terms of 
both first and zero order processes. As a consequence, safety thresholds are primarily 
derived from inferences about the putative pharmacokinetic profiles in the actual treatment 
group. Such an experimental setting has far reaching consequences for the assessment of 
risk, given the assumption that inter-individual differences are implied to result from 
residual variability. Pharmacokinetic and pharmacokinetic-pharmacodynamic parameters 
are treated as point estimates. Factors such as within- and between-subject variability or 
uncertainty in estimation are not accounted for. This is further complicated by another 
major limitation in the way exposure is described by naïve pooling approaches, i.e., the 
impossibility to accurately derive parameters such as cumulative exposure, indirect or 
delayed effects, which may be physiologically more relevant depending on type of drug and 
the mechanism of action. 
Therefore, focus is initially given to the opportunities for optimisation of experimental 
protocols supporting the characterisation of pharmacokinetic properties at therapeutic and 
supratherapeutic levels. In Chapter 3, we show that the estimation of safety thresholds such 
as the NOAEL can be optimised (13).  Using simulation scenarios in which hypothetical 
compounds with different disposition properties are evaluated, our analysis shows the 
feasibility and relative performance of a model-based analysis for the characterisation of 
systemic exposure as compared to empirical, non-compartmental analysis (NCA) methods 
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currently used in general toxicity protocols.  Simulation scenarios are used to illustrate which 
changes are required in experimental protocols with respect to standard non-
compartmental analysis. Expected bias and precision of parameters of interest, such as 
systemic exposure (AUC) and peak concentrations (CMAX), are then computed with both 
methodologies.  In addition, we also assess the predictive accuracy of cumulative exposure 
estimates up to three months beyond the study duration.  It should be noted that such an 
extrapolation represents an important advantage of model-based methods, which cannot be 
derived by descriptive methods such as non-compartmental analysis.  Overall, the scope of 
this evaluation was to show that, despite the need for an iterative process, modelling 
provides the basis for experimental protocol optimisation. 
Given the assumption of unbiased parameter estimation when using a model-based 
approach for the characterisation of pharmacokinetic properties, a natural question arises 
with respect to the principle of the 3 Rs in pre-clinical research.  Irrespective of the 
availability of alternative methods that allow evaluation of drug disposition properties in 
vitro, can experimental protocols be optimised to ensure a significant reduction in the 
number of animals required, whilst still providing sufficient estimation precision for 
measures of exposure such as AUC and CMAX?  
This question is addressed in Chapter 4, where an important methodological challenge is 
overcome, namely the possibility to optimise secondary pharmacokinetic parameters such as 
AUC and CMAX. In contrast to existing optimality software and algorithms, which support 
optimisation of experimental design with respect to primary parameter precision, we show 
that secondary parameters can be optimised without the resource-intensive procedures 
imposed by D-optimality.  Using a range of hypothetical drugs with different 
pharmacokinetic profiles, we illustrate the implementation of optimisation procedures to 
select sampling times and define the minimal number of animals per treatment group. By 
combining the expected Fisher information matrix (FIM) with simulations from uncertainty, 
this exercise ultimately shows that the precision of secondary parameters can be assessed 
and minimally sufficient designs obtained, in line with the principle of the 3 Rs. The method 
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is computationally inexpensive and can provide potential savings to numbers of animals 
without compromising study objectives. 
Still within the scope of protocol optimisation, we also explore the implications of 
introducing biomarkers into the evaluation of a drug’s safety toxicity profile, as biomarkers 
of pharmacological activity can be crucial for the prediction of long term adverse events and 
toxicity. In contrast to traditional protocols, which imply a direct relationship between 
observed systemic exposure and adverse events, in Chapter 5 we apply a model-based 
approach to characterise the PKPD correlations and the time course of biomarker responses 
associated with long-term safety. Our evaluation also compares the analysis of biomarker 
data based on standard non-compartmental methods. In brief, we propose the collection of 
biomarkers at the scheduled pharmacokinetic sampling points to facilitate the 
characterisation of pharmacokinetic-pharmacodynamic relationships.  
Study data are simulated for four hypothetical drugs, each with a different mechanism of 
delayed toxicity. For the purposes of our evaluation, delayed toxicity was parameterised in 
terms of i) an indirect response mechanism, ii) an indirect response mechanism preceded by 
biophase equilibration, iii) cumulative effects as a consequence of chronic dosing and iv) 
formation of a toxic metabolite after repeated dosing. Given the often unknown mechanism 
of toxicity, model misspecification is also considered to ensure that accurate conclusions are 
drawn from experimental protocols. Finally, bias and precision of parameter estimates were 
used as metrics of interest to compare model-based and non-compartmental methods. 
The utility of model-based approaches to predict the risk of adverse events from preclinical 
toxicology protocols is subsequently explored in Chapter 6, where pharmacokinetic, 
biomarker and adverse event data are integrated into a PKPD model.  In this investigation, 
simulation scenarios are used to generate drug-induced adverse events for reversible and 
irreversible drug effects according to three different pharmacological mechanisms (direct, 
indirect, and irreversible binding). To ensure real-life conditions, assumptions are made with 
regard to 1) the presence of background adverse events, including the situation in which 
63 
 
drug-induced and background adverse events are indistinguishable from each other, 2) 
events occur with low frequency, including rare events, 3) the symptoms evolve over time 
but can only be detected once per animal during histological examination and 4) adverse 
events are described by binary data.   
Whereas typical toxicology experiments are designed to show evidence of safety thresholds, 
it can be anticipated that they may not fully support the identification of the underlying 
mechanisms for adverse drug reactions. Therefore, we show the importance of prior 
information and more specifically of background rates from placebo and control-treated 
animals. We also make the effort to quantify model and parameter uncertainty as the basis 
for subsequent risk assessment. At the same time, we show the technical challenges for 
characterising exposure-response relationships, which make the validity and reproducibility 
of models derived by empirical experimentation questionable for predictive purposes.  
Section III:  Case study and practical application 
 
The third part of the thesis aims to illustrate the implementation of experimental protocols 
suitable for model-based analysis. Given the ongoing debate of the benefit-risk balance of 
chronic treatment with non-steroidal anti-inflammatory drugs, naproxen is used as a 
paradigm compound with known acute and chronic toxicities. Naproxen is a non-selective 
cyclo-oxygenase inhibitor, whose activity results in the suppression of pro-inflammatory 
mediators such as prostaglandins and thromboxanes  (14). By considering the requirements 
for a suitable experimental protocol, we also attempt to identify practical challenges and 
difficulties that one may face for the prospective use of the methodology.   
From a clinical pharmacology perspective, the rationale for selecting naproxen is based on 
the differences in housekeeping function of both isozymes and their contribution to the 
inflammatory response in acute and chronic inflammatory conditions (15-17). Unfortunately, 
at present the dose selection of COX inhibitors disregards whether maximum, long-lasting 
blockade of either enzyme systems is strictly required for anti-inflammatory, analgesic 
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response and how its pharmacology relates the observed adverse events (18). These 
considerations become essential when evaluating the side effects associated with long term 
use of COX inhibitors, which include gastric and cardiac adverse events. Whilst the lack of 
selectivity of naproxen and the evidence for distinct mechanisms underpinning acute effects 
(such as bleeding and ulceration) and long term effects (such as renal and cardiovascular 
damage) have evolved over the years and might not have been understood at time of the 
development of the compound, such understanding makes it quite didactic in that it 
demonstrates how human safety and toxicity may require characterisation of drug effects at 
exposure levels corresponding to the therapeutic doses. Toxicity, and in particular, long term 
safety is not a matter of supra-therapeutic exposure: it may be determined by time-
dependent pharmacological activity. 
Using a typical toxicology protocol in rats, in Chapter 7 naproxen, a non-selective cyclo-
oxygenase inhibitor is used as paradigm compound to demonstrate the concept of 
biomarker-guided safety assessment (19-21). Using pharmacokinetic-pharmacodynamic 
techniques, we subsequently illustrate how modelling and simulation techniques can be 
used to ensure accurate estimation of the safe dose levels of naproxen after chronic 
exposure. Furthermore, the pharmacokinetics of naproxen is evaluated in conjunction 
thromboxane (TXB2) and prostaglandin (PGE2) over short, moderate and long-term 
treatment. It is assumed that gastrointestinal bleeding is due continuous COX-1 inhibition, 
whereas ulceration results primarily from the suppression of COX-2, which is known to have 
an important role in the repair of gastric mucosa.  PK and biomarker findings are then 
integrated with experimental data from historical protocols and published literature to 
ensure characterisation of drug properties at putative therapeutic levels. From a 
methodological perspective, it is our endeavour to quantify the impact of nonlinearity in 
pharmacokinetics and in biomarker response.  Given the wealth of clinical data from the 
published literature, we also take the opportunity to evaluate the predictive value of 
nonclinical findings and explore whether species differences exist for naproxen effects on 
TXB2 and PGE2. 
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This evaluation is complemented in Chapter 8 by further integrating the histological data 
obtained at completion of treatment to the observed biomarker effects.  Here we emphasise 
the need for evidence synthesis to quantify and explain the risks associated with long term 
drug exposure. Clearly, efforts are required to ensure the availability of tissue- and 
mechanism-specific data for accurate interpretation of acute and long term safety findings. 
Such an objective may be hampered by the use of empirical experimental protocols, as they 
render the extrapolation of findings across species rather difficult, preventing accurate 
translation of the pharmacological properties to man.  In the current investigation we show 
therefore how pharmacokinetic-pharmacodynamic (PKPD) modelling can be used to unravel 
the relationship between chronic drug exposure, pharmacodynamic effects and overt 
symptoms and signs. The concept is illustrated by the correlation between naproxen 
concentrations, PGE2 and TXB2 inhibition, and gastric ulceration in rats.  Through the use of 
bootstrapping procedures in combination with covariate analysis, we show how model 
diagnostics can be used for model selection as well as for potential identification of the 
explanatory factors for the observed gastric ulceration. 
Section IV: Conclusions and Perspectives 
 
An overview of the results and conclusions drawn from the various chapters is provided in 
Chapter 9. Most importantly, recommendations are provided for physiologically based 
quantitative toxicity assessment. Here we also summarise the answers to the initial 
questions set up at the beginning of this chapter, which underpin the research developed 
throughout the thesis.  We anticipate that the examples used in Section II will make clear 
that there are numerous opportunities for optimisation of experimental protocols for safety 
pharmacology and toxicology. The approach should also shed light on the advantages of 




Lastly, the issues identified in the various simulation scenarios and the challenges 
experienced during the implementation of an integrated experimental protocol are 
discussed. Our findings should make clear that inferences about safe exposure as well as the 
risk associated with long term use of a compound cannot be achieved by scattered empirical 
experimentation.  Given the increased relevance of evidence synthesis as the basis for 
decision-making within regulatory and clinical settings, we expect that some of the meta-
analytical elements presented across the various simulation scenarios will become 
embedded into daily practice in safety pharmacology and toxicology. Irrespective of the 
advancements in the understanding of the mechanisms of toxicity, we envisage that a 
pharmacology or biomarker-based approach will always be required to allow accurate 
inferences about safe drug exposure for low frequency, delayed (long term) and rare 
adverse events.  Future perspectives are then presented taking into account ongoing 
developments in the field of systems pharmacology and its relevance for the prediction of 
drug toxicity and risk assessment in humans.  The work is concluded with a new question 
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Purpose: Current toxicity protocols relate measures of systemic exposure (i.e. AUC, Cmax)  
as obtained by non-compartmental analysis to observed toxicity.  A complicating factor in 
this practice is potential bias in the exposure estimates.  Moreover, it prevents the 
assessment of variability.  The objective of the current investigation was therefore a) to 
demonstrate the feasibility of applying nonlinear mixed effects modelling for the evaluation 
of toxicokinetics and b) to assess the bias and accuracy of systemic exposure for each 
method. 
Methods: Simulation scenarios were evaluated, which mimic standard toxicology protocols 
in rodents.  To ensure differences in pharmacokinetic properties were accounted for, 
hypothetical drugs with varying disposition properties were considered, including a one-
compartment pharmacokinetics with linear and nonlinear elimination as well as a two-
compartment pharmacokinetics.  Data analysis was performed using non-compartmental 
methods and nonlinear mixed effects modelling. Exposure levels were summarised as area 
under the concentration vs. time curve (AUC), peak concentrations (Cmax) and time above a 
predefined threshold (TAT).  Results were then compared with the reference values to 
assess the bias and precision of parameter estimates. 
Results: Population pharmacokinetic modelling yields higher accuracy and precision of 
estimates for AUC, CMAX and TAT irrespective of group or treatment duration, as compared 
with non-compartmental analysis.  Moreover, population pharmacokinetics modelling 
constitutes a basis for PKPD based analysis of safety outcomes. 
Conclusions: Despite the focus of toxicology guidelines on establishing safety thresholds for 
the evaluation of new molecules in humans, current methods neglect uncertainty, lack of 
precision and bias in parameter estimates.  The use of nonlinear mixed effects modelling in 
toxicology provides insight into variability and should be considered for predicting safe 




AUC  - area under the concentration vs. time curve 
Cmax – peak concentrations 
PD - pharmacodynamics 
PK – pharmacokinetics 




The purpose of toxicokinetic studies in the evaluation of safety pharmacology and toxicity is 
the prediction of the risk that exposure to a new chemical or biological entity represents to 
humans (1,2).  Understanding of the relationships between drug exposure, target 
engagement (i.e., activation or inhibition) and downstream biological effects of a given 
physiological pathway can provide insight into the mechanisms underlying both expected 
and ‘unexpected’ toxicity (3) (Figure 1).  In addition, the use of a mechanism-based approach 
has allowed better interpretation of time-dependencies in drug effect, which are often 




Figure 1 – Safety risk assessment based on toxicokinetics and pharmacological basis for target-
related adverse events.  Target efficacy: target engagement endpoint on in vitro or in vivo screening. 





Despite the increased attention to the importance of toxicokinetics in drug discovery and  
during the early stages of clinical development, the extrapolation and prediction of a safe 
exposure range in humans from preclinical experiments continues to be one of the major 
challenges in R&D (Figure 2)  (71).  Irrespective of the choice of experimental protocol, a 
common practice in toxicology remains the assessment of empirical safety thresholds, in 
particular the no observed adverse effect level (NOAEL), which is a qualitative indicator of 
acceptable risk.  Even though support for the existence of thresholds has been argued on 
biological grounds (19-21), the NOAEL has been used to establish safe exposure levels in 
humans. In fact, this threshold represents a proxy for another threshold, i.e., the underlying 
no adverse event level (NAEL). 
 
The definition of the NOAEL varies from source to source (22).  Its calculation involves the 
determination of the lowest observed adverse effect level (LOAEL), which is the lowest 
observed dose level for which AEs are recorded.  The NOAEL is the dose level below this.  If 
no LOAEL is found, then the NOAEL cannot be determined.  Usually, in the assessment of the 
LOAEL measures of systemic exposure are derived, such as area under the concentration vs. 
time curve (AUC) and peak concentrations (Cmax), which serve as basis for the maximum 
allowed exposure in dose escalation studies in humans (10).  The aforementioned practices 
in safety and toxicity evaluation are driven by regulatory guidance (72).  The scope of these 
guidances is to ensure that the systemic exposure achieved in animals is assessed in 
conjunction with its relationship to dose level and the time course of the toxicity or adverse 
events (Figure 2).  Another important objective is to establish the relevance of these findings 
for clinical safety as well as to provide information aimed at the optimisation of subsequent 





Figure 2 –  TK; toxicokinetic study in drug-development process. IND; investigational new drug 
application, NDA; new drug application. Reprinted with permission from Horii, 1998 (3).  General 
toxicity data used for supporting early clinical trials is gathered in the pre-IND stage.  After IND 
submission, the FDA will confirm whether adequate evidence of safety has been generated for 
human trials. 
 
Whilst the scope and intent of such guidance are well described since 1994, when it was 
introduced by ICH, there has been much less attention to requirements for the analysis and 
interpretation of the data.  In fact, precise details on the design of toxicokinetic studies or 
the statistical methods for calculating or estimating the endpoints or variables of interest, 
are not specified (13-15).  Instead, the assessment of exposure often takes places in satellite 
groups, which may not necessarily present the (same) adverse events or toxicity observed in 
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the main experimental group.  This is because of interferences associated with blood 
sampling procedures, which may affect toxicological findings.  For this same reason, blood 
sampling for pharmacokinetics is often sparse (73).   
As a consequence, safety thresholds are primarily derived from inferences about the 
putative pharmacokinetic profiles in the actual treatment group. Furthermore, these 
thresholds rely on the accuracy of composite profiles obtained from limited sampling in 
individual animals.  Composite profiles consist of pooled concentration data, which is 
averaged per time point under the assumption that inter-individual differences are simply 
residual variability, rather than intrinsic differences in pharmacokinetic processes (74).  
Pharmacokinetic parameters such as area-under-concentration-time (AUC) and observed 
peak concentrations (CMAX) can then be either derived from the composite profile or by 
averaging individual estimates from serial profiles in satellite animals when frequent 
sampling schemes are feasible.  Given that the parameters of interest are expressed as point 
estimates, within- and between-subject variability as well as uncertainty in estimation are 
not accounted for.  In addition, pharmacokinetic data generated from different experiments 
are not evaluated in an integrated manner, whereby drug disposition (e.g., clearance) can be 
described mechanistically or at least compartmentally in terms of both first and zero order 
processes.  This is further complicated by another major limitation in the way exposure is  
described by naïve pooling approaches, i.e., the impossibility to accurately derive 
parameters such as cumulative exposure, which may be physiologically a more relevant 
parameter for cumulative effects (e.g. lead toxicity, aminoglycosides) (18-19).  Time spent 
above a threshold concentration may also bear greater physiological relevance for drugs 
which cause disruption of homeostatic feedback mechanisms.  Such parameters cannot be 
described by empirical approaches due to limitations in sampling frequency.  
By contrast, population pharmacokinetic-pharmacodynamic methodologies have the 
potential to overcome most of the aforementioned problems.  Whilst the application of 
modelling in the evaluation of efficacy is widespread and well-established across different 
therapeutic areas (20-22), current practices have undoubtedly hampered the development 
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of similar approaches for the evaluation of adverse events, safety pharmacology and toxicity.  
It should be noted that in addition to the integration of knowledge from a biological and 
pharmacological perspective, population models provide the basis for the characterisation of 
different sources of variability, allowing the identification of between-subject and between-
occasion variability in parameters (23).  These random effects do not only reflect the 
evidence of statistical distributions.  They can be used for inference about the mechanisms 
underlying adverse events and toxicity.  In fact, recent advancements in environmental 
toxicology have shown the advantages of PBPK/PD modelling as a tool for quantifying target 
organ concentrations and dynamic response to arsenic in preclinical species (24).   
The aim of this investigation was therefore to assess the relative performance of model-
based approaches as compared to empirical methods currently used to analyse toxicokinetic 
data.  We show that, modelling is an iterative process which allows further insight into 
relevant biological processes as well as into data gaps, providing the basis for experimental 
protocol optimisation.  We illustrate the concepts by exploring a variety of scenarios in 
which hypothetical drugs with different disposition properties are evaluated. 
Methods 
A model-based approach was used to simulate the outcomes of a 3-month study protocol, in 
which toxicokinetic data for three hypothetical drugs were evaluated.  Experimental 
procedures were defined according to current guidelines for the assessment of toxicity. 
Given the pre-defined pharmacokinetic parameters used in the simulations, true exposure 
and biomarker levels for each individual animal were computed in accordance with Table 3.  
These values were subsequently used as reference for comparison of the methodologies and 
assessment of bias and precision of the parameters of interest.  The sampled data obtained 
according to a sampling matrix was analysed using non-compartmental methods and by 
nonlinear mixed effects modelling.  All simulations and fitting procedures described below 
were performed in NONMEM 7.1 (25).  Data manipulation and statistical and graphical 
summaries were performed in R 3.0.0 (26). 
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Pharmacokinetic models: The impact of differences in drug disposition on bias and precision 
of the typical measures of systemic exposure was explored by including three different 
scenarios based on a one-compartment pharmacokinetics with linear and nonlinear 
(Michaelis-Menten) elimination as well as a two-compartment pharmacokinetics. Parameter 
values for each scenario are shown in Table 1.  In all scenarios, residual variability was 
assumed to be 15%.  For the purposes of this exercise, we have assumed a homogeneous 
population, avoiding the need to explore covariate relationships in any of the models. 
 
 
Table 1 - Pharmacokinetic models used to assess the implications of molecules with varying 
disposition properties. 
Model A: One-compartment model (1 CMT) 
Parameter Pop Estimate BSV 
KA 13.46 h-1 50% 
V 49.4 ml/kg 16% 
CL 2.72 ml/hr 20% 
 
 
Model B: One compartment model with Michaelis-Menten elimination (1 CMT + MM). Parameter 
values were chosen to ensure departure from dose proportionality at the highest dose. 
Parameter Pop Estimate BSV 
Vmax 2.72 mg/hr 20% 
Km 1 mg/ml - 
Ka 13.46 h-1 50% 
V 49.4 ml/kg 16% 
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Model C: Two-compartment model (2 CMT). The values for the absorption and elimination rate 
constants were selected in such a way that slow accumulation of drug is observed at stead-state 
conditions after daily dosing for approximately two weeks. 
Parameter Pop Estimate BSV 
Ka 0.55 h-1 50% 
V 49.4 ml/kg 16% 
CL 2.72 ml/hr 20% 
K12 0.3 h-1 - 





Experimental design: A summary of the sampling schemes and experimental conditions is 
shown in Table 2.  The protocol design for each experiment with the three hypothetical 
drugs was based on protocols typically used for chronic toxicity evaluation.  Four treatment 
groups receiving oral daily doses of vehicle, 10, 30, and 100 mg/kg/day were tested 
throughout this set of virtual experiments.  The same treatment groups were present in all 
duration cohorts (one week, one month or three months).  Satellite groups each were used 
to characterize the pharmacokinetics under the dosing conditions in the animals used for the 
assessment of toxicity.  This procedure ensures the availability of more frequent blood 
samples for toxicokinetics, while not influencing the assessment of the toxicity.  Two 
different sampling schedules were investigated, namely, composite sampling and serial 
sampling.  For the sake of comparison, the same number of samples was collected in both 
cases.  For composite sampling, blood was collected from three animals in the satellite group 
at predetermined sampling time points, namely, 0.1, 0.4, 1, 1.5, 4, 8, 24 hours after drug 
administration on sampling days (see Table 2).  The allocation of animals to each sampling 
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time point was random within the constraint that all animals was sampled an equal number 
of times.  Figure 3 shows PK observations from a typical dataset. 
Table 2 - Experimental design of satellite groups in a general toxicity study with serial and composite 
sampling 
 
Duration Numbers of animals Sampling scheme 
 
1 week 
Toxicity: 4 per dose group 
Satellite: 3 per dose group 
Toxicity: Composite 2 per animal 
Satellite: Serial profiles from Day 1 only 
 
1 month 
Toxicity: 10 per dose group 
Satellite: 3 per dose group 
Toxicity: Composite 2 per animal 
Satellite: Serial profiles from Day 1 and 28 
 
3 months 
Toxicity: 12 per dose group 
Satellite: 3 per dose group 
Toxicity: Composite: Wk 4, wk 13 







Figure 3 – Overview of a simulated dataset for each of the experimental scenarios, in which 3 
animals/sampling time point design are assessed.  Dots represent simulated concentrations at the 
pre-defined sampling times, whereas the solid black line depicts the population predicted profile 
after a dose of 30 mg/kg for hypothetical drugs with different pharmacokinetic characteristics. 
 
Exposure calculations:  Five different measures of exposure were used for calculation of 
exposure, using the predicted concentration profiles obtained from the models used for 
simulation.  These exposure measures can be seen alongside the formula used for their 
calculation in Table 3.  The simulations (n = 200 replicates) were performed assuming repeat 
dosing for up to six months (three months beyond the treatment duration presented the 





Table 3 - Individual predicted drug concentrations are denoted by (). 
Covariate name Model based exposure calculation 
24-hour AUC   !!"#  
24-hour CMAX max	('(():  − 24 < ( < .) 
24-hour time above threshold 
drug concentration. (TAT) 
 1012!34563 !!"#  
Predicted 6-month cumulative 
AUC 
  7	89:!36;  
Predicted 6-month CMAX max	('((): 0 < ( < 6	=>?ℎ(.) 
 
 
For composite sampling, non-compartmental analysis was used to determine overall drug 
exposure, which consisted in averaging the simulated concentrations at each sampling time 
point.  For serial sampling, drug exposure was calculated for each individual animal and then 
averaged over the cohort.  In both cases, the arithmetic mean and geometric mean were 
calculated.  Three different non-compartmental exposure measures were derived, the AUC, 
estimated using the linear-logarithmic trapezoidal rule, the CMAX, and the time above 
threshold drug concentration, 0.01mg/ml.  This value was used based on the assumption 
that adverse events were likely to occur above those levels. 
Population pharmacokinetic modelling: Drug concentration profiles were fitted to 
pharmacokinetic models using first-order conditional estimation method with 
interaction, as implemented in NONMEM.  Model building steps were limited to the 
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same structural models used for the initial simulations under the assumption that 
pharmacokinetic properties of the drugs are known at the time toxicology 
experiments are performed.  Model convergence was determined by successful 
minimisation and estimation of the covariance step.  Data below the lower 
quantification limit (BQL) were omitted to mimic experimental conditions in which 
imputation methods are not applied.  Estimates for all three measures of exposure 
were calculated by using same procedures applied for the reference values obtained 
during the initial simulation step (see Table 3) . 
Comparison: To ensure accurate estimates of bias and precision of the two 
methodologies, the process of simulation and estimation of exposure (using non-
compartmental vs. model-based methods) was repeated 200 times. Bias and 
precision were assessed by the relative error, scaled relative mean error (SRME) and 
the coefficient of variation (CV) respectively (27): 
ABCD = 1E((F=G  − HI)HIJKL × 100 
N = 1OEP(F=G  −=G?=G? QJKL × 100 
 
Results 
The use of simulated data for the evaluation of hypothetical scenarios provided clear insight 
of the impact of current practices on the accuracy and precision of safety thresholds, and in 
particular of the NOAEL. Irrespective of the use of serial or sparse sampling schemes for the 
characterisation of the concentration vs. time profiles, model convergence rates were 
usually high, with successful completion of the covariate step. An overview of the 
convergence rates is presented in Table 4. 
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Table 4 – Rates of successful model convergence and successful covariance (parameter precision) 
estimation. 
Model Successful convergence Successful covariance step 
1 CMT 99.75 99.75 
1 CMT + MM 99.75 99.75 
2 CMT 100 100 
 
To facilitate the comparison of the magnitude of bias and precision, results from modelling 
are shown together with the parameter values obtained from non-compartmental analysis 
where applicable.  Due to the large number of experimental conditions to be summarised, 
here we present a brief description of the relative errors obtained in the 3-month protocol, 
for AUC, Cmax and TAT.  All other experimental conditions, including an overview of the 
scaled relative mean error (SRME) and the coefficient of variation (CV) are presented in 
tabular format as supplemental material (Table 5). 
In Figure 4, the relative errors are presented for the estimates for AUC, CMAX and TAT.  The 
relative errors were clearly smaller when measures of exposure were derived by modelling, 
as compared to the results obtained by non-compartmental analysis.  In fact, the accuracy 
and precision of model-based estimates for all three measures of exposure were similar 
across the different dosing groups and treatment durations.  Non-compartmental estimates 
of exposure showed significantly higher bias and less precision in all scenarios.  The 
performance for model-based exposure estimates obtained in the 3-month protocol is 
summarised in figure 5. 
Our results also reveal the impact of composite versus serial sampling on bias and precision.  
For both model-based and NCA methods, the coefficient of variation increased with 
composite designs (with 8 animals) compared to serial sampling designs (with 3 animals), 
however the increase in precision for NCA method was larger than for model-based 
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estimates.  It should also be noted that CMAX was consistently over-estimated by the non-
compartmental method.  We also demonstrate that the use of arithmetic and geometric 
means for NCA had minor impact in these relatively small groups.  
Lastly, it was found that that nonlinearity in pharmacokinetics also has an important effect 
on bias and precision when sparse samples and limited number of dose levels are evaluated 
experimentally.  Model-based estimates in the 1CMT+MM scenario showed increased bias 













Figure 4 – Relative errors of parameter estimates for AUC (A, left panel), CMAX (B, mid panel) and TAT (C, right panel).  Data refers only to the 3-month 
toxicology protocol design following administration of 30 mg/kg/day of three hypothetical drugs with different pharmacokinetic profiles. Similar results 
were found for other cohorts in which 10 and 100 mg/kg/day were evaluated.  Dots represent the median, boxes show the 25th and 75th percentiles, and 
error bars denote the 5th and 95th percentiles.  The horizontal line shows the reference level for relative error equal to zero. Composite –  composite 
sampling;  GEOMEAN – geometric mean; MEAN – arithmetic mean; MODEL- nonlinear mixed effects modelling; NCA – non-compartmental analysis and 






Figure 5 – Overview of the relative errors of model-based estimators of long-term exposure, as 
determined by a 3-month toxicology protocol following administration of 30 mg/kg/day of three 
hypothetical drugs with different pharmacokinetic profiles. Similar results were found for other 
cohorts in which 10 and 100 mg/kg/day were evaluated. Dots represent the median, boxes show the 
25th and 75th percentiles, and error bars denote 1.5 times the interquartile range from the median. 







In this investigation we have attempted to identify important limitations in existing 
methodologies for the analysis of toxicokinetic data.  Most importantly, we have illustrated 
the feasibility of a model-based approach for the estimation of toxicokinetic profile using a 
well-established parameterisation for drug disposition processes.  Furthermore, given that 
model performance of toxicokinetic data has been previously evaluated (75), we have been 
able to focus the performance of measures of exposure that cannot be derived from 
empirical approaches, i.e., non-compartmental methods (29). 
The chosen models for the hypothetical drugs reflect the likely toxicokinetic profile of many 
compounds in general toxicology studies.  Taking into account the sampling schemes, the 
choice of one- and two-compartment models may apply to the majority compounds 
exhibiting linear pharmacokinetics.  Moreover, consideration was given to the implications 
that high doses may have on drug metabolism and elimination.  A pharmacokinetic model 
with Michaelis-Menten elimination was also included to ensure accurate characterisation of 
dose- and concentration-dependent pharmacokinetics, which is likely to occur for many 
compounds at least in one experimental dose level.  The results presented here should 
therefore be indicative of the most common toxicokinetic profiles and as such we anticipate 
the possibility to generalise the lessons learned to a much wider range of drugs, for which 
pharmacokinetic parameter values may differ considerably from those presented here. 
Parameter precision and bias 
As shown in Table 4, the high convergence rates of models and high success rate of 
computation of the covariance matrix for the scenarios tested here confirm the feasibility 
and reliability of results obtained using nonlinear mixed-effects modelling.  Despite 
variations in bias and precision parameter precision was consistently high.  The model-based 
approach performed particular well (CV<10% and SRME < 10% for within study exposure 
predictions and SRME < 15% for long term exposure predictions).  Such high levels of 
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precision may not be required for safe exposure evaluation where between subject 
variability in humans is expected to be larger and comparatively large uncertainty factors are 
routinely used.  This suggest that a model-based approach may enable the reductions to the 
numbers of animals and/or samples whilst still providing acceptable parameter precision.  
Moreover since optimal design methodologies for model-based analysis are well established, 
further refinement of the experimental protocol design is feasible if experimentalists and 
statisticians choose nonlinear mixed effects modelling as the primary method of analysis.   
On the other hand, the presence of bias in some of the experimental conditions presented 
here has clear implications for the so-called safety margin and toxicological cover to be used 
as proxy for risk during clinical development, especially for CMAX, which is consistently over-
estimated. The cause is due to the definition of the NCA-based Cmax, max! R() being 
necessarily greater than or equal to R( = TTUV), where TMAX represents the time point 
which maximises the true concentration-time profile.  When the sampling scheme contains 
other observations in the region of TMAX there is potential for neighbouring sampling times 
to produce higher than predicted concentrations due to natural variability.  This is a 
fundamental limitation in the methodology in that more samples around TMAX which 
intuitively should increase confidence leads, actually lead to more bias. In other words, with 
NCA analysis, precisely estimating TMAX comes at the unavoidable cost of biased estimation 
of CMAX.  Model based analysis has an additional advantage in this respect.  Without model 
misspecification issues, maximum likelihood estimates are (asymptotically) unbiased and 
have the property of that increased sampling uniformly increases precision.  Model 
specification issues which is discussed further in the limitations sections.  Given that the 
residual variability in the scenarios was not large (i.e., fixed at 15%), the bias seen here may 





In contrast to non-compartmental methods, the data was analysed in an integrated manner, 
by combining the results from all experimental cohorts.  This is undoubtedly the primary 
driver of the increased accuracy and precision in model-based estimates (30-32).  In fact, we 
envisage further improvement by incorporating pharmacokinetic data from other 
experiments in the same species, which are normally collected during preclinical evaluation 
of the molecule, as for instance during the characterisation of drug metabolism.  Such an 
increase in precision would represent further adherence to the reduction, refinement and 
replacement principle (3 Rs) in ethical animal studies (4).  It should also be noted that the 
possibility of data integration provides the basis for combining safety pharmacology and 
adverse event data, enabling the development of toxicokinetic-toxicodynamic models and 
consequently allowing for the evaluation of exposure-response relationships in a continuous 
manner.  Such models would represent advancements in toxicology, as they provide the 
basis for mechanism-based inferences about unwanted effects, irrespective of their 
incidence or occurrence in the actual experimental protocol (4, 35). 
It is important to realise that the typical point estimates of parameters derived from 
empirical methods to describe drug exposure give an undue measure of certainty, allowing 
for the propagation of uncertainty from estimation to uncertainty in safety thresholds such 
as NOAEL.  Whilst there exist methods for estimating uncertainty in a composite or 
destructive sampling approach (76-78), their adoption in experimental research has not 
been widespread due in part to the requirement of normality assumptions on toxicokinetic 
parameters, and an acceptance in guidelines towards possibly large amounts of imprecision 
(79).   
As demonstrated here, model-based methods allow simulations to be performed in 
conjunction with estimation procedures, enabling the assessment of uncertainty associated 
with a variety of causes such as uninformative study design, large variability and/or 
unknown covariates.  This entails an increase in the quality of the decision-making process 
and ultimately in the interpretation of the estimated safety thresholds (39). 
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Given the success of PKPD modelling to aid in drug development (40-42), some attention 
must be paid to why the field of toxicology has yet to embrace it.  There is sometimes 
scepticism of model based approach from a view they require knowing the model in advance 
(80).  This argumentation is however flawed.  The inference principles used for hypothesis 
generation and characterisation of PKPD relationships relies on the use of statistical criteria 
that are sophisticated enough to allow model identification and its suitability for subsequent 
parameter estimation purposes, irrespective of amounts of data available.  Moreover, it 
should be noted that non-compartmental methods also make implicit assumptions about 
the underlying concentration vs. time profile.  For instance, with a linear-logarithmic analysis 
of AUC, first-order elimination kinetics is assumed.  The suitability of measures of central 
tendency will also depend on the assumed distribution characteristics and on residual 
variability.  These assumptions are often implicit and the validity of these assumptions for 
the dataset at hand cannot be checked during the analysis.   
However, NLME is specifically intended to efficiently process sparse data.  The performance 
of the NLME-based PK exposure estimates in the composite designs is illustrative of this. 
 
Potential limitations 
In the present investigation, the impact of model misspecification in the analysis of general 
toxicity data was not investigated.  For exposure measures which have a corresponding 
estimate based on non-compartmental methods (e.g. AUC and CMAX), the impact is likely to 
be small as long as the model fit to the data is good.  This is because these exposure 
measures are highly dependent on the observations.  Therefore, accurate prediction of the 
observed profiles during model evaluation is likely to result in accurate prediction of these 
exposure variables.  Model misspecification however, may lead to significant bias when 
exposure predictions are made outside the experimental context (i.e. longer timescales or 
different dosing regimens) (44,45) .  This is a particular risk when the pharmacokinetics of 
the drug is nonlinear or shows metabolic saturation.  To mitigate such effects we 
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recommend that model selection criteria take into account not only the ability to describe 
data, but also the physiological relevance of model assumptions.  When model development 
ends in multiple competing models performing similarly with respect to the above model 
selection criteria, clear reporting of such model uncertainty is necessary.  Model averaging 
should be discouraged when predictions arising from different model differ significantly  
(64).  Finally, parameter uncertainty should be incorporated into the predictions of exposure 
to ensure accurate evaluation of risk and potential therapeutic window of the compound.  
In summary, evaluation of safety is paramount for the progression of new molecules into 
humans.  Historically, toxicology experiments have evolved based the assumption that 
experimental findings suffice to demonstrate the absence of presence of risk.  This 
assumption disregards growing evidence of bias and poor precision of the derived measures 
of exposure, which should be avoided if data are subsequently used to define safety margins 
or thresholds.  Whilst the challenges R&D faces to translate toxicity findings from animals to 
humans may remain, the use of an integrated approach to the analysis and interpretation of 
toxicokinetic data will be essential to ensure experimental data is unbiased.  Most 
importantly, it represent further adherence to the 3Rs principle, enabling significant 
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The following tables contain all SRME and CV values for all scenarios, cohorts and analysis methods. 
















1CMT SERIAL 24hr AUC 10 1 0.8066 2.787 3.993 10.74 4.15 9.824 
1CMT SERIAL 24hr AUC 10 4 1.403 2.982 5.107 9.256 4.053  10.26 
1CMT SERIAL 24hr AUC 10 12 0.784 2.822 3.055 9.367 3.948 9.826 
1CMT SERIAL 24hr AUC 30 1 0.8066 2.787 4.565 9.472 4.298 9.344 
1CMT SERIAL 24hr AUC 30 4 1.403 2.982 3.721 9.74 4.934 10.58 
1CMT SERIAL 24hr AUC 30 12 0.784 2.822 3.065 9.873 4.258 10.48 
1CMT SERIAL 24hr AUC 100 1 0.8066 2.787 4.615 9.845 3.538 9.214 
1CMT SERIAL 24hr AUC 100 4 1.403 2.982 3.02 9.474 3.939 8.846 
1CMT SERIAL 24hr AUC 100 12 0.784 2.822 4.038 9.928 3.59 10.71 
1CMT COMPOSITE 24hr AUC 10 1 0.4114 4.651 5.245 13.41 4.815 12.93 
1CMT COMPOSITE 24hr AUC 10 4 0.6365 4.324 5.634 12.73 3.838 13.51 
1CMT COMPOSITE 24hr AUC 10 12 1.115 4.373 3.815 13.17 4.564 12.98 
1CMT COMPOSITE 24hr AUC 30 1 0.4114 4.651 6.231 12.56 4.027 13.28 
1CMT COMPOSITE 24hr AUC 30 4 0.6365 4.324 5.212 12.68 4.35 12.98 
1CMT COMPOSITE 24hr AUC 30 12 1.115 4.373 3.564 13.24 4.632 12.19 
1CMT COMPOSITE 24hr AUC 100 1 0.4114 4.651 5.29 12.85 4.466 13.68 
1CMT COMPOSITE 24hr AUC 100 4 0.6365 4.324 4.209 12.18 3.833 13.03 
















SRME% :  
NCA-
GEOMEAN 
CV% :  
NCA -GEOMEAN 
1CMT+MM SERIAL 24hr AUC 10 1 3.454 3.152 4.042 9.245 4.066 9.429 
1CMT+MM SERIAL 24hr AUC 10 4 3.177 3.255 3.784 9.352 5.347 8.897 
1CMT+MM SERIAL 24hr AUC 10 12 3.457 3.167 4.354 9.667 3.889 9.966 
1CMT+MM SERIAL 24hr AUC 30 1 3.165 3.309 3.883 10.35 3.277 9.953 
1CMT+MM SERIAL 24hr AUC 30 4 3.416 3.281 4.477 10.15 3.199 10.62 
1CMT+MM SERIAL 24hr AUC 30 12 3.572 3.226 3.282 11.27 4.358 9.756 
1CMT+MM SERIAL 24hr AUC 100 1 2.993 3.069 4.03 9.883 3.608 10.66 
1CMT+MM SERIAL 24hr AUC 100 4 3.369 3.37 4.945 9.871 3.363 9.435 
1CMT+MM SERIAL 24hr AUC 100 12 3.459 3.024 3.657 9.409 5.191 9.725 
1CMT+MM COMPOSITE 24hr AUC 10 1 3.176 4.932 3.502 12.07 5.057 13.09 
1CMT+MM COMPOSITE 24hr AUC 10 4 3.192 4.768 3.777 12.38 4.02 12.54 
1CMT+MM COMPOSITE 24hr AUC 10 12 3.399 4.88 3.864 13.15 4.442 12.16 
1CMT+MM COMPOSITE 24hr AUC 30 1 4.214 5.316 3.68 13.83 3.438 12.73 
1CMT+MM COMPOSITE 24hr AUC 30 4 3.262 5.196 5.853 12.8 4.427 12.42 
1CMT+MM COMPOSITE 24hr AUC 30 12 3.496 5.407 3.888 13.18 7.559 13.46 
1CMT+MM COMPOSITE 24hr AUC 100 1 3.868 5.214 4.33 12.11 3.738 13.41 
1CMT+MM COMPOSITE 24hr AUC 100 4 3.502 4.82 5.149 13.12 2.725 13.61 


















CV% :  
NCA-
GEOMEAN 
2CMT SERIAL 24hr AUC 10 1 0.5484 2.819 3.009 10.21 4.508 9.854 
2CMT SERIAL 24hr AUC 10 4 0.8587 3.256 4.84 10.01 5.346 9.577 
2CMT SERIAL 24hr AUC 10 12 0.5528 2.943 3.429 9.583 3.767 10.48 
2CMT SERIAL 24hr AUC 30 1 0.5484 2.819 4.379 10.31 3.721 9.561 
2CMT SERIAL 24hr AUC 30 4 0.8587 3.256 3.079 10.8 3.865 9.479 
2CMT SERIAL 24hr AUC 30 12 0.5528 2.943 3.966 10.32 4.311 9.826 
2CMT SERIAL 24hr AUC 100 1 0.5484 2.819 4.732 10.38 3.649 10.28 
2CMT SERIAL 24hr AUC 100 4 0.8587 3.256 2.261 9.635 3.11 9.859 
2CMT SERIAL 24hr AUC 100 12 0.5528 2.943 4.047 10.43 3.432 9.983 
2CMT COMPOSITE 24hr AUC 10 1 0.6988 4.286 2.96 13.31 4.885 13.99 
2CMT COMPOSITE 24hr AUC 10 4 0.8458 4.847 5.062 12.59 6.413 12.44 
2CMT COMPOSITE 24hr AUC 10 12 0.5273 4.514 5.177 12.45 4.647 13.75 
2CMT COMPOSITE 24hr AUC 30 1 0.6988 4.286 4.258 13.9 4.463 12.16 
2CMT COMPOSITE 24hr AUC 30 4 0.8458 4.847 3.757 12.9 2.889 14.08 
2CMT COMPOSITE 24hr AUC 30 12 0.5273 4.514 4.381 12.81 4.018 12.59 
2CMT COMPOSITE 24hr AUC 100 1 0.6988 4.286 5.057 13.23 3.703 13.07 
2CMT COMPOSITE 24hr AUC 100 4 0.8458 4.847 3.908 14.25 6.301 13.07 



















CV% :  
NCA-
GEOMEAN 
1CMT SERIAL 24hr CMAX 10 1 0.7306 2.899 11.54 9.945 10.8 9.747 
1CMT SERIAL 24hr CMAX 10 4 0.5798 2.893 10.74 9.382 11.41 10.37 
1CMT SERIAL 24hr CMAX 10 12 0.8339 3.045 11.58 10.51 10.32 9.832 
1CMT SERIAL 24hr CMAX 30 1 0.7306 2.899 11.72 8.873 11.42 9.831 
1CMT SERIAL 24hr CMAX 30 4 0.5798 2.893 10.6 9.846 12.38 10.74 
1CMT SERIAL 24hr CMAX 30 12 0.8339 3.045 9.94 10.25 11.82 10.21 
1CMT SERIAL 24hr CMAX 100 1 0.7306 2.899 11.92 8.828 11.23 10.8 
1CMT SERIAL 24hr CMAX 100 4 0.5798 2.893 11.55 10.67 12.12 9.98 
1CMT SERIAL 24hr CMAX 100 12 0.8339 3.045 12.1 10.27 11.61 9.536 
1CMT COMPOSITE 24hr CMAX 10 1 0.6322 4.557 10.61 12.68 11.85 12.11 
1CMT COMPOSITE 24hr CMAX 10 4 0.647 4.659 9.818 12.3 11.59 14.16 
1CMT COMPOSITE 24hr CMAX 10 12 0.3693 4.73 9.869 13.41 10.37 13.76 
1CMT COMPOSITE 24hr CMAX 30 1 0.6322 4.557 12.7 12.29 10.56 13.33 
1CMT COMPOSITE 24hr CMAX 30 4 0.647 4.659 12.34 12.77 11.76 13.51 
1CMT COMPOSITE 24hr CMAX 30 12 0.3693 4.73 12.21 13.67 13.15 13.48 
1CMT COMPOSITE 24hr CMAX 100 1 0.6322 4.557 12.12 12 10.8 12.03 
1CMT COMPOSITE 24hr CMAX 100 4 0.647 4.659 11.19 13.89 12.08 12.21 

















CV% :  
NCA-
GEOMEAN 
1CMT+MM SERIAL 24hr 10 4 3.916 3.461 7.387 13.15 14.32 15.12 
1CMT+MM SERIAL 24hr 10 12 1.814 2.586 15.26 6.701 11.92 8.455 
1CMT+MM SERIAL 24hr 30 1 2.997 2.533 12.89 9.863 6.667 7.948 
1CMT+MM SERIAL 24hr 30 4 2.195 3.013 11.01 12.71 13.32 8.925 
1CMT+MM SERIAL 24hr 30 12 2.997 4.675 12.79 7.512 11.2 9.27 
1CMT+MM SERIAL 24hr 100 1 2.539 2.99 9.542 6.405 4.643 10.42 
1CMT+MM SERIAL 24hr 100 4 2.236 4.535 13.72 9.105 13.44 11.59 
1CMT+MM SERIAL 24hr 100 12 3.108 3.104 8.219 10.94 16.4 9.72 
1CMT+MM COMPOSITE 24hr 10 1 4.193 3.414 22.85 17.18 12.08 13.98 
1CMT+MM COMPOSITE 24hr 10 4 3.428 6.017 13.7 14.06 13.61 14.29 
1CMT+MM COMPOSITE 24hr 10 12 3.076 4.608 14.43 17.99 13.83 15.88 
1CMT+MM COMPOSITE 24hr 30 1 3.89 4.507 16.05 12.46 17.38 18.27 
1CMT+MM COMPOSITE 24hr 30 4 2.88 3.301 17.05 12 17.62 10.72 
1CMT+MM COMPOSITE 24hr 30 12 4.101 7.039 12.73 17.45 14.67 10.93 
1CMT+MM COMPOSITE 24hr 100 1 5.108 3.725 15.38 10.59 14.11 16.02 
1CMT+MM COMPOSITE 24hr 100 4 0.8694 3.595 10.94 9.899 10.14 8.477 



















CV% :  
NCA-
GEOMEAN 
2CMT SERIAL 24hr CMAX 10 1 0.7472 3.015 10.9 10.33 12.4 9.994 
2CMT SERIAL 24hr CMAX 10 4 0.8701 2.938 11.06 10.1 11.89 9.653 
2CMT SERIAL 24hr CMAX 10 12 0.6139 2.959 11.32 10.4 10.68 10.7 
2CMT SERIAL 24hr CMAX 30 1 0.7472 3.015 11.35 9.376 10.76 10.76 
2CMT SERIAL 24hr CMAX 30 4 0.8701 2.938 11.19 10.82 10.64 9.939 
2CMT SERIAL 24hr CMAX 30 12 0.6139 2.959 11.19 9.61 11.63 9.976 
2CMT SERIAL 24hr CMAX 100 1 0.7472 3.015 10.86 8.862 11.59 9.721 
2CMT SERIAL 24hr CMAX 100 4 0.8701 2.938 11.34 9.274 10.92 9.915 
2CMT SERIAL 24hr CMAX 100 12 0.6139 2.959 10.53 10.36 10.95 10.01 
2CMT COMPOSITE 24hr CMAX 10 1 0.9441 4.693 10.16 14.9 9.881 12.51 
2CMT COMPOSITE 24hr CMAX 10 4 0.7777 4.718 10.49 12.52 11.22 12.73 
2CMT COMPOSITE 24hr CMAX 10 12 0.6393 5.002 11.36 14.06 11.31 13.68 
2CMT COMPOSITE 24hr CMAX 30 1 0.9441 4.693 11.82 14.28 13.13 12.84 
2CMT COMPOSITE 24hr CMAX 30 4 0.7777 4.718 12.67 12.09 12.69 12.89 
2CMT COMPOSITE 24hr CMAX 30 12 0.6393 5.002 11.43 13.28 11.23 12.88 
2CMT COMPOSITE 24hr CMAX 100 1 0.9441 4.693 11.76 11.98 11.6 14.2 
2CMT COMPOSITE 24hr CMAX 100 4 0.7777 4.718 12.52 13.27 12.34 11.92 

















CV% :  
NCA-
GEOMEAN 
1CMT SERIAL 24hr TAT 10 1 1.104 2.855 3.516 10.72 3.06 9.718 
1CMT SERIAL 24hr TAT 10 4 0.9731 2.95 3.725 9.746 4.782 9.684 
1CMT SERIAL 24hr TAT 10 12 0.7183 2.738 3.945 9.307 3.261 10.24 
1CMT SERIAL 24hr TAT 30 1 1.104 2.855 3.846 10.61 3.263 9.204 
1CMT SERIAL 24hr TAT 30 4 0.9731 2.95 3.112 10.22 4.793 10.36 
1CMT SERIAL 24hr TAT 30 12 0.7183 2.738 3.944 10.07 4.197 9.843 
1CMT SERIAL 24hr TAT 100 1 1.104 2.855 5.182 10.92 4.328 9.798 
1CMT SERIAL 24hr TAT 100 4 0.9731 2.95 4.906 10.05 3.802 10.18 
1CMT SERIAL 24hr TAT 100 12 0.7183 2.738 3.106 10.58 4.077 9.474 
1CMT COMPOSITE 24hr TAT 10 1 0.1905 4.511 3.011 12.53 3.635 12.95 
1CMT COMPOSITE 24hr TAT 10 4 1.022 4.251 4.875 12.75 5.447 12.87 
1CMT COMPOSITE 24hr TAT 10 12 0.1963 4.784 6.422 12.15 4.639 12.27 
1CMT COMPOSITE 24hr TAT 30 1 0.1905 4.511 2.807 13.83 4.701 13.07 
1CMT COMPOSITE 24hr TAT 30 4 1.022 4.251 6.049 12.4 2.792 13.49 
1CMT COMPOSITE 24hr TAT 30 12 0.1963 4.784 3.696 11.97 4.605 14.31 
1CMT COMPOSITE 24hr TAT 100 1 0.1905 4.511 3.725 11.97 3.86 12.92 
1CMT COMPOSITE 24hr TAT 100 4 1.022 4.251 4.092 13.38 5.199 13.95 


















CV% :  
NCA-
GEOMEAN 
1CMT+MM SERIAL 24hr TAT 10 1 3.51 2.891 3.178 10.52 5.906 9.741 
1CMT+MM SERIAL 24hr TAT 10 4 3.492 3.447 4.244 10.57 4.249 10.57 
1CMT+MM SERIAL 24hr TAT 10 12 2.956 3.273 3.632 10.48 4.573 10.21 
1CMT+MM SERIAL 24hr TAT 30 1 3.473 3.036 2.326 10.07 4.185 9.986 
1CMT+MM SERIAL 24hr TAT 30 4 3.747 3.168 4.568 10.9 3.938 10.14 
1CMT+MM SERIAL 24hr TAT 30 12 2.577 3.079 3.717 9.856 2.89 10.71 
1CMT+MM SERIAL 24hr TAT 100 1 2.873 3.179 3.713 10.02 4.367 9.592 
1CMT+MM SERIAL 24hr TAT 100 4 3.447 2.947 3.826 10.31 4.132 9.726 
1CMT+MM SERIAL 24hr TAT 100 12 3.263 3.185 3.388 10.08 3.888 10.4 
1CMT+MM COMPOSITE 24hr TAT 10 1 3.786 4.678 4.308 13.54 2.909 11.91 
1CMT+MM COMPOSITE 24hr TAT 10 4 3.544 4.288 5.699 13.18 4.995 12.28 
1CMT+MM COMPOSITE 24hr TAT 10 12 3.001 4.644 4.643 13.52 3.367 11.96 
1CMT+MM COMPOSITE 24hr TAT 30 1 3.472 4.949 2.865 14.24 5.8 12.81 
1CMT+MM COMPOSITE 24hr TAT 30 4 3.562 4.826 4.148 13.6 2.608 12.83 
1CMT+MM COMPOSITE 24hr TAT 30 12 3.763 5.2 5.31 13.39 4.779 13.14 
1CMT+MM COMPOSITE 24hr TAT 100 1 3.168 4.877 3.489 14.78 5.073 11.72 
1CMT+MM COMPOSITE 24hr TAT 100 4 3.176 5.163 3.82 13.59 5.091 13.09 


















CV% :  
NCA-
GEOMEAN 
2CMT SERIAL 24hr TAT 10 1 0.7214 3.072 5.377 10.74 4.592 10.37 
2CMT SERIAL 24hr TAT 10 4 0.5198 2.962 4.408 10.03 4.979 9.128 
2CMT SERIAL 24hr TAT 10 12 0.7113 2.8 2.965 10.73 5.301 10.43 
2CMT SERIAL 24hr TAT 30 1 0.7214 3.072 3.161 9.763 3.817 9.643 
2CMT SERIAL 24hr TAT 30 4 0.5198 2.962 3.984 9.413 4.117 9.773 
2CMT SERIAL 24hr TAT 30 12 0.7113 2.8 3.268 9.713 4.137 9.669 
2CMT SERIAL 24hr TAT 100 1 0.7214 3.072 3.36 10.37 4.292 10.07 
2CMT SERIAL 24hr TAT 100 4 0.5198 2.962 5.182 9.81 2.393 10.03 
2CMT SERIAL 24hr TAT 100 12 0.7113 2.8 3.436 10.14 3.129 9.555 
2CMT COMPOSITE 24hr TAT 10 1 0.63 4.583 4.218 11.94 3.532 13.95 
2CMT COMPOSITE 24hr TAT 10 4 0.9004 4.939 4.626 14.21 3.189 12.9 
2CMT COMPOSITE 24hr TAT 10 12 1.214 4.747 3.387 14.45 4.046 12.71 
2CMT COMPOSITE 24hr TAT 30 1 0.63 4.583 3.724 12.65 4.101 12.58 
2CMT COMPOSITE 24hr TAT 30 4 0.9004 4.939 5.745 12.5 5.615 13.23 
2CMT COMPOSITE 24hr TAT 30 12 1.214 4.747 4.28 12.28 4.449 13.19 
2CMT COMPOSITE 24hr TAT 100 1 0.63 4.583 3.513 12.72 5.004 11.98 
2CMT COMPOSITE 24hr TAT 100 4 0.9004 4.939 4.212 11.98 4.553 12.29 









1CMT SERIAL 6 mth CMAX 10 1 0.3527 2.86 
1CMT SERIAL 6 mth CMAX 10 4 0.4266 3.159 
1CMT SERIAL 6 mth CMAX 10 12 0.5896 3.19 
1CMT SERIAL 6 mth CMAX 30 1 0.3527 2.86 
1CMT SERIAL 6 mth CMAX 30 4 0.4266 3.159 
1CMT SERIAL 6 mth CMAX 30 12 0.5896 3.19 
1CMT SERIAL 6 mth CMAX 100 1 0.3527 2.86 
1CMT SERIAL 6 mth CMAX 100 4 0.4266 3.159 
1CMT SERIAL 6 mth CMAX 100 12 0.5896 3.19 
1CMT SERIAL 6 mth cum.AUC 10 1 0.6984 2.862 
1CMT SERIAL 6 mth cum.AUC 10 4 0.7434 3.223 
1CMT SERIAL 6 mth cum.AUC 10 12 0.8577 3.317 
1CMT SERIAL 6 mth cum.AUC 30 1 0.6984 2.862 
1CMT SERIAL 6 mth cum.AUC 30 4 0.7434 3.223 
1CMT SERIAL 6 mth cum.AUC 30 12 0.8577 3.317 
1CMT SERIAL 6 mth cum.AUC 100 1 0.6984 2.862 
1CMT SERIAL 6 mth cum.AUC 100 4 0.7434 3.223 
1CMT SERIAL 6 mth cum.AUC 100 12 0.8577 3.317 
1CMT COMPOSITE 6 mth CMAX 10 1 1.031 4.775 
1CMT COMPOSITE 6 mth CMAX 10 4 0.8082 4.768 
1CMT COMPOSITE 6 mth CMAX 10 12 0.7882 4.773 
1CMT COMPOSITE 6 mth CMAX 30 1 1.031 4.775 
1CMT COMPOSITE 6 mth CMAX 30 4 0.8082 4.768 
1CMT COMPOSITE 6 mth CMAX 30 12 0.7882 4.773 
1CMT COMPOSITE 6 mth CMAX 100 1 1.031 4.775 
1CMT COMPOSITE 6 mth CMAX 100 4 0.8082 4.768 
1CMT COMPOSITE 6 mth CMAX 100 12 0.7882 4.773 
1CMT COMPOSITE 6 mth cum.AUC 10 1 0.1272 4.794 
1CMT COMPOSITE 6 mth cum.AUC 10 4 0.808 4.862 
1CMT COMPOSITE 6 mth cum.AUC 10 12 0.7279 4.937 
1CMT COMPOSITE 6 mth cum.AUC 30 1 0.1272 4.794 
1CMT COMPOSITE 6 mth cum.AUC 30 4 0.808 4.862 
1CMT COMPOSITE 6 mth cum.AUC 30 12 0.7279 4.937 
1CMT COMPOSITE 6 mth cum.AUC 100 1 0.1272 4.794 
1CMT COMPOSITE 6 mth cum.AUC 100 4 0.808 4.862 












1CMT+MM SERIAL 6 mth CMAX 10 1 12.84 2.748 
1CMT+MM SERIAL 6 mth CMAX 10 4 12.57 2.88 
1CMT+MM SERIAL 6 mth CMAX 10 12 13.02 3.121 
1CMT+MM SERIAL 6 mth CMAX 30 1 12.78 3.111 
1CMT+MM SERIAL 6 mth CMAX 30 4 13.11 3.019 
1CMT+MM SERIAL 6 mth CMAX 30 12 12.6 3.09 
1CMT+MM SERIAL 6 mth CMAX 100 1 12.62 3.252 
1CMT+MM SERIAL 6 mth CMAX 100 4 13.14 2.978 
1CMT+MM SERIAL 6 mth CMAX 100 12 13.02 3.437 
1CMT+MM SERIAL 6 mth cum.AUC 10 1 3.455 3.015 
1CMT+MM SERIAL 6 mth cum.AUC 10 4 3.266 3.138 
1CMT+MM SERIAL 6 mth cum.AUC 10 12 3.178 3.18 
1CMT+MM SERIAL 6 mth cum.AUC 30 1 3.387 3.581 
1CMT+MM SERIAL 6 mth cum.AUC 30 4 3.396 3.254 
1CMT+MM SERIAL 6 mth cum.AUC 30 12 2.9 3.18 
1CMT+MM SERIAL 6 mth cum.AUC 100 1 3.306 3.238 
1CMT+MM SERIAL 6 mth cum.AUC 100 4 3.021 3.041 
1CMT+MM SERIAL 6 mth cum.AUC 100 12 2.919 3.32 
1CMT+MM COMPOSITE 6 mth CMAX 10 1 12.83 5.214 
1CMT+MM COMPOSITE 6 mth CMAX 10 4 13.02 5.138 
1CMT+MM COMPOSITE 6 mth CMAX 10 12 12.93 5.137 
1CMT+MM COMPOSITE 6 mth CMAX 30 1 12.9 5.171 
1CMT+MM COMPOSITE 6 mth CMAX 30 4 13.25 4.735 
1CMT+MM COMPOSITE 6 mth CMAX 30 12 12.7 5.002 
1CMT+MM COMPOSITE 6 mth CMAX 100 1 12.74 5.135 
1CMT+MM COMPOSITE 6 mth CMAX 100 4 12.55 4.757 
1CMT+MM COMPOSITE 6 mth CMAX 100 12 12.34 4.913 
1CMT+MM COMPOSITE 6 mth cum.AUC 10 1 3.005 4.78 
1CMT+MM COMPOSITE 6 mth cum.AUC 10 4 3.895 4.873 
1CMT+MM COMPOSITE 6 mth cum.AUC 10 12 3.81 5.018 
1CMT+MM COMPOSITE 6 mth cum.AUC 30 1 3.572 4.78 
1CMT+MM COMPOSITE 6 mth cum.AUC 30 4 3.798 5.084 
1CMT+MM COMPOSITE 6 mth cum.AUC 30 12 3.044 4.721 
1CMT+MM COMPOSITE 6 mth cum.AUC 100 1 3.439 4.822 
1CMT+MM COMPOSITE 6 mth cum.AUC 100 4 3.656 5.019 
1CMT+MM COMPOSITE 6 mth cum.AUC 100 12 3.076 5.491 
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2CMT SERIAL 6 mth CMAX 10 1 0.6298 2.803 
2CMT SERIAL 6 mth CMAX 10 4 1.158 3.014 
2CMT SERIAL 6 mth CMAX 10 12 0.6211 3.021 
2CMT SERIAL 6 mth CMAX 30 1 0.6298 2.803 
2CMT SERIAL 6 mth CMAX 30 4 1.158 3.014 
2CMT SERIAL 6 mth CMAX 30 12 0.6211 3.021 
2CMT SERIAL 6 mth CMAX 100 1 0.6298 2.803 
2CMT SERIAL 6 mth CMAX 100 4 1.158 3.014 
2CMT SERIAL 6 mth CMAX 100 12 0.6211 3.021 
2CMT SERIAL 6 mth cum.AUC 10 1 0.3169 2.891 
2CMT SERIAL 6 mth cum.AUC 10 4 0.811 3.139 
2CMT SERIAL 6 mth cum.AUC 10 12 0.6379 2.703 
2CMT SERIAL 6 mth cum.AUC 30 1 0.3169 2.891 
2CMT SERIAL 6 mth cum.AUC 30 4 0.811 3.139 
2CMT SERIAL 6 mth cum.AUC 30 12 0.6379 2.703 
2CMT SERIAL 6 mth cum.AUC 100 1 0.3169 2.891 
2CMT SERIAL 6 mth cum.AUC 100 4 0.811 3.139 
2CMT SERIAL 6 mth cum.AUC 100 12 0.6379 2.703 
2CMT COMPOSITE 6 mth CMAX 10 1 0.611 4.481 
2CMT COMPOSITE 6 mth CMAX 10 4 0.4159 4.665 
2CMT COMPOSITE 6 mth CMAX 10 12 0.8378 4.972 
2CMT COMPOSITE 6 mth CMAX 30 1 0.611 4.481 
2CMT COMPOSITE 6 mth CMAX 30 4 0.4159 4.665 
2CMT COMPOSITE 6 mth CMAX 30 12 0.8378 4.972 
2CMT COMPOSITE 6 mth CMAX 100 1 0.611 4.481 
2CMT COMPOSITE 6 mth CMAX 100 4 0.4159 4.665 
2CMT COMPOSITE 6 mth CMAX 100 12 0.8378 4.972 
2CMT COMPOSITE 6 mth cum.AUC 10 1 0.9684 4.76 
2CMT COMPOSITE 6 mth cum.AUC 10 4 1.059 4.849 
2CMT COMPOSITE 6 mth cum.AUC 10 12 0.6126 4.281 
2CMT COMPOSITE 6 mth cum.AUC 30 1 0.9684 4.76 
2CMT COMPOSITE 6 mth cum.AUC 30 4 1.059 4.849 
2CMT COMPOSITE 6 mth cum.AUC 30 12 0.6126 4.281 
2CMT COMPOSITE 6 mth cum.AUC 100 1 0.9684 4.76 
2CMT COMPOSITE 6 mth cum.AUC 100 4 1.059 4.849 
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Abstract 
Purpose: In toxicology experiments measures of drug exposure are calculated using non-
compartmental methods, despite evidence that population pharmacokinetic (PK) modelling 
can provide accurate estimates of the parameters of interest.  Here we explore the utility of 
optimised protocol design and PK modelling on the precision of exposure measures for a 
variety of hypothetical compounds. 
Methods: Optimal design concepts were applied to a range of hypothetical drugs with 
different pharmacokinetic profiles.  Protocol designs were optimised both in terms of 
sampling schedule and number of animals per group.  The precision of secondary 
parameters, namely AUC and CMAX was used as target for optimization purposes.  Adequate 
precision levels were defined as expected CV% < 40%.  Absolute changes in expected 
precision of less than 10% were deemed acceptable. 
Results: Independent of differences in drug disposition, our results show that the number of 
animals used in experimental protocols can be reduced by 2/3 with acceptable loss of 
precision in AUC and CMAX estimates.  Even though some PK parameters were found to be 
imprecisely estimated when drug disposition involves more than one compartment, this 
does not significantly affect the secondary parameters describing systemic exposure, which 
showed adequate precision (all CVs  <36%). 
Conclusions: The accuracy and precision of measures of systemic exposure such as AUC and 
CMAX are essential to ensure appropriate interpretation of experimental findings and make 
inferences about safety risk in humans.  However, our analysis reveals that for composite 
methods, which are commonly used in toxicology protocols, sample size does not determine 
the precision of the pharmacokinetic parameters of interest.  Rather, it is the sampling 
scheme and dose levels which matter. In contrast to current practice, precise calculation of 
safety thresholds can be obtained with a considerable reduction in the number of animals 




Despite the evidence for important limitations in the assessment of non-clinical safety and 
toxicology, experimental protocols and data analysis have not advanced in the same way risk 
management concepts have evolved over the last decade (81). Drug exposure remains a 
proxy for risk even when other markers of safety and toxicity might be better predictors of 
adverse drug reactions (5). In fact, the establishment of safe exposure levels prior to first 
time in human studies is still one of the most important milestones in drug development 
(6,7).  Yet, the reliability of these estimates depends on the quality, accuracy and precision 
of the data obtained from preclinical toxicology experiments.  Even though statistical 
considerations are described in current guidelines, these methodological aspects appear to 
remain beyond the scope of the scientific debate on the relevance of safety thresholds.  
Undoubtedly, prediction of safety thresholds is fraught with various challenges from a 
scientific, statistical and practical perspective.  As shown in Table 1, strengths and 
weaknesses exist for the different methods currently used for the assessment of safe 
exposure, whether based on thresholds or not (8).  These challenges are often compounded 
by the restrictive nature of regulatory guidelines for the evaluation of safety pharmacology 
and toxicity.  Typically, experimental protocols for general toxicity used for defining safe 
exposure ranges in dose escalation (i.e., first-time-in-humans) studies rely on sparse 
sampling of pharmacokinetic data and other relevant safety measures.  Samples are 
collected according to a pre-defined sampling matrix with a fixed number of animals per 
time point.  Measures of drug exposure are then derived by naive pooling of the data to 
generate using composite parameters such as AUC and CMAX. Subsequently, these 
parameters are used to establish the no-adverse-event-level (NOAEL), which determines the 
maximum allowed exposure during dose escalation in clinical trials (82). 
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Table 1 Safety thresholds and prediction of risk in humans.  Reprinted with permission from Edler et 
al. (7).  
 
 Strengths Limitations and Weakness 
SAR and TTC 
• Avoids unnecessary animal testing • Assumes that structure predicts toxicity 
• Depends on current exposure estimates 
for the population 
Threshold 
• Is simple to apply and readily 
understood 
• Assumes the existence of a threshold 
• The NOAEL does not exclude biologically 
significant effects below the sensitivity 
of the test 
• The value of the NOAEL depends on 
experimental conditions such as group 
size, sensitivity of measurement of the 
adverse effect, and dose spacing. 
• Does not make full use of the dose-
response information 
• Uses default UFs 
CSAF 
modelling 
• Chemical specific data can be 
incorporated to reduce 
uncertainty 
• Depends on the validity of the 
subdivision of the 10-fold factors 
• Is a data intensive method 
Non-
threshold 
• Linear extrapolation is simple to 
apply 
• Linear extrapolation is thought to be 
highly conservative. 
• LMS cannot be validated as a model for 
low doses and extrapolation is model 
dependent 
• Differing balances between reactivity 
and repair between low and high doses 
are not accommodated. 
BMD 
• Makes full use of the dose-
response data 
• Allows confidence limits for point 
estimates 
• An optimal experimental design 
may allow reduction of the 
number of animals tested (does 
not require a large number of 
• Obtaining consensus defining a 
benchmark response level for the 
adverse effect (e.g. 5 or 10%) is difficult 
• Is not applicable to studies with few 
dose groups 
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animals per group) 
Probabilistic 
RA 
• Uncertainties associated with all 
aspects of the quantitative 
methods of the RA process can be 
taken into account 
• Appropriate chemical specific 
information can be incorporated 
to reduce uncertainty 
• Provides effect estimates at actual 
exposure levels 




• Takes all studies into account and 
not only the most sensitive one 
• Allows the prediction of a severity 
effect category at a particular 
dose (e.g. above ADI) 
• Requires toxicological judgement for the 
categorisation. 
• The interpretation of fitted model 
(different endpoints, observer variation 
etc.) is difficult 
PBTK 
• Is able to model the time course 
of the amount of the active 
compound at the target site 
• Is possible for any species and for 
different exposure (e.g. route to 
route extrapolation) and lifetime 
conditions 
• Allows extrapolation from animal 
to human without having to have 
human exposure data 
• Allows target organ dose-
response relationships to be used 
for low-dose extrapolation 
• Is a data intensive method 




Given the importance to explore pharmacologically relevant exposure levels in humans, it 
should be clear that the accuracy of such estimates can become a critical factor during the 
dose escalation.  To date, current guidelines do not describe the implications of variability or 
bias in these estimates. Yet, the NOAEL is often presented as point estimates to describe the 
population (22).  This ignores variability which can be decomposed into two parts; variability 
associated with estimation methods and biological variation in pharmacokinetics which 
arises from inter- and intra-individual differences.  Most importantly the exposure estimates 
from composite measures such as AUC do not allow accurate inferences about the 
underlying pharmacokinetic processes and individual concentration-effect relationships. 
In a previous investigation we have shown that lack of precision exists in exposure 
estimates derived from the empirical methods currently used for the estimation of 
toxicokinetic (Sahota et al, unpublished results).  One of the main problems is that drug 
exposure levels observed in satellite animals do not necessarily mirror those assigned to the 
primary treatment group, in which safety pharmacology and toxicity are evaluated.  
Evidence form long-standing pharmacokinetic research in pre-clinical species clearly shows 
that such an approach ignores important differences that may exist between the two 
experimental groups (11, 12).  It is equivalent to assuming that all animals have the same 
exposure and variability in exposure, i.e., that the underlying physiological processes do not 
vary between animals.  By contrast, the use of a model-based approach enables one to 
incorporate prior knowledge and additional data from other experiments into the analysis, 
providing accurate estimates of between- and within-subject variability.  This information is 
essential to ensure a more quantitative, unbiased evaluation of safety pharmacology and 
toxicology findings. 
Arguably, one should not consider only the implications of the statistical method for the 
analysis and interpretation of safety thresholds, but also question whether experimental 
protocols are informative enough to allow accurate estimation of the parameters of interest. 
In this context, there has been an increase in the awareness about the relevance of 
optimality concepts for the optimisation and selection of suitable protocol designs for the 
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evaluation of pharmacokinetic data in conjunction with non-linear mixed-effects modelling.  
The statistical method was first proposed by Fedorov and later adopted into the PKPD field 
(83).  The approach enables the prospective prediction of parameter precision in the 
protocol development phase using the expected fisher information matrix (FIM).  Variations 
or adaptations to the original methods have been introduced, which have enable further use 
of optimality concepts in experimental protocols involving different types of continuous, 
repeated measurements (84,85).  In addition to enhancing the informative value of 
experimental protocols, the use of optimal design has proven to be an opportunity for 
reduction in total sample size and consequently in the number of animals required for an 
experiment (86).  Of particular relevance for the evaluation of safety protocols is the 
possibility of building robust designs to prior uncertainty in pharmacokinetic parameters.  
Model uncertainty can be explored via sensitivity analysis or by of applying ED-optimality 
which assumes a prior distribution around the parameters of interest (87). 
In the current investigation, simulations are used to illustrate how a model-based approach 
can be implemented in conjunction with D-optimality software to improve the design of 
protocols for safety pharmacology and toxicology experiments.  It can be anticipated that 
improved parameter precision and accuracy will allow appropriate dose escalation with less 
uncertainty about the safety thresholds (20).  In fact, our analysis includes an evaluation of 
the sensitivity to model and parameter uncertainty (21).  Furthermore, we also show how to 
account for the principle of the 3 Rs to ensure that the optimisation procedures do not 




Currently available software programs have two major limitations for optimising general 
toxicity protocols.  The first is that optimisation is performed with respect to primary model 
parameters (e.g. CL, Vd).  This is restrictive because measures of interest in toxicology are 
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secondary parameters such AUC and CMAX.  For instance, for AUC estimation, the precision of 
KA is of little importance.  Similarly, for most drugs, precise estimation of CMAX will not 
depend on the precision of CL and peripheral compartment parameters.  An optimisation 
routine that optimises over all parameters may not be suitable either. Ideally, it would be 
useful to reparameterise the model so that derived measures of exposure are treated as 
optimisation variables, but this is not always possible as there may be no closed form 
solution relating primary and secondary model parameters. 
The second problem arises from the tendency of software to only provide optimal solutions.  
In practice there are many other factors to consider (e.g. logistical, ethical, financial, and/or 
minimal false positive rate) which can be difficult to account for within the optimisation 
options in a software program.  For example, there may be suboptimal designs (in terms of 
expected parameter precision) that are much more cost effective or ethical.  It is therefore 
important to be able to explore the space of candidate study designs achieving a desired 
level of precision. 
To address the aforementioned problems we proposed to use a simulation-re-estimation 
approach to study design.  However, this is computationally intensive and can quickly 
become unfeasible when applied to variety of candidate designs and proposal models.  For 
this reason, here we employ a hybrid approach where candidate designs are evaluated in 
PopED v. 2.10 (University of Uppsala, Sweden) and then expected primary parameter 
(co)variances are converted to secondary parameter variances using traditional PKPD 
simulation procedures, as implemented in NONMEM v.6.2 (ICON Development Solutions. 
Hanover, Maryland). 
The studies under consideration were a one week, one month, and three-month general 
toxicology protocol, in which toxicokinetic data for three different hypothetical drugs were 
evaluated.  Given the pre-defined pharmacokinetic parameters used in the simulations, the 
true exposure for each individual animal was computed using a variety of measures which 
were subsequently set as reference for further assessment of the no adverse effect level 
(NOAEL).   
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Finally, it should be noted that one of the main issues with the estimation of the NOAEL is 
that it is limited to the computed exposure at one of the pre-specified experimental doses 
(22).  Consequently, the estimated exposure at any one of the dose levels is a candidate 
threshold depending on the observed adverse events. To overcome this limitation, the 
assessment of experimental designs was primarily based on the estimates from secondary 
parameters (AUC and CMAX) across all treatment groups. In addition, our design space was 
limited to sampling schedule and number of animals per group to ensure that the NOAEL 
estimates could be obtained both by NCA and non-linear mixed effects methods.  In fact, 
only experimental designs which allowed for the analysis of the data according to both 
methods were evaluated.   
Given that in typical experimental protocols, three animals are sampled per time point for 
toxicokinetic analysis, alternative candidate designs were aimed at reducing total sample 
size, including two or even one animal per sampling time point.  These alternative designs 
represent therefore a reduction in the total number of samples and in the number of 
animals required per study.  Details of the experimental protocols, pharmacokinetic models 
and optimisation procedures are described in details in the next paragraphs. 
Experimental protocols: Three hypothetical drugs were considered to account for differences 
in disposition properties.  We assumed the availability of prior information in the form of 
single dose pharmacokinetic experiments performed across a range of doses with putative 
pharmacological activity (1, 3, and 10 mg/kg), in which 8 animals were tested per cohort.  
The toxicology protocol design was based on an initial set-up commonly used for chronic 
toxicity evaluation.  Four treatment groups (N= 8 per group) receiving oral daily doses of 
vehicle, 10, 30, and 100 mg/kg/day were tested throughout this set of virtual experiments, 
which lasted either one week, one month or three months.  Satellite groups with 3 
animals/time point were used to mimic the dosing conditions in the animals used for the 
assessment of toxicity (see Figure 1 for a simulation of typical satellite group data). This 
procedure ensures the availability of more frequent blood samples for toxicokinetics.  Blood 
sampling scheme included four occasions based on feasibility, namely days 1, 8, 25, and 89. 
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Sampling times on those days were determined by ED-optimality.  For the purposes of 
optimisation, we assumed that all three hypothetical drugs could be fitted by a one-
compartment model (model A1) and assumed a 50% CV on all parameters. This was 
intended to represent standard use of ED-optimality for the optimisation of sampling times.  
Sampling times were rounded to the nearest 15 minutes. 
Pharmacokinetic models: To ensure accurate evaluation of the impact that differences in 
drug disposition may have on the requirements for experimental design optimisation, three 
different scenarios were considered in which hypothetical drugs showing on a one-
compartment pharmacokinetics with linear and nonlinear (Michaelis-Menten) elimination as 
well as a two-compartment pharmacokinetics were tested.  Parameter values for each 
scenario are shown in Table 2.  In all scenarios, residual variability was assumed to be 15%.  
Moreover, for the purposes of this exercise, we have assumed a homogeneous population, 
avoiding the need to explore covariate relationships in any of the models. 
Optimisation criteria: See the appendix for background information on the optimality 
concepts used in this investigation.  ED-optimality can be used to incorporate parameter 
uncertainty into the optimisation process.  However, ED optimality only provides an 
assessment of expected parameter precision and provides no basis for exploration of 
suboptimal, yet sufficient designs, i.e. reduced designs.  Therefore, our decision to use the 
expected FIM explicitly for the prediction of parameter precision is motivated by a need to 
have a fast, reliable and flexible method to assess and optimise experimental designs for a 
model-based analysis whilst adhering to the principle of the 3 Rs.  The expected FIM 
provides a close approximation of expected parameter uncertainty (23,24).  In addition, we 
have favoured the practice of explicitly running the optimisation at different perturbations in 
model parameters (Table 3). Model parameters were changed in the three PK models tested 
(one compartment with linear and nonlinear elimination and two compartments), yielding to 





Figure 1:  Plots of simulated data for scenarios A1, B1, and C1 overlaid with population prediction 
(black line).  Top panel shows 10mg/kg dosing group using the 3 samples per time point.  Bottom 
panel shows pharmacokinetic profiles at the lower dose level (1 mg/kg) with 8 animals per cohort. 
 131 
Table 2: Parameters and corresponding between-subject variability used to characterise the 
pharmacokinetic profiles of hypothetical compounds showing one-compartment, two-compartment 
and Michaelis-Menten disposition in rats.  Doses were defined according to a general toxicology 
protocol design.  Ke: first order rate constant of elimination, Ka: first order rate constant of 
absorption V: volume of distribution, K12: hybrid constant, K21: hybrid constant; Vmax: maximum 
metabolic rate ; Km: Michaelis-Menten constant (substrate concentration corresponding to 0.5 Vmax) 
     MODEL  A: 
Parameter Value BSV (%) 
CL (ml/h) 10 20 
Ka (h-1) 14.82 50 
V (mL) 49 16 
 
     MODEL B: 
Parameter Value BSV (%) 
CL (ml/h) 10 20 
Ka (h-1) 14.82 50 
V (mL) 49 16 
K12(h-1) 2.17 16 
K21(h-1) 3.554 69 
 
     MODEL C: 
Parameter Value BSV (%) 
Vmax (mg/h) 0.3 20 
Ka (h-1) 14.82 50 
V (mL) 49 16 
Km(mg/L) 30 0 FIX 
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Table 3: Perturbations in the parameters for the three different pharmacokinetic models. CL: clearance, Ka: first order rate constant of absorption V: volume 
of distribution, Vmax: maximum metabolic rate.  
Model KA V CL Model KA V CL Model KA V VMAX 
A1 - - - B1 - - - C1 - - - 
A2 - +50% +50% B2 - +50% +50% C2 - +50% +50% 
A3 - +50% -50% B3 - +50% -50% C3 - +50% -50% 
A4 - -50% +50% B4 - -50% +50% C4 - -50% +50% 
A5 - -50% -50% B5 - -50% -50% C5 - -50% -50% 
A6 -80% +50% +50% B6 -80% +50% +50% C6 -80% +50% +50% 
A7 -80% +50% -50% B7 -80% +50% -50% C7 -80% +50% -50% 
A8 -80% -50% +50% B8 -80% -50% +50% C8 -80% -50% +50% 
A9 -80% -50% -50% B9 -80% -50% -50% C9 -80% -50% -50% 
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All evaluations were performed in PopED v.2.10 (University of Uppsala, Sweden) (88), a 
software developed in O-Matrix® (Harmonic Software Inc., Seattle, WA, USA).  Data 
manipulation and statistical and graphical summaries were performed in R 2.10.0 (26).  In 
our analysis, the expected FIM was used to compute the expected covariance matrix from 
which, the expected precision of primary pharmacokinetic parameters was quantified 
(89,90). 
The expected precision of the derived parameters of interest, namely AUC and CMAX, were 
calculated from the expected covariance matrix of primary parameters in NONMEM 6.2 
(ICON Development Solutions. Hanover, Maryland) (27).  First, 1000 pharmacokinetic 
profiles were simulated from the primary parameters uncertainty distributions by including 
the covariance information in the $PRIOR subroutine.  For each pharmacokinetic profile, the 
AUC and CMAX were calculated as follows: 
AUC = W  !!"#  
CMAX = max	('(():  − 24 < ( < .) 
where individual predicted drug concentrations are denoted by (). 
The expected precision (standard error) of the parameters was then summarised.  Adequate 
precision was defined as expected CV% < 40%.  Absolute changes in expected precision of 




Our analysis shows that optimal design concepts can be used in toxicology research to 
improve the precision of the parameters of interest whilst allowing for a reduction in the 
total number of animals required per experiment.  As shown in figure 1, plots of the 
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simulated profiles for a typical individual together with simulated samples, representing 
“observed” data are depicted to illustrate the impact of different disposition characteristics 
on the concentration vs. time profiles.  
The optimised sampling times for all scenarios were 0.25, 0.5,0.75, 1, 1.5, 2, 8 and 24 hours 
after dosing.  Results show that for all designs the precision of AUC and CMAX associated with 
a reduced sample size of 2/3 from the initial sample size resulted in an acceptable loss of 
precision (the absolute difference in expected precision was <10% for all scenarios for 
sample size reduction of 2/3).  Therefore, optimised protocols result in a reduction of up to 
2/3 in the number of animals utilised in toxicokinetic experiments. 
An overview of the point estimates and coefficient of variation (CV%) obtained for AUC and 
CMAX is presented in Table 5.  The differences in parameter precision associated with varying 
sample size, including the NOAEL, is summarised for each model in Figures 2, 3 and 4).  We 
show how precision changes when one or two animals are sampled at each time point 
instead of using 3 animals per sampling time point. Interestingly, the expected precision was 
very high for the one-compartmental model but there was less precision for the two-
compartmental model, where a distribution phase is evident.  In addition, our analysis 
reveals that metabolic saturation, as described by Michaelis-Menten kinetics does not 
further affect the precision of parameter estimates.  Further assessment of the precision of 
the primary parameters indicates that the parameters governing peripheral compartment 
distribution will be the least precisely estimated, with a loss of precision as high as 75% for 
some parameter perturbations.  Between-subject variability was also found to be 
imprecisely estimated and would have to be fixed to 0 for some parameters during data 













Figure 2. Bar charts of CVs of selected parameters for models A.x, where x range from 1-9 and is indicated on the x-axis.  The y-axis shows expected 
precision of the various scenarios. 
 












Figure 3. Bar charts of CVs of selected parameters for models B.x, where x range from 1-9 and is indicated on the x-axis.  The y-axis shows expected 
precision of the various scenarios. 
 
 
1 animal per sample point 3 animals per sample 2 animals per sample point2 
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Figure 4. Bar charts of CVs of selected parameters for models C.x, where x range from 1-9 and is indicated on the x-axis.  The y-axis shows expected 




Experimental protocols based on repeated-dose treatment arms are essential for accurate 
inferences about the risk associated with the exposure to new chemical entities in the early 
phase of clinical development.  These studies provide the basis for the calculation of safety 
thresholds such as the no-observed-adverse-effect level (NOAEL) or lowest-observed-
adverse-effect level (LOAEL), which are used to extrapolate the concentration or exposure 
above which adverse effects can be expected in humans (82,91).  
Despite the efforts and attention given to different methodologies for the estimation of such 
safety thresholds, it is now acknowledged that the use of NOAEL or LOAEL as traditional 
thresholds or point of departure for risk assessment has significant limitations.  The NOAEL 
and LOAEL are determined by the selected dose levels and intervals used in an experimental 
protocol. 
To date, these measures remain a requirement for regulatory purposes (2).  However, there 
is a wide consensus that they do not mathematically relate to the underlying exposure-
response curve (92).  In addition, it has been shown that differences in protocol design can 
influence the precision and accuracy of the parameters of interest, yielding biased NOAEL 
and LOAEL estimates.  In fact, the bench mark dose (BMD) as the threshold or point of 
departure has been proposed as an alternative method to avoid many of these pitfalls (41).  
Unfortunately, similar challenges exist with regard to the accuracy and precision of 
estimates obtained by the BMD (18,93).  The experimental data are not integrated nor 
parameterised in a mechanistic manner so as to benefit from the advantages of a model-
based approach.  
Whilst risk assessment methods need undoubtedly to incorporate mechanistic aspects of 
drug action to ensure better characterisation of potential hazards to humans, it should be 
noted that improvements are also required from a statistical perspective.  Thus far 
empiricism and regulatory-related issues have dominated traditional toxicological testing 
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paradigms (32-35).  Minimal efforts have been made to introduce optimality concepts in 
experimental design as a means to increase accuracy and precision of the parameters of 
interest.  
In this investigation we have attempted to show the feasibility of implementing a model-
based approach in conjunction with optimal design based on techniques, which have been 
developed for the field of pharmacokinetics for more than two decades ago (13,36,37).  By 
considering a number of hypothetical scenarios in which drugs with different disposition 
properties were simulated, we have demonstrated that accurate estimates of AUC and CMAX 
can be obtained for drugs showing different pharmacokinetic profiles.  Our results also 
highlight the impact of optimisation procedures on the estimation of secondary parameters.  
We have shown that even when precision of the primary pharmacokinetic parameter is 
poor, as in the case of parameters governing distribution into peripheral compartments, the 
precision of the secondary parameters remains unaffected.  This can be attributed to the 
fact that the selected candidate designs systematically yield estimates of clearance and 
volume of distribution with acceptable precision.  These two parameters ultimately 
determine systemic exposure and peak concentrations, respectively.  
Although it may seem a disadvantage to use model-dependent estimates for the assessment 
of safety thresholds, this approach presents various important advantages (38-39). First, it is 
unbiased and predictive, allowing for the incorporation of the physiological factors 
underlying the pharmacokinetic properties of the drug under investigation.  Moreover, it 
enables ne to integrate prior information, including data from other experiments.  We 
anticipate that many areas in toxicology research which can benefit from such an approach.  
New methodology does not necessarily mean that human safety will be placed at risk.  On 
the contrary, newer methods provide an opportunity to remove much of the guess work 
involved with older methodologies, which rely on assumptions which clearly prevent the 





In assessing and optimising the protocol we found that existing routines in optimality 
software were insufficient to meet our assessment criteria.  In particular, existing software 
did not enable the assessment and optimisation over arbitrary secondary parameters, and 
did not allow for the impact of parameter perturbations on expected precision to be 
assessed.  The alternative brute force approach to account for these limitations would have 
been to perform multiple simulation-re-estimation procedures across our design and model 
space.  However, this would have involved extensive computation times.  Our approach 
instead consisted of FIM evaluations followed by calculation of the expected secondary 
parameter precision.  This exercise ultimately showed that optimisation can be performed 
on secondary parameters of interest, and minimally sufficient designs can be obtained.  Both 
of these procedures are computationally inexpensive.  Our approach therefore enables 
exploration of large design and model spaces without the aforementioned limitations in 
current optimality software.  
Limitations 
Our work does involve a number of assumptions, which may represent potential theoretical 
and practical limitations.  First, it should be noted that we have constrained ourselves to 
candidate designs that enable estimation of exposure using non-compartmental methods for 
each treatment group.  Further gains in terms of reduced burden and/or parameter 
precision are likely to be achieved if a model-based analysis was the only intended analysis 
of the data.  
Another requirement is the availability of a well-defined population pharmacokinetic model, 
which is feasible, but in practice not used in routine pre-clinical research.  It should be clear 
that the computation of expected (co)variance by means of the FIM, cannot directly account 
for the possibility of unidentifiably of parameters.  Hence, the validity of any optimisation 
procedures implies accurate knowledge of the pharmacokinetic properties and 
corresponding parameterisation.  Parameter unidentifiability will likely manifest in terms of 
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large standard errors, high correlations in the correlations and/or large differences in 
eigenvalues.  On the other hand, optimal design does tackle another common issue 
observed during data fitting and parameter estimation, i.e., numerical unidentifiability, 
which may be caused by poor experimental design. 
An additional assumption is that parameter estimates will be unbiased. This assumption may 
not hold true for more complex models, but the reader should be aware that this issue may 
be equally important when non-compartmental methods are used to describe complex 
pharmacokinetic profiles, as for instance in the case of metabolic inhibition or drugs with 
long elimination half-life (40).  To ensure further characterisation of bias, a full bootstrap 
(simulation-re-estimation) procedure is recommended.  Lastly, one should realise the 
implications of our own objectives, i.e., to compare designs which are suitable for both non-
compartmental and model-based methods.  Further gains in terms of reduced burden 
and/or parameter precision are likely to be achieved if a model-based analysis was the only 
intended analysis of the data.  
In summary, it can be concluded that despite the biological debate about the relevance of 
safety thresholds, the accuracy and precision of estimates are essential to ensure 
appropriate interpretation of experimental findings and make inferences about risk in 
humans.  We have shown that the use of a model-based approach is critical for appropriate 
data integration and informative value of experimental protocols.  Our work also 
demonstrates that population size is not the critical variable when evaluating precision and 
accuracy of the parameters of interest.  This feature allows for comparable results to be 
obtained with considerable lower number of animals and consequently reduction in the cost 
of experiments.  Overall, these results make the need to explore the requirements for 
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In an optimal design exercise, design variables are variables that describe properties of the 
biological system, drug or experimental protocol which can be changed to explore their 
impact on the information contents of the experiment.  Typically these include dose, 
sampling scheme, number of samples, number of individuals or other covariates (94). Even 
though the number of animals is constrained (88), the main use of this technique is to 
optimise sampling times.  It has been shown that sample times can have significant influence 
in the accuracy and precision of parameters (95,96). By optimising sampling times it is 
possible therefore to improve the overall efficiency of PK experiments (96,97). 
Here we summarise the statistical framework for the evaluation and optimisation of 
experimental designs using D-optimality.  There are various software programs for optimal 
design, making them equally suitable for the purposes of this type of analysis. They differ 
primarily in the features available for optimisation and in the optimisation method.  
 
Statistical summary 
There are various numerical methods to fit a model to data. The mostly commonly used is 
the maximum likelihood (ML) estimator.  The maximum likelihood is calculated by 
maximising the following likelihood function (L):  
X() = R(Y|) 
where θ is the vector of parameters, D is the data. The results of a maximum likelihood 
estimation are [, the maximum likelihood estimate and cov([), the covariance matrix 
determining the parameter precision.  The information contents within the study data, D is 
what determines cov([).  Prior to running the experiment, assuming the availability of a 
model, it is possible to compute an expected covariance matrix by the use of the Cramer-Rao 
inequality: 
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\>]([) ≥ 1_`B([) 
where the Fisher Information Matrix (FIM) is given by  
_`B[ = D ab cc X()de b cc X()df 
 
Although this function constrains the lower bound of cov([), in practice such a lower bound 
is reached as indicated by comparisons with bootstrapped expected covariance estimates 
(98,99). Thus, by computing the FIM of a given design, under the assumption of no or minor 
model and parameter misspecification, one can estimate the covariance matrix and 
consequently assess parameter precision values.  By maximising the determinant of the FIM 
over design variables, such, as for instance the sampling schedule, it is possible to identify 
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Abstract 
Purpose: Toxicology assessment relies on the evidence of a direct relationship between 
observed systemic exposure and adverse events.  This empirical approach prevents the 
identification and the use of suitable biomarkers associated with the underlying 
pharmacodynamic processes, which ultimately determine delayed toxicity.  The objective of 
this investigation was therefore to explore the feasibility of applying a model-based 
approach to characterise the PKPD correlations and the time course of biomarker responses 
associated with long-term safety as compared to standard non-compartmental methods. 
Methods: A hypothetical toxicology protocol was designed by simulating the 
pharmacokinetics and pharmacodynamics (biomarkers responses) of four different drugs, 
each with a different mechanism of delayed toxicity.  The mechanisms of delayed toxicity 
were: i) indirect response mechanism, ii) indirect response mechanism preceded by 
biophase equilibration, iii) cumulative effects of chronic dosing and iv) formation of a toxic 
metabolite.  In the simulations data were sampled according to standard experimental 
designs.  Data for each drug were then analysed using non-compartmental methods and by 
nonlinear mixed effects modelling, as implemented in NONMEM v7.1.  Given the often 
unknown mechanism of toxicity, a variety of models was evaluated to explore model 
misspecification.  Finally, bias and precision of parameter estimates were compared for each 
method. 
Results: The true underlying model was often unidentifiable.  However, model 
approximations were identified for each scenario with satisfactory performance.  NCA-
derived estimates showed more bias and less precision for all methods in all scenarios.  The 
relative errors were smaller for parameter estimates obtained by data fitting.   
Conclusions: Integration of toxicokinetic and biomarker data is essential for the evaluation 
of long-term safety and toxicity.  Despite issues due experimental protocol design, the use of 
a model-based approach enables the assessment of putative mechanisms of toxicity.  
Traditional techniques, such as non-compartmental methods are unsuitable for the 




Understanding of toxicokinetics during the evaluation of safety pharmacology and 
nonclinical toxicity has been considered essential for accurate prediction of safety thresholds 
for a new chemical or biological entity (1,2) (Figure 1).  Increasingly, however, it has become 
evident that characterisation of the relationship between drug exposure, target engagement 
(i.e., activation or inhibition) and downstream biological effects associated with a given 
physiological pathway can provide further insight into the mechanisms underlying both 
expected and ‘unexpected’ toxicity.  In fact, several novel toxicity biomarkers have emerged 
as sensitive tools for detection, monitoring, quantification and prediction of organ toxicity 
(3-5) (Figure 2).  In addition, the use of a more mechanism-based approach for the 
evaluation of drug effects has allowed better interpretation of time-dependencies, which are 
often observed following chronic exposure to a drug (e.g., delayed toxicity) (6).  
Whilst the availability of tissue-specific data can provide valuable information for decision 
making during toxicological assessment (7), empirical safety thresholds based on systemic 
drug exposure continue to prevail as the mainstream approach for assessing the safety 
profile of new chemical entities, preventing wider use of biomarkers and potential 
translation of pharmacological properties of a molecule from animals to man (8,9).  These 
hurdles are perpetuated by the existing view or notion that experimental data represent the 
basis for characterising phenomena arising from causes that are unknown or uncertain, as is 
often the case in early drug development. 
Thus far, little attention has been given to the possibility of evaluating toxicity using a 
mechanism-based approach whereby adverse events are assessed from a pharmacological 
perspective.  Such an approach would allow information from putative biomarkers to be 
integrated with pharmacokinetic data to support inferences about observed and unobserved 
adverse events (10-12).  In addition, the use of modelling and simulation would provide the 
opportunity to predict sub chronic and chronic safe exposure range in humans from 
preclinical experiments as well as investigate short and long term treatment effects. 
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Figure 1 TK toxicokinetic studies in drug-development process. IND; investigational new drug 
application, NDA; new drug application. Reprinted with permission from Toxicology Letters 102-103, 


















Figure 2 Safety risk assessment based on toxicokinetics.  Target efficacy: target engagement endpoint 





One of the problems non-clinical scientists face when considering the implementation of 
alternative methodologies is,  however, the fact that pre-clinical toxicity studies are not 
designed for the assessment of concentration-effect relationships, i.e., they are aimed 
primarily at establishing a safety threshold (e.g., NOAEL) (13, 14).  A common justification for 
current experimental protocol designs is often the complexity and limited understanding of 
the biological processes involved on one hand and the challenges to obtain regulatory 
acceptance of an alternative method on the other (15).  This is further compounded by the 
shortcomings of non-compartmental data analysis methods, which are currently 
recommended for estimating and summarising measures of exposure such area under the 
concentration vs. time curve (AUC) or peak concentrations (CMAX).  These methods cannot be 
easily adapted to account for nonlinearities in the time course of drug effects, nor allow for 
extrapolation or interpolation procedures.  Such limitations pose important questions about 
the rationale and relevance of such experiments for the translation of findings across species 
and accurate inferences about the risk associated with the proposed treatment or 
intervention in humans.  
In the current investigation we explore the feasibility of using a model-based approach to 
describe time-dependent pharmacokinetic-pharmacodynamic relationships and incorporate 
biomarkers as a proxy of drug exposure in general toxicity studies.  In addition, we show how 
the accuracy and precision of experimental parameters compare when analysing data based 
on nonlinear mixed effects modelling instead of the traditional non-compartmental 
methods.  We illustrate the concepts using simulations in which hypothetical drugs with 
different pharmacological properties are tested in a variety of scenarios.  For the sake of 
simplicity, in all scenarios the biomarker is assumed to be inhibited by the active treatment. 
Although a myriad of pathological mechanisms may exist, our scenarios are limited to a few 
examples, including biophase equilibration, (re)active metabolite formation, irreversible 
binding and indirect response mechanisms, which can be easily expanded or generalised, 
enabling accurate inferences about known causes of nonlinearity and time-dependencies 





A model-based approach was used to generate drug exposure and safety biomarker data for 
five hypothetical drugs.  Experimental protocols were defined according to current 
guidelines for the evaluation of toxicity and safety pharmacology with the exception of 
additional safety biomarker data collected in parallel to the scheduled pharmacokinetic 
sampling points.  All simulations and fitting procedures described below were performed in 
NONMEM 7.1 (ICON Development Solutions. Hanover, Maryland) (16).  Data manipulation 
and statistical and graphical summaries were performed in R 3.0.0 (17).   
For the purposes of our investigation, pharmacokinetic and pharmacodynamic parameters 
were considered to accurately reflect the risk of adverse events and toxicity.  Whilst all drugs 
were assumed to have the same pharmacokinetic characteristics, different scenarios were 
used to explore five toxicodynamic mechanisms leading to biomarker inhibition.  No 
covariate relationships were included in any of the models to facilitate the interpretation 
and comparison of the results.  Data was subsequently analysed using standard non-
compartmental methods and by nonlinear mixed effects modelling.  The estimates obtained 
from these virtual experiments were then compared to the true values used initially to allow 
the assessment of bias and precision.  Methods regarding the simulation and reanalysis of 
the PK data can be found in Chapter 3 of this thesis, in which the feasibility of PK modelling 
in general toxicity study is evaluated (18). 
Experimental design: The protocol design used for each of the hypothetical drugs was based 
on an initial set-up commonly used for chronic toxicity evaluation.  Four treatment groups 
(N= 8 per group) receiving oral daily doses of vehicle, 10, 30, and 100 mg/kg/day were tested 
throughout this set of virtual experiments, which lasted either one week, one month or 
three months. Satellite groups with 24 animals each were used to mimic the dosing 
conditions in the animals used for the assessment of toxicity.  This procedure ensures the 
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availability of more frequent blood samples for toxicokinetics.  The sampling schedule 
investigated was composite sampling where blood was collected from three animals in the 
satellite group at predetermined sampling time points, namely 0.1, 0.4, 1, 1.5, 4, 8, 24 hours 
after dosing.  It was assumed that sufficient blood could be collected for plasma drug 
concentration and biomarker measurements.  The allocation of animals to each sampling 
time point was random within the constraint that all animals must be sampled an equal 
number of times. An overview of the experimental conditions is summarised in Table 1.  
Table 1: Experimental design of treatment and satellite groups in a general toxicity study with serial 










Sampling scheme Sampling  time 








3 per animal. 3 per time point 
 
Serial profiles from Day 1 only 
0.1, 0.4, 1, 1.5, 









3 per animal. 3 per time point 
 
Serial profiles from Day 1 and 12 
0.1, 0.4, 1, 1.5, 









3 per animal. 3 per time point 
 
Serial profiles from Day 1, Wk 4, 12. 
0.1, 0.4, 1, 1.5, 
4, 8, 24 hours 
after dose 
 
Pharmacokinetics: The pharmacokinetic model for all scenarios was a one-compartment 
pharmacokinetic model with first order absorption and first order elimination. This 
corresponded to Model A in Chapter 3 of this thesis (18).  Parameter values for each 





Table 2: Pharmacokinetic model used to simulate concentrations and derive measure of drug 
exposure in the experimental groups.  For the sake of simplicity, a one-compartment model 
(1 CMT) was selected for the purpose of this analysis.  Parameters reflect data previously 
reported in Chapter 3 of this thesis (18).  
Parameter Pop Estimate BSV 
KA 13.46 h-1 50% 
V 49.4 ml/kg 16% 
CL 2.72 ml/hr 20% 
 
Pharmacodynamic effects: Five hypothetical mechanisms of drug-induced toxicity were 
simulated.  Their parameterisation is summarised in Table 3. In brief, a number of scenarios 
were included, which are representative of onset and dynamics of the effect, i.e., that take 
into account the time dependencies and delays between the start of treatment, the onset, 
maintenance and waning of the pharmacodynamic effects: 1) a direct IMAX model, describing 
immediate onset of effect and direct relationship between drug exposure and biomarker 
inhibition at the target site; 2) an indirect response model, describing the presence of 
turnover mechanisms with a delayed onset of effect and disconnect between drug exposure 
and biomarker inhibition; 3) indirect response model preceded by biophase equilibration 
processes, which emphasise the role of tissue kinetics for the characterisation of 
pharmacodynamic effects; 4) a model describing the cumulative effects of chronic dosing 
regimen associated with slow-offset and irreversible binding and 5) a model describing 
delays due to metabolite formation with immediate inhibitory effects on biomarker levels. 
All scenarios were evaluated under the assumption that assay error was small in relation to 
the magnitude of the drug effects on biomarker levels. 
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Figure 3 Diagrams depict the different pharmacokinetic-pharmacodynamic models associated with 
the hypothesised pharmacological mechanisms leading to toxicity. 
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 Table 3: Simulation scenarios modelled a range of pharmacological mechanisms.  Base: baseline effect, IC50: concentration required for 50% 
inhibition of biomarker response, Kout: first order elimination of biomarker response, Kelm: first order elimination rate of metabolite, Kon: 






Rationale Modelling strategies 







- IC80 similar to Ctrough at 
lowest dosing level. 
-Normalised biomarker 
concentrations. 
1) Direct Imax 









-Fast elimination of 
biomarker 
1) Indirect 
2) Direct Imax 
3) Biophase 




1 - Ke0 selected to give 
similar biomarker levels to 
indirect response model 
1) Biophase + Indirect response 
2) Indirect response 











- 100% conversion to 
metabolite assumed.  
metabolite thh= 8h 
1) Metabolite + Imax 
2) Direct Imax 






- 24 hr turnover for 
(off)target assumed 
1) Irreversible binding 




Biomarker exposure measures:  Five different measures of biomarker exposure were used 
for calculation of the true pharmacodynamic effects, as determined by the simulated 
profiles.  These measures can be seen in Table 4 alongside their calculation method.  AOC24 
and CMIN24 are intended to mimic the AUCτ and CMAXτ exposure variables typically calculated 
for the analysis of pharmacokinetic data. They provide a measure biomarker inhibition on 
the final day of measurement (i.e., at steady state conditions).  On the other hand, time 
under threshold biomarker concentration (TUT) is a measure of time spent, on final day of 
measurement, under a clinically significant threshold.  The threshold in this case was 
0.2mg/ml, which represents 20% change from baseline and which was assumed to be 
physiologically meaningful.  Given that at three months the scenario describing slow-offset 
and irreversible binding is not at steady-steady at the end of treatment, simulations were 
performed assuming repeat dosing up to six months (three months beyond the time frames 
of the investigated studies).  This procedure was required to ensure comparability of the 
results obtained for all five mechanisms of action. 
Non-compartmental analysis: Biomarker exposures were calculated on the composite 
profile.  Two different, commonly used, averages were investigated, the arithmetic mean 
and geometric mean.  Since the standard sampling scheme is limited to a particular day 
during the course of treatment, composite profiles over six months cannot be estimated. 
Therefore, only AOC, CMIN, TUT (in Table 4) were calculated by non-compartmental analysis. 
Model-based estimates: Each simulated dataset was an integration of all pharmacokinetic 
and pharmacodynamic data for all experimental groups.  Then drug concentration and 
biomarker profiles were fitted to multiple PKPD models (as shown by the multiple modelling 
strategies in Table 3) using the FOCEI estimation method.  In Table 3, modelling strategies 
for each scenario are ordered by decreasing numbers of parameters, starting with the true 
model.  Model convergence for each modelling strategy was determined by standard 
minimisation success criteria.  Below quantification limit (BQL) data were omitted to mimic 
experimental conditions in which imputation methods are not applied.  The model-based 
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calculation of biomarker and exposures measures are summarised in Table 4.  Estimates of 
exposure were all calculated by using same methods as for the true exposure calculation but 
with the estimated model.  Overall performance of competing modelling strategies was 
assessed by convergence rate and bias/precision of exposure/biomarker level. 
Bias/precision of exposure/biomarker levels: The process of simulation and estimation of 
exposure (using non-compartmental and model-based methods) was repeated 200 times.  
Bias and precision were assessed via the scaled relative mean error (SRME) and the 
coefficient of variation (%CV), respectively.  Relative error was also calculated for graphical 
comparison. 
Table 4:  Measures of biomarker exposure obtained with the simulated and estimated models for 
calculation of the true pharmacodynamic effects 
Covariate name Symbol Model based biomarker level 
calculation 
Area above biomarker levels vs. 
time profile 
AOC24 g01(0) −  g01 !!"#  
Minimum biomarker level over 
24 hour period 
CMIN24 min	(jg01(():  − 24 < ( < k) 
Time under threshold (80% 
inhibition) 
TUT  1lm1n.lm1(;) !;  
Predicted 6-month cumulative 
area above biomarker 
concentration vs. time profile 
CAOC g01(0) ∗ 6=>?ℎ( − g01 7	89:!36;  
Predicted 6-month trough 
biomarker levels 
CMIN min	(jg01((): 0 < ( < 6	=>?ℎ(k) 




Table 5: Convergence rate of different modelling strategies (as determined by NONMEM 





As described below, the use of simulated data for the evaluation of hypothetical scenarios 
provided clear insight of the impact of current practices on the identification of putative 
mechanisms underlying the observed pharmacological effects as well as on the accuracy and 
precision of safety thresholds, and in particular of the NOAEL.  Results from modelling are 
shown together with the parameter values obtained from naïve pooling and non-
compartmental analysis where applicable.  
It is clear from the different profiles (Figure 4) that not only the dose level under 
investigation, but also the mechanism of action underlying drug toxicity, contribute to 
differences in the onset, magnitude and duration of the effects.  Moreover, these 
Simulation Scenario Modelling strategies Convergence rate (%) 
1) Direct effect  1) Direct Imax 94.2 
2) Indirect response 
1) Indirect 
2) Direct Imax 
100 
13.5 
3) Biophase equilibration + Imax 
1) Biophase + Indirect response 
2) Indirect response 




4) Metabolite formation + Imax 
1) Metabolite + Imax 
2) Direct Imax 
0 
100 
5) Irreversible binding  
1) Irreversible binding 




differences may or may not be evident depending on the dose rationale and sampling 
scheme used in the experimental protocol (Figure 5). 
Model 1 - IMAX 
 
Model 2 – Indirect response 
 
 
Model 3- Biophase + IMAX 
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Model 4: Metabolite + IMAX 
Model 5: Irreversible binding 
 
Figure 4: Full pharmacokinetic and pharmacodynamic profiles observed for each hypothetical 
mechanisms on selected sampling days. Lines represent the typical population estimates.  Dots 
represent simulated concentrations at the pre-defined sampling times.  Since all simulation scenarios 
share the same pharmacokinetics, PK is only shown for scenario 1.  
 
As can be observed from the summary of convergence rates in Table 5, the inability to 
discriminate the underlying mechanism of action based on the available experimental data 
can lead to obvious issues with model identifiability.  On the other hand, despite this 
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limitation, the large differences in convergence rate suggest that model-based estimates 
might be suitable to explore or exclude possible or plausible causes of toxicity. 
Despite variations in bias and precision between analysis methods and sampling schemes, 
parameter precision was relatively high (<30%).  This suggests that when bias is acceptable, 
reductions in numbers of animals may be possible whilst still achieving study objectives.  For 
all scenarios tested, we have assumed that the safety biomarkers levels are closely related to 
target engagement of targets relevant to downstream toxicity findings.  In other words, the 
safety biomarkers are in the causal pathway between drug exposure and manifest toxicity.  
Therefore, for all scenarios, AOC, CMIN, TOT, CAOC are expected to be more highly correlated 
with toxicity than their pharmacokinetic equivalents (AUC, CMAX, TUT and CAUC, 
respectively).  The relative relevance of AOC, CMIN, TUT and CAOC will depend on the 
downstream pathway between target engagement and toxicity finding.  For chronic enzyme 
inhibitors and receptor antagonists and/or long term toxicity, cumulative biomarker 
inhibition is likely to be more pharmacologically relevant.  For toxicity that involves 
overriding homeostatic control, TUT using a physiologically relevant threshold may be most 
relevant. 
With regard to the method of analysis, our results show that the accuracy and precision of 
model-based estimates for AOC, CMIN and TUT were similar across different dosing groups 
and treatment durations.  Non-compartmental estimates showed more bias and less 
precision in all scenarios.  In addition, relative errors were also smaller for model-based 
estimates (Figure 5).  For both model-based and compartmental methods, the coefficient of 
variation increased with composite designs (with 8 animals), as compared to serial sampling 
designs (with 3 animals).  Interestingly, the use of arithmetic and geometric means for non-
compartmental methods had minor impact on the parameter estimates.  CMIN was 




Figure 5.  Relative errors of model-based and NCA estimators of exposure obtained for the different 
models: IMAX model (a) Imax (b), indirect model (c), biophase equilibration + IMAX model (d) 
prodrug+IMAX , (e), the irreversible binding.  X-axis shows the different measures of exposure, as 
described in Table 1.  NCA estimates are repeated in each panel for comparison purposes.  For the 
sake of clarity, only data from the 30mg/kg/day following 3-month treatment are summarised. 





Any drug can produce an adverse response at therapeutic or supratherapeutic exposures.  It 
is imperative therefore to identify not only the response but also the exposure at which the 
effect is observed (19).  Yet, over the past decade, it has also become clear that detection of 
organ-specific toxicity is critical, both for improved preclinical/clinical translatability and 
accurate prediction of toxicity at early stages of development.  Despite the scientific 
rationale, few successful examples exist that demonstrate the development and consequent 
use of specific markers of organ toxicity during preclinical safety evaluation (20, 21).  The 
limited impact of biomarkers has been associated with the fact that early prediction of 
specific organ function, such as hepatic, dermal or immunologic, is not well established. With 
the possible exception of cardiac function, very few novel biomarkers have been identified 
and accepted over the past decade.  On the other hand, markers of tissue injury have been 
identified, but they are not predictive of overall organ function and often do not correlate 
with overt pathology (22).  These conclusions have been drawn without careful 
consideration of the impact current experimental protocol designs and data analysis 
methods have on the characterisation of the underlying pharmacokinetic-pharmacodynamic 
relationships.  Instead, here we have shown how a model-based approach can be used to 
integrate toxicokinetic and biomarker data for the evaluation of long-term safety and 
toxicity.  Based on a series of hypothetical drugs, simulation scenarios have been used to 
show the feasibility of introducing biomarkers as a proxy of drug exposure in general toxicity 
studies.  Furthermore, our work highlights the impact that modelling can have on the 
evaluation of exposure measures that cannot be derived from empirical protocols.   
From a conceptual perspective, the evaluation of hypothetical compounds whose 
mechanisms of action reflect nonlinearity and time-dependencies in the onset, maintenance 
and waning of drug effects also sheds light on the shortcomings of current protocols and 
data analysis methods, for which data and knowledge integration have remained marginal.  
Current mainstream research in toxicology and safety pharmacology is performed under the 
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assumption that evidence from data or lack thereof is sufficient to make inferences about 
the risk or hazard in humans.  Our approach comes from a quite different perspective, in 
that it incorporates oncoming data into a modelling framework, i.e., a mathematical 
representation of existing knowledge.  Whilst scepticism exists about the predictive 
reliability of models due to uncertainties (23), they facilitate the assessment of causation 
and provide the basis for the exploring the plausibility of alternative mechanisms or causes 
(24).  Most importantly, models when used as an ancillary tool during planning and design of 
experimental protocols can significantly increase the informative value and reduce bias. In 
fact, mechanism-based pharmacokinetic-pharmacodynamic modelling has evolved 
successfully as an important tool for the evaluation of exposure-response relationships and 
as such has represented a major contribution to the dose rationale in clinical research 
(25,26).  In conjunction with nonlinear mixed effects techniques, it has become possible to 
integrate efficacy and safety measures under the assumption that wanted and unwanted 
pharmacological activity is directly or indirectly associated with drug action on primary or 
secondary targets, rather than treating such effects by default as the result of an unknown 
off-target binding site, which is often assumed to be the cause of toxicity (27,28).  It should 
be noted, however, that thanks to the use of model parameterisation describing 
(patho)physiological phenomena in terms of zero, first and second order processes, it is 
possible to establish correlations between drug exposure, biomarkers and effects even if the 
underlying mechanisms are not fully understood. 
As indicated by the differences in convergence rate (table 5), our findings reveal that even 
with the incorporation of biomarkers, it may be sometimes impossible to identify the true 
model and consequently, characterise the true mechanism of toxicity.  Yet, despite model 
identifiability issues, these results also show the potential benefits of model parameters to 
rank compounds (e.g., by differences in potency) and quantify the effects associated with a 
given exposure or effect.  Moreover, the various scenarios can be used to elucidate how 
differences in mechanism of action may lead to biased estimation of the relationship 
between drug exposure and toxicity, as well as to inaccurate safety thresholds.  We believe, 
therefore, that greater awareness is required about the limitations of current experimental 
 170 
protocols, particularly in a period in which long-term safety have become a major clinical 
and regulatory concern (29-31).  On the other hand, model misspecification, even when 
convergence is successful, may lead to significant bias when predictions are made beyond 
the experimental context (i.e., longer timescale or different dosing regimens). To mitigate 
such effects we recommend careful consideration of model selection during model 
development and model uncertainty (32-34).  Model selection criteria should be guided not 
only by ability to describe data but also by assessing the physiological relevance of model 
assumptions.  When model development ends in multiple competing models performing 
similarly with respect to the above model selection criteria, clear reporting of such model 
uncertainty is necessary.  In any case, model averaging should be discouraged when 
predictions arising from different model differ significantly (35).  Finally, parameter 
uncertainty should be incorporated when performing simulations or using the model to 
make predictions. 
Since the model-based methods outperformed non-compartmental analysis, further 
refinement of experimental protocols can be achieved if the data are analysed using 
nonlinear mixed effects modelling.  Despite the conceptual challenges, maximum likelihood 
based model estimates, statistically speaking, are asymptotically efficient.  This means that 
model parameters extract maximum information from the dataset when compared to any 
other statistical technique. In this respect, the use of a model-based approach is not only an 
improvement on non-compartmental methods in terms bias and precision, but is optimal for 
the datasets under consideration.   
Limitations 
All scenarios depicted here corresponded to the case where substantial inhibition of a 
biomarker, relative to assay and normal physiological variability, was correlated with 
toxicity.  In the present study we focused on biological systems with built in control for 
minor fluctuations in biomarker levels so that substantial inhibition could be seen in the 
data.  An example of such a biomarker and system would be prostaglandins, which exert 
their protective role in conjunction with other mediators (36-39).  The findings presented 
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here are expected to also reflect other mechanisms such as induction or tolerance, if the 
profiles and magnitude of effect are similarly large relative to the assay error. 
We also acknowledge that detection of signals above variability may not always be possible 
due to a variety of factors, including large between or within subject variability or poor assay 
precision.  In this case non-compartmental analysis and model-based approaches will fail to 
detect systematic variations without additional information. 
Lastly, we believe that complex systems pose little problem to estimation procedures as long 
as viable simplifications are available and able to describe important trends in the data.  
Clearly, there may be instances where the biological response to drug exposure manifest in 
trends in data which cannot be described accurately by more simplistic models.  In these 
circumstances, knowledge that an experiment cannot be used to describe the underlying 
exposure-effect relationships could be invaluable as the basis for further improvement of 
experimental design in subsequent phases of drug development. 
In summary, toxicology need to evolve from a discipline largely devoted to routine 
performance and interpretation of safety tests, to a quantitative discipline in which advances 
in pharmacology and molecular biology can be applied in an integrated manner, enabling 
better understanding the nature and mechanism of adverse effects caused by chemicals.  
Model-based analysis of biomarkers and toxicokinetic data provides the basis for 
differentiating settled toxicological knowledge of risk from mere possibility, and facilitating 
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Utility of model based approaches to predict the risk of adverse 
events from preclinical toxicology protocols. 





Purpose: Current toxicity protocols use the NOAEL approach to relate observed systemic 
exposure to the observed AEs.  However, biomarker data can provide information on 
mechanisms of toxicity and historical placebo data can help distinguish non-drug induced 
AEs to ADRs.  The objective here is to determine the feasibility of model-based risk 
assessment with the aforementioned data and to compare this with the NOAEL approach. 
Methods: An in-silico approach based on simulation scenarios and nonlinear mixed effects 
models was used to generate drug-induced and background adverse events. The test species 
was rats and data was generated according to standard preclinical toxicological designs.  A 
total of six scenarios were simulated, in which reversible and irreversible drug effects were 
evaluated under the assumption of three different pharmacological mechanisms (direct, 
indirect, and irreversible binding).  Data was then analysed using standard NOAEL approach 
and by nonlinear mixed effects modelling in NONMEM 7.1 and WinBUGS 1.4.3. 
Results: Three out of six scenarios had a viable therapeutic window.  The NOAEL approach 
showed significant bias by overestimation of toxicity.  The potential impact of bias to drug 
development programs is summarised for each scenario.  Model-based approaches showed 
high convergence rates, however model identifiability prevented model discrimination 
indicating that although risk can be predicted the underlying causes of risk cannot be 
determined. 
Conclusions: Our results indicate that standard toxicology experiments are likely to provide 
enough information to detect drug related ADRs with a model based approach, but are 
unlikely to have the power to precisely indentify the mechanisms of AE formation for rare 
events.  Quantifying model uncertainty enables this uncertainty to be reported to aid project 
teams in future study planning.  A model-based approach outperforms the NOAEL 
methodology in terms bias and precision and should therefore be recommended as method 




One of the main purposes of safety pharmacology and toxicology screening is the prediction 
of risk that exposure to a new chemical or biological entity represents to humans.  A major 
challenge in this endeavour is the prediction of the safe exposure in humans based on 
preclinical experiments.  Historically, numerous approaches have been considered for the 
assessment of safety and risk, which differ in their data requirements, degree of complexity, 
their applicability in different situations and the type and quality of resulting risk estimates 
(100).  Among the accepted methods, safety thresholds have been derived under the 
assumption that there is a level of exposure below which a biologically significant effect is 
unlikely to occur, i.e., no-observed adverse- effect level (NOAEL) (2,3).  Even though 
estimation of such a threshold has little or no mechanistic basis and is greatly influenced by 
experimental design factors, it has become one of preferred methods for regulatory 
evaluation of risk.  This choice has been made irrespective of the frequency of the events of 
interest or whether the occurrence of events is delayed relative to the duration of 
treatment. In these circumstances the evidence generated from small experiments may be 
affected by censoring or other shortcomings in the experimental design (4,5).  As a 
consequence, derived measures of safe exposure may become biased and imprecise.  
By contrast, a model-based analysis rooted in statistical inference and mechanistic 
description of physiological processes can have several advantages over safety thresholds, 
but its uptake has been very limited (6).  Another important point to consider is that the 
application of pharmacokinetic-pharmacodynamic modelling and simulation concepts 
enables one to explore the relationship between drug exposure and pharmacological or 
toxicological effects in a mechanistic manner, relating experimental findings to target 
engagement (See Figure 1) (7).  By using pharmacokinetic models, factors that are known or 
expected to influence the relationship between the administered dose and the target 
exposure may be accounted for (8).  Pharmacokinetic models may also be used to optimize 
protocol design and strengthen the extraction of information from experimental results by 
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linking data obtained under different experimental conditions in a uniform model (9,10).  
Thus, modelling is often hypothesis generating and may have utility for discriminating 
between markers of exposure and markers of risk (Figure 2).  Thereby, some of the 
uncertainty factors associated with the true hazard or risk may be reduced.  Furthermore, 
specific questions on mode of action may be addressed, and these models can provide a 
stronger basis for extrapolation across species, routes of exposure, dosing patterns, and 
ultimately human risk assessment.  
 
 
Figure 1 The diagram illustrates different steps that lead to disruptions of biologic pathways: 
‘‘biologic responses are results of an intersection of exposure and biologic function. The intersection 
results in perturbation of biologic pathways. When perturbations are sufficiently large or when the 
host is unable to adapt because of underlying nutritional, genetic, disease, or life-state status, 
biological function is compromised; this leads to toxicity and disease’’. A model-based approach can 
be used to parameterised both pharmacokinetic and pharmacodynamic processes. Of particular 
interest is the evaluation of the outcome from function impairment when incidence of events is low 
or processes rate are such that the events are delayed relative to the period of intervention. (From 






Figure 2 Inferences from risk of toxicity or disease from drug exposure data. Different approaches 
can be considered in which markers of exposure are used in conjunction or independently of markers 
of risk to predict safe exposure in humans. This diagram clearly indicates the need to discriminate 
drug reactions from adverse events during drug screening and early characterisation of the safety 




Despite the aforementioned advantages, regulatory agencies still tend to favour the view 
that risk assessment should remain qualitative until important issues, primarily those related 
to quantitative decision-making concepts, have been addressed (101).  From a scientific and 
clinical perspective, the main concern, however, is the potential for overconfidence in the 
numerical answers obtained from small experiments.  At the same time, it must be 
acknowledged that characterising exposure-response relationships does face technical 
challenges when data is too uninformative (12).  One of the issues is model and parameter 
identifiability, which make the validity and reproducibility of models derived by empirical 
experimentation questionable for predictive purposes.  Another important point to consider 
is that toxicology studies are designed to show evidence for safety not for risk. 
To address the issue of uncertainty and data sparseness arising from safety pharmacology 
and toxicology screening, here we illustrate how population pharmacokinetic-
pharmacodynamic modelling can be implemented to characterise the relationship between 
drug exposure and the risk of adverse events.  The ultimate goal of our investigation is to 
demonstrate how limitations in the informative value of experimental data can be overcome 
by integrating non-linear mixed effects modelling with MCMC sampling algorithms.  An 
important advantage is that by simulating from uncertainty, one can eliminate the need for 
empirical safety factors when scaling up findings from animals to humans.  In addition, 
relevant biomarker data can be integrated into the analysis either as priors or as historical 
baseline data, allowing incorporation of pharmacodynamic processes and other covariates in 
the overall estimates of drug-induced risk (13-15).  Focus is given to the evaluation of events 
with low incidence under the assumption of different mechanisms of action for the observed 
events. For the sake of completeness, model-based estimates are subsequently compared 







A model-based approach was used to generate three month toxicokinetic data for a variety 
of hypothetical drugs.  The experimental protocols for simulation were defined according to 
current guidelines for the evaluation of toxicity and safety pharmacology with the one 
exception that data characterising a safety biomarker be collected at the scheduled 
pharmacokinetic sampling points.  Information on the occurrence of adverse events was 
assumed to be limited to terminal observations upon post-mortem examination.  Each 
simulation scenario, detailed below, was intended to detect the NOAEL in an unbiased 
manner, i.e. when the computed NOAEL was most likely to be associated with the treatment 
group receiving the lowest dose level being test0ed.  In this respect, the experimental design 
and the selection of the dose levels were such that further analysis could be performed 
using standard methods, i.e., the NOAEL approach.   
The proposed scenarios have taken into account conditions in which adverse events are rare 
or have very low incidence.  In this respect, this also represents a challenge for model-based 
analysis techniques due to low information content of the datasets.    Two different PKPD 
models were used for the simulation of pharmacokinetic and biomarker data. On the other 
hand, a variety of models were considered for the simulation of adverse events, based on 
different incidence rates and mechanisms for the onset and cessation of adverse events.  
Data was then analysed using standard NOAEL approach and by a variety of model-based 
analysis techniques.  Results were assessed for accuracy, precision and suitability for 
informed decision making.  A schematic showing the general workflow is shown in Figure 3. 
Data 
Toxicology Protocols: The experimental design of the general toxicity studies was chosen to 
mimic existing practices including treatment and satellite groups, as shown in Table 1.  
Different treatment durations were evaluated, in which four dose levels are considered 
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(vehicle, 3, 10, and 30 mg/kg/day).  The experimental protocol was based on the assumption 
that all animals are dosed daily via oral administration. Animals in the treatment groups are 
sacrificed at the end of the experiment, after the last sampling time. Satellite animals receive 
the same dose levels used in the main experimental groups.  AE information from these 
groups is not used due to the potential confounding effect of frequent blood sampling. In 
contrast to the traditional sampling schemes for pharmacokinetics, biomarkers of 
pharmacology are also sampled at pre-defined 0.1, 0.4, 1,1.5, 4, 8, 24 hours after dosing) and 
random time points so that an equal number samples are taken at each time point. 







Sampling scheme Sampling  
time 






Composite with 2 animals  per time 
point 
Serial profiles from Day 1 only 
0.1, 0.4, 1, 
1.5, 4, 8, 24 
hours after 
dose 




Composite with 2 animals  per time 
point 
Serial profiles from Day 1 and 28 
0.1, 0.4, 1, 
1.5, 4, 8, 24 
hours after 
dose 




Composite with 2 animals per time 
point on Week 4 and Week 13.  
Serial profiles from Day 1, Week 4 
and Week 13. 
0.1, 0.4, 1, 





Ancillary pharmacology protocols (PK): It was assumed that additional data was available 
from drug metabolism and pharmacokinetics studies.  Typical experimental protocols were 
assumed which provided serial blood sampling based on eight animals per dose level, which 
received a for single dose oral administration (0.3, 1, and 3 mg/kg).  Only drug 
concentrations were obtained from these animals, no biomarker concentrations. 
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Ancillary pharmacology protocols (placebo AE): Monitoring of placebo animals enables the 
assessment of non-drug induced risk. However, the quantification of rare adverse events 
requires a far larger database than general toxicity studies provide.  Therefore, it was 
assumed that historical placebo datasets were also available from acute and chronic general 
toxicity experiments consisting of 400 animals for each type of study and treatment 
duration. 
Simulation scenarios:  All simulations and fitting procedures described below were 
performed in NONMEM 7.1 (ICON Development Solutions. Hanover, Maryland ) (25). Data 
manipulation and statistical and graphical summaries were performed in R 3.0.0 (26).  We 
assumed a population with high homogeneity and therefore no covariate relationships were 
included in any of the models. 200 simulated datasets were produced per scenario. 
Simulation of PK data: The pharmacokinetic model for all scenarios was a one-compartment 
pharmacokinetic model with first order absorption and first order elimination.  Parameter 
values for each scenario shown in Table 2.  Residual variability for PK observations was 
assumed to be 15%.  
Table 2: Pharmacokinetic model used to simulate concentrations and derive measure of drug 
exposure in the experimental groups.  For the sake of simplicity, a one-compartment model (1 CMT) 
was selected for the purpose of this analysis. 
Parameter Pop Estimate BSV 
KA 13.46 h-1 50% 
V 49.4 ml/kg 16% 
CL 2.72 ml/hr 20% 
 
Simulation of biomarker data: Two different pharmacodynamic models were investigated 
which related drug concentration to safety biomarker to risk of adverse events.  A schematic 
diagram of the two models is shown in Figure 4.  The rationale was to see how both 
empirical and model-based methodologies performed when time dependencies exist, i.e., 
the onset of the adverse events is delayed with regard to the start of treatment.  The first 
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model was an indirect response model where the biomarker was assumed to be directly 
related to risk of adverse events.  The second was an irreversible binding model where the 









Figure 3 Schematic representation of the simulations performed for the evaluation and comparison 
of model-based vs. standard approach. 
 
Simulation of adverse event data: In total, six scenarios were investigated (Table 3). All 
adverse events were modelled as a two state continuous time Markov process, in which a 
state 0 corresponds to health and a state 1 corresponds to the presence of toxicity.  This 
assumption provided for simulated data yielding low information for subsequent model-
based analyses. For both hypothetical mechanisms, multiple Markov models were used to 
define different types of adverse events.  These adverse events were classified into 
reversible and irreversible.  Irreversible adverse events were events for which the remission 
rate was set to zero.  On the other hand, reversible adverse events always maintained a non-
zero probably of spontaneous remission.  The irreversible adverse event scenarios also 
happen to reflect a reversible event with left censored observation time, e.g. where 
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histological examination provides evidence of incidence (e.g. scarred tissue).  For all adverse 
events, it was assumed that symptoms and signs could only be detected at the end of the 
study duration.  This further challenges a model-based approach to analyse the data without 
compromising the standard methods. 
Indirect 
 
Cumulative effect (irreversible binding) 
 
Figure 4 Diagrams depict the different pharmacokinetic-pharmacodynamic models associated with 
the hypothesised pharmacological mechanisms leading to toxicity.  
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Table 3: Summary of simulation scenarios for a range of putative mechanisms associated with 
reversible and irreversible adverse events. None corresponds to conditions in which the compound is 
not toxic; Low corresponds to scenarios in which the occurrence of false positives and false negative 
is most relevant. Here the probability of NOAEL being the lowest dose level in the 1 month study is 
maximised.  
 
With regard to the assessment of the relationship between exposure and drug-induced risk, 
two possibilities were considered. A category “none” corresponded to drug effect having no 
influence on toxicity, so only non-adverse events were observed.  For the purposes of 
subsequent data analysis, it was assumed that drug-induced and non-drug induced adverse 
events were indistinguishable from each other.  The NOAEL analysis therefore treated all 
events as adverse drug reactions.  The second category was “low” toxicity.  Here, the drug 
effect parameters governing the simulation of adverse events in these scenarios were 
optimised so that the likelihood of the low dose of the 1 month study being the NOAEL dose 
was maximised.  The maximisation of NOAEL likelihood was performed by the R function 
optimise().   
For each scenario the occurrence of adverse events was described by a time-inhomogeneous 
Markov model for transition rates (Rxy): 
 
Scenario PKPD model AE type Drug toxicity 
n1 NA Reversible None 
n2 NA Irreversible None 
a1 Indirect Reversible Low 
a2 Indirect Irreversible Low 
b1 Irreversible Reversible Low 


















where BIO is an independent variable representing putative (bio)markers. B01 and B10 
correspond to baseline transition rates.  For irreversible adverse events, B10 was fixed to 0. 
For reversible adverse events it was set to 1/168, so that mean duration of an adverse event 
was 1 week.  B10 was fixed to a value which corresponded to a prevalence of adverse events 
of 1% at three months.  Transition times were simulated by sampling from their cumulative 
distributions (i.e. cumulative hazard function) to obtain a continue state vs. time relationship 
for all subjects. 
 
Estimation steps 
Estimation of NOAEL: A NOAEL was obtained for each study duration. It corresponded to the 
maximum daily dosing level for which no adverse event were observed.  The NOAEL was 
expressed as the area under the concentration vs. time curve (AUC) at that dosing level, as 
determined by the composite method.  Calculation of composite AUC values entails naïve 
pooling of drug concentration data on the day of sacrifice.  AUCs were calculated by the 
trapezoidal rule using mean concentrations for each sampling time point.  
Model-based risk assessment: Pharmacokinetics and biomarker concentration-effect 
relationships were refitted using NONMEM 7.1 with FOCEI estimation.  Predicted 
exposure and biomarker estimates were obtained using empirical Bayes estimates 
(EBEs). Derived exposure and biomarker variables were then used independent 
variables for the characterisation of the relationship between exposure and risk of 
adverse events. 
A logit transformation was used to describe the incidence of AEs.  The general equation 
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(q, = 1) = rst(uvwux∗0yz,{)Lwrst(uvwux0yz,{)    (equation 5) 
 
where  P(Ui,j) represents the probability of the presence of ulceration in individual i at time   .  COVi,j is the aforementioned independent variable individual i and time .  Possible 
values for COV were 24 hour AUC (AUC24), cumulative AUC (CAUC), 24hr area under 
biomarker-time curve (AUEC24) and cumulative AUEC (CAUEC). θ1, is a parameter governing 
the background logit probability and θ 2 is the slope parameter.  A basic model was also 
tested where θ 2 was fixed to 0 and no covariate was used. 
All adverse events were modelled in WinBUGS 1.4.3 with time, exposure and biomarker 
levels as independent variables using a proportional hazards model for left censored adverse 
events and an exponential model for current state observations.  To assess the implications 
of different strategies for the analysis of adverse event data, multiple strategies were used 
to refit the data.  These are listed in Table 5.  In addition to the five covariates models, two 
different averaged models were attempted on each simulated dataset.  The first averaging 
approach was where model predictions from all five covariate models were weighted 
equally.  The second approach was to use the Bayesian information criterion (BIC) to weight 
models.  This is consistent with weighting according to posterior model probability assuming 
a uniform prior weighting of models.  The unweighted average equally weighted all models 
ignoring model performance for the weighting scheme. 
For each model refit, prediction intervals for the risk of each observation were obtained, for 
plotting and calculation of predicted coverage.  Predictive coverage was defined as the 
number of observations where the true simulated risk falls within the 95% prediction 
interval.  Model convergence was determined by stationarity of the MCMC chain for all 
parameters by calculation of the Geweke statistic.   Unsuccessful runs were given a 0 weight 
in all average and discarded from summaries. 
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 Table  5: Overview of the methods and measurements applied to the different scenarios. The table also summarises how data are integrated to distinguish 
between adverse drug reactions (ADRs) and adverse events (AEs).  
 Assessment Data to be generated 













Observed PK exposure 
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- Predicted AE incidence 
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As described below, the use of simulated data for the evaluation of hypothetical scenarios 
provided further insight into the limitations of current practices for the assessment of safety 
thresholds, and in particular of the NOAEL when taking into account differences in the 
underlying mechanisms of toxicity.  Results from modelling are shown together with the 
parameter values obtained from naïve pooling and non-compartmental analysis where 
applicable.  
It is clear from the profiles observed for scenario a1 (Figure 5) that the risk of adverse events 
changes in a time-dependent manner, irrespectively of the point estimates for drug 
exposure or effect, as determined by pharmacodynamics (biomarker levels).  Such time-
dependencies impose further attention to the experimental design as not only the dose level 
under investigation, but also the mechanism of action underlying drug toxicity will 
contribute to the experimental results.  Moreover, these differences may or may not be 
captured by typical variables of interest (Table 6).  The inability to discriminate the 
underlying mechanism of action based on the available experimental data can lead to 
obvious issues with model identifiability.  On the other hand, despite this limitation, the 
large differences in convergence rate suggest that model-based estimates might be suitable 
to explore or exclude possible or plausible causes of toxicity. 
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Table 6: Overview of the predicted coverage (%) for model predictions, and corresponding 
model selection rates (%) for each of the scenarios (lower panel).  The basic model was not 




Scenario AUC24 CAUC CAUEC AUEC24 
n1 23 29 40 22 
n2 61 25 22 6 
a1 11 0 13 76 
a2 0 29 28 43 
b1 3 0 10 87 








model Basic AUC24 CAUC CAUEC AUEC24 
a1 65 78 48 78 65 65 78 
a2 65 78 48 48 65 65 96 
b1 48 65 30 65 65 78 78 
b2 48 78 30 48 30 48 96 
n1 78 78 91 78 78 78 78 
n2 96 96 96 96 96 96 96 
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Figure 5.  Plot of study data for scenario a1.  This increase in risk represents approximately a 10-fold 
increase from baseline risk, however, overall risk is low (risk = 13% per individual; expected number 
of events per cohort = 1.04). 
 
 
With regard to the method of analysis, our results show that the accuracy and precision of 
model-based estimates for AUC24, CAUC, AUEC24 and CAUEC were similar across different 
dosing groups and treatment durations.  For all scenarios, BICs for competing models with 
different covariate relationships (AUC24, AUC, AUEC and AUEC24) were broadly similar.  This 
suggests that whilst the parameters of a given model may be estimated accurately, the 
binary adverse events datasets simulated here provide insufficient information for model 
discrimination between competing models. 
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The success rates for convergence of models was high, the success rate being less than 100% 
was due to false negatives in the Geweke diagnostics.  Given the alpha level of 0.05, this 
would result in a 9.8% failure by random chance for a model including two parameters.  On 
the other hand, the observation that the BIC, AIC and DIC tend to overweight models 
without drug affect for rare adverse events implies that a conservative approach should be 
taken where the weighting of models should be decided by a priori confidence in a model 
specification rather than data fitting criteria (Table 6).  A general strategy, supported by our 
results, to account for model uncertainty is model averaging with model weighting being 
independent of data fitting criteria (such as the BIC).  Modellers should define models to fit 
to the data before conducting the analysis focusing on physiologically plausible 
specifications.  Prior model weights should be assigned and reflect the prior belief in a model 
specification.  Deviation from these model weights should only take place when it is strongly 
justified by the data (i.e. a large drop in BIC). 
Safety threshold vs. exposure-risk relationships 
NOAEL probability distributions are depicted in figure 6.  The mostly likely outcome for the 
NOAEL is the peak of the distributions.  An overview of the most likely outcome of the 
analysis of each scenario is shown in Table 7. 
Lastly, Table 8 shows the likelihood for each scenario, of concluding that the compound is 
safe, given that based on the lack evidence of adverse events by traditional methods would 
imply progression of the compound.  The results show that despite the characterisation of a 
viable therapeutic window for scenarios n1, n2, and a1, a different conclusion would be 
drawn by empirical methods.  In fact, scenario n2 is only 43% likely to be deemed safe, 
whereas this figure would be even lower for scenario a1 (27%).  This is likely due to the 
inability of these methods to quantitative account for background adverse events.  
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Table 7 - Likely study outcome using a standard approach (NOAEL) for a range of putative 
mechanisms associated with reversible and irreversible adverse events. 
 
  
Scenario Likelihood outcome given strict adherence to NOAEL approach 
n1 No adverse events will be observed.  Drug will appear safe at all duration 
levels. 
n2 Drug will appear safe at 1 month and below, but at three months, the 
NOAEL  will most likely fall  below the lowest tested dose 
a1 Most likely NOAEL dose at 1 week treatment is overestimated, i.e., it 
appears to be the mid dose level. 
Most likely NOAEL dose at 1 month is the low dose, but it has only 47% 
chance of being selected. 
 At three months, the NOAEL will most likely fall below the lowest tested 
dose . 
a2 At 1 week no NOAEL can be established due to lack of adverse events. 
 Most likely NOAEL dose at 1 month is the low dose, but it has only 47% 
chance of being selected. 
 At three months, the NOAEL will most likely fall  below the lowest 
tested dose 
b1 At 1 week no NOAEL can be established due to lack of adverse events. 
Although low dose at 1 month has been maximised,  the NOAEL will 
most likely fall below the lowest tested dose for treatment duration > 
1month. 
b2 At 1 week no NOAEL can be established due to lack of adverse events. 
 Although low dose at 1 month has been maximised,  the NOAEL will 
most likely fall below the lowest tested dose for treatment duration > 
1month 
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Table 8. Expected probability (%) of progression beyond the different stages of development 
assuming an empirical analysis where AEs observed at the low dose would lead to the compound 
being discontinued. To better interpret these figures, the reader is advised to compare the results 
presented in Figure 6, where the true NOAEL levels are presented. As it can be noticed scenarios 
n1,n2 and a1 are shown to have a viable therapeutic window and therefore high probability of 
progression. Scenarios a2, b1, and b2 are not deemed safe and therefore have low probability of 
progression into further development. 
 
SCENARIO 1 week 1 month 3 months total 
n1 97.37 90.14 87.98 77.22 
n2 98.14 83.76 52.73 43.34 
a1 87.87 59.74 51.02 26.79 
a2 95.26 61.29 15.68 9.156 
b1 94.44 50.06 8.076 3.818 





   
Figure 6:  Probability distributions of the NOAEL dose (left) and exposure (right) for each simulated scenario.  (left) Pink indicates the cohort where 
p(dose=NOAEL dose) is maximised.  Blue indicates that a NOAEL could not be determined where either no cohorts exhibit AEs or the lowest dose cohort 
exhibits AEs.  (Right) Red line indicates true exposure corresponding to the threshold ADR risk (threshold set to ADR risk at low dose of 1 month cohort).  
















Figure 7.  Relationship between predicted risk of adverse event and different measures of drug exposure, as described by the different scenarios 




Empirical experimental protocols are used to evaluate safety pharmacology and toxicity in 
preclinical species as the basis for defining safe exposure in humans.  These protocols are 
not designed to understand toxicological mechanisms or provide insight into mechanism-
based extrapolation across species (2,16,17).  Such a limitation in experimental protocols can 
lead to biased conclusions about drug safety especially when the events of interest occur at 
low frequency or are delayed. In these circumstances, shortcomings in current approaches 
cannot be ignored. 
In the current investigation we have illustrated the implication of low incidence adverse 
events on the estimates of a safety threshold (i.e., NOAEL) as compared to those obtained by 
the characterisation of the relationship between drug exposure and risk of adverse events.  
Although there may be fundamental differences in toxicity pathways at different parts of the 
exposure–response curve, we have assumed that examples based on a single mechanism 
would be sufficiently realistic to introduce the concept.  The phenomenon of exposure-
dependent transitions in mechanisms of toxicity can be explored in a similar manner by 
introducing interaction factors (18,19).  Thanks to the statistical features of nonlinear mixed 
effects modelling, we have also shown how individual susceptibility can be incorporated into 
the evaluation of the exposure-response relationships, whilst taking into account differences 
in the underlying mechanisms involved in the continuum between exposure and adverse 
events. 
In this regard, it is helpful to think of a multistage process, which starts with systemic 
exposure and progresses through target exposure, yielding early biological effects (e.g., at 
the sub-cellular level), altered structure or function and subsequently clinical disease (20-
22).  The introduction of biomarkers of pharmacology can therefore not only contribute to 
further understanding of target exposure, but it also enables discrimination between dose-
dependency, class effects and regimen-related mechanisms without the risk of inaccuracies 
and poor precision which seem to prevail  when relying on NOAEL estimates (23). 
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From a pharmacological perspective, the selection of exposure measures (i.e. the parameter 
of interest) forms the basis for defining “safe exposure”.  Arbitrary selection of the measure 
of exposure to be used as a marker of safety can add unnecessary, correlated noise into the 
data, which may subsequently lead to bias and loss of precision (24,25).  In this context, our 
analysis has shown that toxicity findings associated with direct effects were most accurate 
represented by AUC or CMAX.  Moreover, in these cases, it appears that performance relative 
to the NOAEL approach is improved even when biomarker data was not available. By 
contrast, the availability of biomarker data was shown to help in the estimation of adverse 
events when delays occur between the beginning of treatment and onset of the effects.  
Other measures of exposure such as cumulative AUC proved more effect with indirect 
mechanisms.   
The results presented here also provide guidance for prospective use of model-based 
approaches in the evaluation of safety pharmacology and toxicology.  In contrast to current 
practice, in which experimental data is generated to define a safety threshold, we have 
shown how current understanding pharmacokinetic processes can be integrated with 
knowledge about the putative mechanisms of action to characterise exposure-risk 
relationships during safety screening in early drug development.  In fact, we demonstrate 
how important additional, ancillary data can be when dealing with rare or low frequency 
events. Statistical methods are available that enable formal inclusion of such knowledge as 
informative priors (26, 27).  However, prior distributions need be defined in advance of the 
analysis to minimise subjective bias.  The alternative strategy of aggregating datasets is also 
useful if additional study data is available from a population which is exchangeable with 
experimental data under investigation.  This underpinned the use of the aggregated placebo 
data set in our analysis.   
From a methodological perspective, the various scenarios have shown that despite the 
known advantages of parametric, model-based approaches, model identifiability can be an 
important issue.  The inability to separate models based on diagnostic criteria may lead to 
bias in predicted risk.  Care therefore needs to be taken not to over-interpret good 
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performance on model diagnostics as an indication of a well specified structural model.  The 
specification of the structural models for rare adverse events needs to be primarily justified 
on biological grounds.  It is also important to emphasise that reporting of model outputs 
(e.g. parameters, model predictions) should clearly incorporate parameter and model 
uncertainty.  Clear and accurate reporting of uncertainty enables us to understand and 
formally account for uncertainties arising from limitations in data collection and model 
estimation.   
One last methodological aspect that deserves attention concerns the accuracy and precision 
of the estimates of safe exposure.  The incorporation of placebo aggregated data allowed for 
quantification of baseline and drug-induced risk in a similar manner to what is currently 
performed for the clinical evaluation of drug safety (28,29).  Parameters for baseline risk 
were likely to be large without sufficiently large amounts of placebo data.  This would in turn 
inflate uncertainty around remaining parameters determining drug-induced risk.  Therefore, 
we have modelled both components of risk together.  Nevertheless, it is also feasible to 
model baseline risk a priori to ensure the uncertainty distributions will be narrow enough to 
precisely estimate drug-induced risk. 
The high success rates observed with a model-based approach also shows that incorporating 
model uncertainty is feasible. In turn, realistic estimation of uncertainty enables more 
informed decision-making with regard to risk.  There is a caveat that outside the 
experimental range, the positioning of the 95% risk bound will likely depend on a single 
model if equal weighting is used.  This will be the model that produces highest predictions of 
risk at low exposures.  If this proposed model is physiologically plausible and a priori equally 
likely to other proposed models, then this is appropriate (30).  However, a linear model in 
this context was the least plausible and provided overly conservative estimates.  A way of 
handling plausible, but a priori unlikely mechanisms would be to assign appropriately small 
model priors. 
Finally, it should be noted that missed adverse events were also easily quantified using the 
proposed strategies.  Differently, from the empirical approach to treating missing events as 
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absent, the use of MCMC methods provides evidence of the parameter distribution, 
enabling imputation of the events, even if they have not been observed. 
Limitations 
 
The scenarios used in this investigation were not intended to provide a comprehensive 
review of all possible toxicological mechanisms.  Therefore, it should be noted that no 
covariate effects other than baseline incidence and treatment itself were considered to drive 
adverse events.  As the number of potential covariates increases, the chance of selecting a 
false positive covariate relationship increases.  This is an important consideration whenever 
several competing models perform similarly.  Our recommendation is a pragmatic approach 
of restricting the model search to physiologically plausible models and the use statistical 
tools to guard against over-fitting (31).  In the present study, this would have involved an 
increase in computational time by a factor of more 1000 times. 
The simulated adverse events were related to descriptors of occurrence such as incidence 
and prevalence.  These were idealised situations that represent two extremes, either where 
none or complete information was available.  In reality adverse event data will contain a 
spectrum of varying degrees of information on incidence for example with interval censoring 
or imperfect sensitivity in detection.  For instance, gastric ulceration may form and heal 
before the end of treatment, making histological data inaccurate for the estimation of risk.  
Poor specificity in detection for another adverse event may similarly overestimate risk.  
Resolving this uncertainty, however, is only possible with additional information regarding 
the pathophysiology, sensitivity and specificity of detection of the methods used to 
investigate these events.  
 
In conclusion, evaluation of safety is paramount for the progression of new molecules into 
humans.  However, current methods in preclinical toxicology do not support the integration 
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of pharmacokinetic and pharmacodynamic data as basis for predicting safe exposure in 
humans.  By contrast, a model-based approach represents a viable tool for characterising 
risk-exposure relationships, including estimates of parameter and model uncertainty.  A 
benefit this strategy lends to decision-making is that clinical judgment can be applied to 
consider the entire risk-response relationship of each adverse event, rather than a point 
estimate or threshold. 
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Abstract 
The assessment of safety in traditional toxicology protocols rely on evidence arising from 
observed adverse events (AEs) in animals and on establishing their correlation with different 
measures of drug exposure (e.g., Cmax and AUC).  Such correlations, however, ignore the 
role of biomarkers, which can provide further insight into the underlying pharmacological 
mechanisms. Here we use naproxen as a paradigm drug to explore the feasibility of a 
biomarker-guided approach for the prediction of AEs in humans.  A standard toxicology 
protocol was set up for the evaluation of effects of naproxen in rat, in which four doses were 
tested (7.5, 15, 40 and 80mg/kg).  In addition to sparse blood sampling for the assessment of 
exposure, thromboxane B2 and prostaglandin E2 were also collected in satellite groups.  
Nonlinear mixed effects were performed to evaluate the predictive performance of the 
approach.  A one-compartmental model with first order absorption was found to best 
describe the pharmacokinetics of naproxen.  A nonlinear relationship between dose and 
bioavailability was observed which leads to a less than proportional increase in naproxen 
concentrations with increasing doses.  The PD of TXB and PGE was described by direct 
inhibition models with maximum pharmacological effects achieved at doses > 7.5 mg/kg.  
The predicted PKPD relationship in humans was within 10-fold of the previously published 
values.  Moreover, our results indicate that biomarkers can be used to assess interspecies 
differences in PKPD and extrapolated data from animals to humans.  Biomarker sampling 





Long term safety issues have increasingly become a cause of late stage attrition (1), 
prompting regulatory authorities to increase requirements for sponsors to demonstrate a 
favourable benefit-risk balance for new medicines.  Such a prerequisite has implications for 
current practices in early drug discovery and development.  Thus far, pharmaceutical 
companies seem to have adopted the concept of measuring any markers based on known 
pharmacology of the drug under development.  One challenge is the expectation/early 
identification of unknown mechanisms and the timely implementation of the assessment, 
the other challenge is the effective translation or interpretation of the data accumulated. 
Both from a clinical perspective and a pharmacological perspective, the demonstration of 
safety can only be tackled by a strategy that ensures the characterisation, in a mechanistic 
manner, of the relation between drug dosing and response (Danhof et al., 2008).  The vast 
majority of experimental protocols currently used for the evaluation of toxicity and safety 
pharmacology use dose and systemic drug exposure as a proxy for risk.  However, other 
markers of safety and toxicity may be better predictors of adverse drug reactions.  This is 
particularly important given the high degree of nonlinearity in the relation between 
pharmacokinetics and pharmacodynamics as well as the potential interspecies differences in 
these relations.  Ultimately, these nonlinearities may cause downstream biomarkers, other 
than target or systemic exposure to a drug, to better describe and predict the outcome or 
response to treatment (Bai et al., 2013).  
There is therefore an urgent need to evaluate and refine the methodology for the 
assessment of safety.  To this purpose, the classification scheme devised by Rawlins and 
Thompson, 1991, constitutes a scientific basis for the establishing correlations between 
adverse drug reactions and pharmacological effects.  Briefly, this scheme defines adverse 
drug reactions according to seven different categories, which correspond to the underlying 
pharmacological effects.  As shown in Figure 1, the different categories nicely match the 
mechanistic classification of biomarkers proposed by Danhof et al., 2005, which defines the 
 
requirements for establishing further correlations with drug exposure. As such, this 
mechanistic classification could be used for the evaluation of safety and toxicity and 
consequently for the accurate assessment of (long term) risk in humans. 
 
 
Figure 1.  Mechanistic classification of biomarkers (Reprinted with permission from Danhof 
2005). This concept can be linked to the classification for adverse events proposed by Rawlins and 
Thompson, which clusters unwanted pharmacological effect into seven
mechanism of action or characteristics of their manifestation. A type A event is one that is due to an 
extension of the active pharmacologic properties of the drug (A indicates augmented). They are also 
called predictable or anticipated events. They are generally less severe and more frequent than type 
B events. This augmented pharmacologic action may occur at the targeted receptors or at other 
nontargeted receptors producing lateral effects, parallel effects, or side effects. Types C
are not mechanisms but characteristics of their manifestations. Type C refers to reactions associated 
with long-term drug therapy. Type D is linked to carcinogenic and teratogenic effects. These 
reactions are delayed in onset and are very r
studies are done before drug is licensed. Type E refers to end of use or rebound effects. Type “F” 
reactions indicate failure of treatment.  Type “G” reactions are due to genetic polymorphism.
 
In the current investigation we therefore explore the feasibility of a model
for the evaluation of long term adverse events in which biomarkers of pharmacology are 
used as proxy of drug exposure. 
as paradigm compound to demonstrate the concept of biomarker
(Berger et al., 2011; Bai et al.
we subsequently illustrate how modelling and simulation techniques can 
accurate estimation of the safe dose levels of naproxen after chronic exposure. 
Non steroidal anti-inflammatory drugs exert their actions though an interaction with cyclo
oxygenase (COX).  Selective blockade of COX
suppression of the formation
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 of pro-inflammatory mediators such as  thromboxanes (TXB) 
et al., 




be used to ensure 
 
-
results in direct 
 217 
and prostaglandins (PG) (102).  The perceived role of COX-2 in inflammation has 
substantiated the extensive use of selective COX-2 inhibitors as analgesic drugs in acute and 
chronic inflammation.  Yet, despite a putative reduction in gastrointestinal bleeding and 
ulceration by selective inhibition (13,103), cardiovascular events have arisen after prolonged 
use of rofecoxib, a selective COX-2 inhibitor which led to its withdrawal from the market, 
followed by considerable changes in the regulatory requirements for approval of novel non-
steroidal anti-inflammatory drugs (Fitzgerald, 2007).  
Continuous COX-1 inhibition following prolonged administration of non-selective COX 
inhibitors is known to induce gastrointestinal adverse effects, in particular ulcerations and 
haemorrhagic bleeding.  Unfortunately, at present the dose selection of COX inhibitors 
disregards whether maximum, long-lasting blockade of either enzyme is strictly required for 
response (Huntjens et al., 2005).  An important question that needs to be answered is 
therefore how much and how long COX-2 and COX-1 should be inhibited to ensure an 
optimal risk-benefit balance allowing for a sustained analgesic response and an appropriate 
safety margin in the treatment of chronic inflammatory conditions.  Given the mechanism of 
COX inhibition and the nature of the inflammatory response, PG and TXB can be used as 
biomarkers of pharmacological effects (Huntjens et al., 2006).  
Using the biomarker classification proposed by Danhof at al., 2005 and a model-based 
approach for the analysis and interpretation of the results, we show how a relationship can 









In this investigation the safety of the non-selective COX inhibitor naproxen was evaluated at 
three different treatment durations using a slightly modified version of a typical general 
toxicology protocol.  Endpoints included adverse events, including GI histology, 
pharmacokinetics and pharmacodynamics.  The intent of the study was explore the 
feasibility and impact of proposed methodology.  Briefly, rats received varying daily oral 
doses of naproxen.  A predefined sampling scheme was used to monitor for adverse events, 
which included sacrifice of individual animals for histopathology of the GI tract.  Satellite 
animals receiving identical doses had blood samples collected at various time points during 
the course of treatment for the assessment of both pharmacokinetics in plasma and 
biomarkers (TXB2 and PGE2).  An overview of the study protocol is depicted in Figure 2.  The 
diagram shows a typical experimental protocol including different treatment duration and 
satellite animals sampled according to composite sampling scheme. 
Animals 
The experimental protocol was approved by the Ethical Committee on Animal 
Experimentation of the University of Leiden.  Experiments were performed on male Sprague-
Dawley (SD) rats (Charles River B.V., Maastricht, The Netherlands) with an initial weight of 
256 ± 19 g.  The animals, 4 per cage, were housed in standard plastic cages with a normal 12-
hour day/night schedule (lights on 07.00 a.m.) and a temperature of 210C.  The animals had 
access to standard laboratory chow (RMH-TM; Hope Farms, Woerden, The Netherlands) and 
acidified water ad libitum. 
Drug administration 
Naproxen Sodium (Sigma Aldrich BV, Zwijndrecht, The Netherlands) was dissolved in sterile 
Millipore distilled H2O. The animals received daily doses via oral gavage for periods of 
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Figure 2: Schematic representation of the experimental protocol design. As the primary purpose of 
the study was to investigate the utility of biomarker data collection, modifications were made to a 
standard toxicology protocol.  Only male animals were investigated and organ histology and 
pathology were limited to the known drug-induced toxicology findings, i.e., stomach ulceration. The 
use of an integrated approach implied the combination of additional data from (standard) 
pharmacokinetic experimental data (DMPK experiments). Animals were stratified into groups by 
treatment duration and dose level. Treatment duration varied between one, two and four weeks. For 
each treatment duration, four groups were tested each of which received four different dose levels 
(n = 8 animals/dose level in the toxicology group and n= 24 animals /dose level in the satellite arm, 
i.e.,  3 animals/sampling time point).  
 
Study Design 
As the primary purpose of the study was to investigate the utility of biomarker data 
collection, modifications were made to a standard toxicology protocol.  Only male animals 
were investigated and organ histology and pathology were limited to the known drug-
induced toxicology findings, i.e., stomach ulceration.  Animals were stratified into groups by 
treatment duration and dose level.  Treatment duration varied between one, two and four 
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weeks. For each treatment duration, four groups were tested each of which received four 
different dose levels (n = 8 animals/dose level in the toxicology group and n= 24 animals 
/dose level in the satellite arm, i.e., 3 animals/sampling time point).  Details of the final 
experimental protocol are depicted in Figure 2.  It should be noted that the initial regimens 
included oral daily doses of 0, 15, 40 and 80 mg/kg naproxen.  However due to adverse 
events observed in the 1-week 80 mg/kg group, the protocol was amended to 0, 7.5, 15, and 
40 mg/kg cohorts. The animals receiving 80 mg/kg suffered from unacceptable weight loss 
and were sacrificed immediately after the first week on treatment.  Unacceptable weight 
loss was defined as either a weight loss on three or more consecutive day or a total weight 
loss of more than 10% relative to the baseline value.  Histological evaluation of the stomach 
was performed to establish a correlation between acute and long term adverse events.  
After euthanasia, stomachs were removed immediately and were cut open along the greater 
curvature and washed with warm saline.  The inner surface was photographed to allow the 
measurement of the area covered by hemorrhagic ulceration.  The area of ulceration was 
determined under a dissecting microscope.  Gastric ulceration was measured as percentage 
stomach surface area affected by ulceration.  A software (Image J version 1.43) was used for 
calculating ulcer area and total stomach surface area.  The person who performed the 
ulceration measurement was blinded as to treatment group. 
Given the need to establish a correlation between drug exposure, biomarkers, and adverse 
events, optimality concepts were used to ensure accurate characterisation of 
pharmacokinetics and biomarkers.  In addition, an integrated approach was used which 
takes into account the pharmacokinetics of the naproxen at putative therapeutic levels (i.e., 
the so-called DMPK group).  In contrast to standard protocols, sparse and serial blood 
sampling schemes were considered.  For the DMPK group, serial samples were collected at 0, 
0.25, 0.75, 1.5, 8, 24 hours after dosing.  The sampling times in this set of animals were not 
optimised for subsequent modelling.  On the other hand, optimal design methodology was 
used to select a sampling scheme and individual sampling times for satellite and toxicity 
animals (Josa et al., 2001).  Optimisation of the sampling scheme has been performed 
according to D-optimality principles, as implemented in PopED (University of Uppsala, 
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Sweden).  Due to practical constraints, optimized sampling time points were rounded to the 
nearest 15 min after dosing.  The final schedule included therefore the following sampling 
times:  0, 0.25, 0.5, 0.75, 1, 1.5, 2, 8, 24 hours post dose.  Blood samples of 250μl were taken 
from the tail vein and split into aliquots, namely 100μl for naproxen concentrations and 
PGE2 and 50μl for TXB2.  Animals allocated to the toxicology groups were sampled only at 
the beginning and end of the treatment, prior to sacrifice.  Satellite animals were each 
sampled four times throughout the study after dosing on day 1, 7, 14 and 28.  Blood samples 
for pharmacokinetics were placed into heparinised tubes and centrifuged at 5000 rpm for 10 
min. Plasma was stored at –200C until analysis. Blood samples for TXB2 analysis were placed 
into tubes and allowed to clot for 1 hour at 370C in a stirring water bath. Serum was 
collected after centrifugation and stored at –200C until analysis.  Tubes for the analysis of 
PGE2 were prepared by evaporating aspirin (10 µg/ml in methanol and heparin (10 IU)). 
Blood samples were placed in tubes together with 10 µg/ml lipopolysaccharide (LPS).  
Samples were incubated and stirred for 24 hours at 370C in a water bath.  Plasma was 
separated by centrifugation and stored at –200C until analysis. 
  
Bioanalysis of naproxen 
Naproxen concentrations were analysed via HPLC in accordance with the method described 
by Satterwhite and Boudinot (1988).  50μl Plasma samples were spiked with 50μl internal 
standard (1000mg/ml ketoprofen in methanol).  The pH was then adjusted via addition of 
0.2ml 1M phosphate solution at pH 2.  The extraction process was performed with 5ml 
diethyl ether, after which the residue was then dissolved in 100μl mobile phase and then 
50μl of this solution was injected into the HPLC system.  The HPLC system consisted of a 
Water 501 solvent pump, a Waters 717plus autosampler (Millipore-Waters, Milford, MA, 
USA), Superflow 757 Kratus UV absorbance detector (Shimadzu, Kyoto, Japan).  A C18 3μm 
cartridge column (100 x 4.6mm i.d., Chrompack, Bergen op Zoom, The Netherlands) was 
equipped with a guard column for the chromatography process.  Mobile phase was made up 
of an 82:18v/v of 0.02M phosphate buffer (pH 7.0) and acetonitrile and was set to a flow 
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rate of 1.0ml/min.  Measurement of ultraviolet absorbance was performed at a wavelength 
of 258nm.  The data was acquired and processed using a Chromatopac CR3A integrator 
(Shimadzu, Kyoto, Japan).  The calibration curves showed linearity over range of known 
concentrations (250-100,000ng/ml).  Validation was carried out and the analytical process 
was shown to have a mean accuracy and precision of 96.3% and 2.94%, respectively.  The 
intra-assay variability was shown to be 2.97%. 
 
Analysis of TXB2 and PGE2 
PGE2 and TXB2 were quantified by an in vitro whole blood assay (WBA) using a validated 
enzyme immunoassay (Amersham Biosciences Europe GmbH, Freiburg, Germany).  Samples 
were diluted in assay buffer (2-50 times for PGE2, 200-2000 times for TXB2) and a 50 µl 
sample was transferred into a coated well plate.  After addition of 50 µl antibody and 50 µl 
peroxidase conjugate, samples were incubated for 1 hour, washed four times and incubated 
for 15 min (TXB2) or 30 min (PGE2) after which 150 µl substrate was added.  The enzyme 
reaction was halted by addition of 100 µl 1M sulphuric acid and optical density was 
measured in a plate reader at 450 nm. 
 
Data analysis  
Pharmacokinetic and biomarker data from all experimental groups were combined for an 
integrated analysis of pharmacokinetics and pharmacodynamics of naproxen using nonlinear 
mixed effects modelling, as implemented in NONMEM version 7.2.0.  Convergence was 
determined by successful minimisation and covariance step.  Final model parameters were 
estimated by the first order conditional estimation method with interaction (FOCEI).  This 
approach allows the estimation of inter- and intraindividual variability in model parameters.  
All fitting procedures were performed on a computer (AMD-Athlon XP-M 3000+) running 
under Windows XP with a FORTRAN compiler (Compaq Visual Fortran, version 6.1).  Data 
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processing, management and graphical display were performed in R (R Development Core 
Team, 2012).  Model diagnostics and validation were performed according to graphical and 
statistical criteria.  Goodness-of-fit plots, including observed (OBS) versus individual 
prediction (IPRED), OBS versus population prediction (PRED), conditional weighted residuals 
(CWRES) versus time and CWRES versus OBS were used for diagnostic purposes (104).  
Model validation included numerical predictive checks (NPC), visual predictive checks (VPC) 
and normalised prediction distribution errors (NPDE). If shrinkage was found to be high 
(>20%),  diagnostics using empirical Bayes estimates (EBEs), e.g. plots involving IPRED or 
individual parameter estimates, were not performed due to their reduced diagnostic value. 
Pharmacokinetic (PK) model: The pharmacokinetics of naproxen was described initially by a 
one-compartmental model with first order absorption and first order elimination assuming a 
(relative) bioavailability of 1.  Additional compartments and dose-dependent kinetics were 
also evaluated during model building.  Model selection and identification was based on the 
likelihood ratio test, parameter point estimates and their respective 95% confidence 
intervals, parameter correlations and goodness-of-fit plots.  For the likelihood ratio test, the 
significance level was set at p<0.01, which corresponds with a decrease of 6.6 points, after 
the inclusion of one parameter, in the minimum value of the objective function (MVOF) 
under the assumption that the difference in MVOF between two nested models is χ2 
distributed.  
Based on model selection criteria, naproxen pharmacokinetics was best described by a one 
compartment model including absorption rate constant (Ka), clearance (CL) and volume of 
distribution (V) as primary parameters.  The analysis was performed by use of the ADVAN13 
routine in NONMEM.  Variability in pharmacokinetic parameters was assumed to be log-
normally distributed in the population.  An exponential distribution model was used to 
account for inter-individual variability: 
( )iiiP ηθ exp⋅=       equation (1) 
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where θ is the population estimate for parameter P, Pi is the individual estimate and ηi is the 
normally distributed interindividual random variable with mean zero and variance ω2.  The 
coefficient of variation (CV %) of the structural model parameters is expressed as percentage 
of the root mean square of the interindividual variance term.  
Selection of an appropriate residual error model was based on inspection of the goodness-
of-fit plots.  A combination of a proportional and an additive error model was then proposed 
to describe residual error in the plasma drug concentration: 
( ) 2,1,,, 1 ijijijpredijobs CC εε ++⋅=     equation (2) 
where Cobs,ij is the jth observed concentration in the ith individual, Cpred,ij is the predicted 
concentration, and εij is the normally distributed residual random variable with mean zero 
and variance σ2.  The residual error term contains all the error terms that cannot be 
explained by other fixed effects including experimental error (e.g., error in recording 
sampling times) and structural model misspecification.  
Pharmacokinetic-pharmacodynamic (PKPD) model: The PKPD data were analysed 
sequentially using the so-called PPP&D approach (105,106).  In the PPP&D sequential 
analysis, population pharmacokinetic parameters are fixed, but individual pharmacokinetic 
parameters are estimated simultaneously with pharmacodynamic parameters based on both 
PK and PD data.  Even though more computationally intensive, we have preferred this 
strategy to the more common usage of simulated plasma concentration from empirical 
Bayes estimates as an independent variable since the high expected shrinkage would result 
in overestimation of the variance of PKPD random effects parameters (Karlsson et al., 2007).  
PGE2 and TXB2 concentrations were used in this study as markers of the underlying 
pharmacological effects with the aim of identifying their relevance as a proxy for safety after 
naproxen exposure. The sigmoid Imax model was used to relate naproxen plasma 
concentration (C) to the drug effect by the equation: 
))/((*)( 50max00
nnn ICCCIIIEffect +−−=   equation (3) 
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where I-max represents the maximal inhibitory effect to naproxen, I0 the baseline production 
of PGE2 or TXB2 and n the Hill coefficient. This equation is an adaptation from the Emax model 
in order to obtain the absolute values for I0 and Imax for the direct calculation of maximal 
inhibition in percentages.  To allow for further comparison with historical data, the model 
was re-parameterised during the final analysis to obtain estimates of IC80, i.e., the 
concentration corresponding to 80% biomarker inhibition.  The relationship between IC50 
and IC80 can be implemented by the following equation: 
nICIC 45080 ⋅=      equation (4) 
Covariates: The role of potential covariate factors on PK and PKPD model parameters was 
evaluated using the stepwise covariate method (SCM) in PsN (107).  Potential influential 
factors included clock time, body weight, age and biomarker levels at baseline.  Covariates 
were incorporated into the model by stepwise forward inclusion. A significance level  of 
p<0.01 was used for inclusion, which represented a drop of least 6.63 units in the objective 
function for each additional parameter.  A final evaluation of the statistical significance of all 
factors identified during the previous step was performed by subtracting each covariate 
individually (backward elimination).  The final structural model (i.e., fixed effects model) 
included only those covariates whose subtraction resulted in a decrease of at least 3.84 units 
in the objective function (p<0.05). 
Posterior predictive performance evaluation: The performance of the population PK and 
PKPD models were assessed by numerical and visual predictive checks. To that purpose, 
1000 data sets were simulated with the final model parameter estimates. The mean and the 
95 % confidence intervals were calculated for naproxen, PGE2 and TXB2 concentrations at the 
pre-defined sampling time points used in the experimental protocols. Validation procedures 
also included normalised prediction distribution errors (NPDE), which are based on the 
assumption that the normalised (decorrelated) prediction distribution errors (discrepancies) 
are normally distributed (Comets et al., 2008). One hundred datasets were simulated using 
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the final model, which was then tested for the assumption of normality of the prediction 
distribution errors. 
Exposure calculation: In addition to the use of a model-based approach to estimate relevant 
pharmacokinetic parameters, naproxen plasma data from the satellite groups were also 
analysed using traditional non-compartmental (NCA) methods for comparison with the 
predicted values of systemic exposure.  Data for each cohort was aggregated by time point 
to produce composite, geometric mean naproxen concentrations at each time point.  
Summary statistics were performed on this composite profile for the peak concentrations 
(CMAX) and area under the concentration vs. time curve (AUC).  Composite CMAX was taken to 
be the highest point on the composite profile (at time TMAX).  Composite AUC was calculated 
via the log-linear trapezoidal rule where a linear increase in the concentration vs. time 
profile was assumed till TMAX, and a log-linear decline thereafter. 
Model performance was first assessed by means of a predictive check using 1000 
simulations. Composite AUCs and composite CMAX values were calculated on each simulated 
dataset and then compared to the observed values.  The model performing well on this 
predictive check was used to compute model-based AUC and CMAX.  To ensure higher 
precision of the predicted measures of systemic exposure, 100 animals were simulated per 
cohort.  Empirical exposure calculations were then compared to model-based results. 
Simulations: As described previously, inferences about the safety profile of a drug in humans 
may be more accurate if biomarkers are considered in conjunction with or eventually as 
proxy for naproxen exposure.  Extrapolation of preclinical findings into drug effects in 
humans was therefore based on the predicted exposure-biomarker relationships in humans 
(108)  Using the PKPD models developed for PGE2 and TXB2 inhibition, simulation scenarios 
were evaluated for wide range of naproxen concentrations.  Despite some evidence of 
differences in the homeostasis of prostacyclins in rats, for the purpose of this investigation 
downstream effects were assumed to reflect the mechanisms by which adverse drug 
reactions emerge both in rats and humans. The inhibition levels were then compared to 
previously reported data on the PKPD relationship obtained in vitro by Huntjens et al., 2006 
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using healthy subject blood and to the AUC and CMAX observed after the recommended 
500mg b.i.d. dose, as described in the naproxen prescriber information (Roche 
Pharmaceuticals Australia, 2012).   
Results  
 
In total, the dataset consists of 550 samples were collected for the evaluation of the 
pharmacokinetics (n=113) and toxicokinetics of naproxen (n=437).  16.7% of the samples had 
concentrations below the lower limit of quantification. Due to calibration curve issues, not 
all samples could be evaluated in a pairwise manner with the pharmacokinetic data. In total, 
65 samples were analysed for PGE2 and 73 TXB2 levels, none falling below the limit of 
quantification.  
As shown in Figure 3, histological examination revealed gastric ulceration in all dose levels; 
therefore no NOAEL could be obtained for any of the treatment durations.  Ulceration 
occurred at an incidence of 11% after administration of the 7.5 mg/kg dose, which was 
defined as the lowest observed adverse effect level (LOAEL).  
All animals receiving 80 mg/kg in the 1 week cohorts suffered from unacceptable weight 
loss.  The animals in this cohort were immediately sacrificed, and due to ethical reasons this 
dose level was discontinued.  Different dose levels of naproxen were considered for the two-
week and one-month cohorts, which received lower doses (7.5, 15, and 40mg/kg).  
Histological examination and terminal blood samples were performed on these animals.  No 




















Figure 3.  Plots of gastric ulcer incidence and severity after oral administration of 7.5, 
15 and 40 mg/kg naproxen to rats.  Ulcer severity is measured as % of stomach area 
covered in ulcers. The dots in the upper panel represent observed events in individual 
animals, whereas the solid line and shaded grey area represent the regression line and 






Naproxen pharmacokinetics in plasma was best described by a one-compartment model 
with first order absorption, first order elimination and dose-dependent bioavailability (Figure 
4).  Interindividual variability was identified on all model parameters, whereas residual 
variability was described by a combined proportional error model.  As expected, η and ε 
shrinkage was high (>20%) due to the sparseness of the data.  Weight was found to show a 
statistically significant effect on both clearance and volume of distribution.  An overview of 
the final parameter estimates is presented in Table 1. 
 
 
Figure 4: Naproxen concentrations vs. time profiles after oral administration of 7.5, 15 and 40 mg/kg 
to rats.  The dots represent observed concentrations, whereas the solid line represents the 
population predicted profiles. 
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Table 1. Final parameter estimates 
PK Parameter Final estimate Precision (CV%) 
Ka (h-1) 3.7 14.95 
CL/F (L/h) 6.42 7.85 
V/F (L) 67 7.43 
F1diff 2.47 5.75 
SLOPEWT,CL/F
a 0.00531 - 
SLOPEWT,V/F 
b 0.00229 - 
BSV in Ka (%CV) 15.8 196 
BSV in CL/F (%CV) 43.0 13.46 
BSV in V/F (%CV) 12.7 66.25 
Residual variability 41.59 8.97 
PGE Parameter Final estimate Precision (CV%) 
I0 (ng/ml) 57.97 5.09 
IC50 (mg/L) 0.0132 8.27 
HILL 1.51 - 
BSV in I0 (%CV) 12.69 49.3 
BSV in IC50 (%CV) 33.91 63.0 
Residual variability 14.76 41.4 
Residual variability (additive) 1.43 35.4 
TXB Parameter Final estimate Precision (CV%) 
I0 (ng/ml) 192.48 - 
IC50 (mg/L) 0.000599 - 
HILL 1 FIX - 
BSV in I0 (%CV) 42.78 - 
Residual variability 14.76 - 
Residual variability (additive) 33.62 - 
aCovariate relationship was modelled as CL/F*(1 + SLOPEWT,CL/F *(WT - 296.60)) 
bCovariate relationship was modelled as V/F*(1 + SLOPEWT,V/F *(WT - 296.60)) 
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Pharmacokinetic-pharmacodynamic models 
Given the fast onset of effect, the naproxen-induced inhibition of PGE2 and TXB2 could be 
characterised by direct sigmoid IMAX models.  The final model for PGE2 included estimates of 
Hill coefficient different from 1, whereas for the TXB this parameter was fixed to 1.  Clearly, 
the doses used in this experimental protocol has led to considerable level of inhibition of 
TXB2, which nears complete suppression at the highest concentrations.  A similar pattern 
was observed for PGE2, but the profiles are much more variable (Figure 5).  No relevant 
deviation or model misspecification was observed in any of the diagnostics measures.  In 
addition, NPDE plots suggested no significant discrepancies across the range of predicted 
concentrations (Figure 1S, supplemental material).  Yet, it should be noted that 24-hour TXB2 
samples were not well predicted due to a rebound effect at the end of treatment, which 
could not be captured by the model.   
 
Figure 5: Pharmacokinetic-pharmacodynamic relationships for PGE2 and TXB2, after administration of 
increasing doses of naproxen (7.5, 15 and 40 mg/kg). Data pooled from animals treated during 1, 2 
and 4 weeks. Pharmacological effects are assumed to be time independent, i.e., no tolerance or 
hypersensitisation is observed at the different durations of treatment. Dots represent observed 
levels of PGE2 and TXB2, whereas the solid line depicts the population predicted inhibition.  
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Exposure calculation 
The predictive check shown in Figure 6 was performed to assess the model’s ability to 
accurately predict drug exposure, as defined non-compartmentally in terms of AUC and CMAX. 
It shows that model predictions are slightly different from the observed exposure estimates 
obtained parametrically.  As depicted in the predictive check for derived measure of 
exposure (see Figure 2S, supplemental material), this bias may remain undetectable when 
data analysis is performed by non-compartmental methods, which handle variability as 
random noise.  By contrast, hierarchical modelling of pooled data assumes part of variation 
to be caused by inter-individual differences in the underlying parameters that determine the 
time course of drug concentrations.  With the exception of the last time point of the 40 
mg/kg dose group, CMAX and AUC values derived by NCA are systematically overestimated.  
In addition, it should be noted that one cannot discriminate the impact of drug accumulation 
based on NCA results.  Naproxen accumulation over time upon repeated dosing is evident 
from the model-predicted.  Model predicted-curves shows also reveal a risk of significantly 
higher than average AUCs for some individuals in the 40 mg/kg group. 
Simulations 
Figure 7 shows the PKPD relationship for PGE2 and TXB2 obtained from the pooling of data 
from the present study as compared to the ex vivo results published by Huntjes and 
collaborators (Huntjes et al., 2006).  In contrast to the observed pharmacological profile 
using human blood, which suggests similar IC80s for the inhibition of both PGE2 and TXB2, 
naproxen was found to show higher potency in terms of TXB inhibition in rats.  These 
differences strengthen our assumption that the differences in homeostasis in pre-clinical 
species must be considered when interpreting toxicology and safety pharmacology findings.  
On the other hands, the PKPD curves reveal two important features of the safety 
pharmacology of naproxen.  First, it can be observed that the exposure range associated 
with the LOAEL dose, where GI toxicity was evident in rats lies above the predicted IC80 
values in rats. Second, one can see that the exposure range observed after the currently 
recommended doses of naproxen also lies above the IC80 estimates in humans.  This finding 
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Figure 6: Model-based predictions and estimated non-compartmental values for systemic exposure 
(AUC) and peak concentrations (CMAX) after single and repeated oral administration of 7.5, 15 and 40 
mg/kg naproxen to rats. Observed exposure (triangles and dotted line) is shown together with model 
predicted parameter estimates.  Solid line represents the predicted median values, whereas the 
shaded area indicates the 95% prediction intervals. The discrepancy between model predictions and 






Figure 7: Estimated PKPD relationships for TXB2 and PGE2 in rats. The solid curve with shaded area 
representing 95% prediction interval, vertical line shows corresponding IC80) whilst the green-shaded 
bar depicts the drug levels associated with the LOAEL dose (7.5 mg/kg) observed in animals. The 
preclinical findings are compared to the corresponding concentration-effect relationships in humans, 
as determined by ex vivo assays in whole blood using a wide range of naproxen doses. The dashed 
line depicts PKPD curves in healthy subjects along with the IC80 values (dashed vertical line). The 
distance between the solid and dashed lines shows the magnitude of inter-species differences in 
terms of the sensitivity to the thromboxane (anti-platelet aggregation) effects.  The orange-shaded 







Historically, general toxicity experiments have been designed with the primary objective of 
deriving estimates of systemic drug exposure and a safety threshold, i.e., the NOAEL 
(Parasuraman, 2011).  Another major goal of repeat-dose general toxicology experiments is 
to identify target organs.  However, important limitations in protocol design such as the 
sparseness of the data collected, the inferences made from separate satellite groups and the 
descriptive nature of the data analysis preclude their use for further characterisation of 
concentration-effect relationships.  There is barely any consideration about the degree of 
receptor occupancy or target engagement at tissue and organ levels. In addition, 
experimental and statistical methods rely on sparse sampling schemes which prevent the 
identification of the different sources of variability at the proposed dosing regimens (Chain 
and Dubois et al., 2013).  Here we have attempted to circumvent these conceptual and 
experimental limitations using a biomarker guided approach in which the primary objective 
is not to obtain a NOAEL, but rather to characterise the exposure-effect relationships 
associated with the observed adverse events.   
Firstly, it should be noted that by incorporating data from typical pharmacokinetic studies at 
pharmacological levels with serial sampling we were able to accurately describe the changes 
in drug absorption and disposition which occur with increasing dose levels.  Secondly, we 
have analysed all the data generated on toxicokinetics and toxicodynamics in a single, 
integrated model, rather than separately according to the traditional group by group 
comparison.  Finally, we performed sequential pharmacokinetic-pharmacodynamic 
modelling of the data  using the so called PPPD approach,  which ensures that 
pharmacodynamic parameter estimation properly accounts for the individual uncertainty in 
pharmacokinetics (due to sparse sampling) in those animals where biomarkers information 
was available (105).  In summary, this approach combines the necessary statistical rigour for 
accurate characterisation of the exposure-effect relationship.  
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From a conceptual point of view, it is worth mentioning that despite current understanding 
about the contribution of drug target to the safety profile of a compound, chronic toxicology 
protocols still rely on the assumption that unwanted events will occur at some frequency, 
making the conclusions about risk highly dependent on the experimental conditions (Lazarou 
et al., 1998; Guzelian et al., 2005; van Vliet, 2011).  We understand that during drug 
development there will be instances in which the mechanisms of toxicity may not or cannot 
be established. In fact, from a regulatory perspective, this information is actually only very 
rarely obtained.  In addition, in many cases toxicity may result from off-target effects and 
biomarkers may not be available.  This is a common feature in some therapeutic areas where 
intended pharmacology does not involve host targets (e.g., antiviral drugs, antibiotics).  In 
such circumstances, a model-based approach would still be preferred to standard methods, 
but drug exposure rather than biomarkers should be considered.  Yet, these limitations 
should not preclude us from advancing developing more integrated protocols, incorporating 
measures of primary and secondary pharmacological activity into the assessment of safety 
and toxicity.   
Our experiments yielded suitable data for modelling of the inhibitory effects of naproxen on 
TXB2 and PGE2, as shown by the goodness of fit diagnostics.  Moreover, our analysis enabled 
the incorporation of non-linearity in the pharmacokinetics of naproxen, which occurs at high 
dose levels (Runkel et al., 1974; Josa et al., 2001).  Unfortunately, due to the lack of 
intravenous data, it was not possible to establish whether dose-dependent 
pharmacokinetics results from incomplete absorption, possibly limited by surface area, 
saturations of transporters or by first-pass metabolism.  Our findings also corroborate the 
data published previously by Huntjens et al. (2006).  Moreover, the characterisation of the 
PKPD relationships for TXB2 and PGE2 provides a more useful summary of findings than one 
normally can deduce from the reporting of observed drug exposure, NOAEL and LOAEL, 
which, in general, are gender and strain-dependent (Urushidani et al., 1978; Nicolson et al., 
2010).  The predicted levels of biomarker inhibition across a wide concentration range and 
the evidence from human in vitro experiment indicates how interspecies differences in the 
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underlying pharmacological effects may be used to translate safety findings.  The incidence 
of adverse events at exposure levels that correspond to IC80 values suggests a possible causal 
association between adverse events and prostanoids (Laine et al., 2008).  Hence, it can be 
concluded that both analgesia and gastrointestinal adverse events seem to occur at 
therapeutic drug levels.   
 
Biomarkers of drug effects as proxy of drug exposure 
Here we make a plea for the use of biomarkers of pharmacology as the basis for defining 
interspecies validity and interpreting risk in humans.  Our investigation shows how a model-
based approach can be used to integrate pharmacokinetic and pharmacodynamic data for 
the evaluation of safety pharmacology and long term toxicity, enabling the incorporation of 
biomarkers of pharmacological activity into the assessment of safety margin and other 
measures of risk. In addition, these results emphasise the role of construct validity to 
account for the potential impact of interspecies differences in the underlying exposure-
response relationships (Knight, 2007).  As indicated by the level of biomarker inhibition 
observed at the selected doses inferences from the preclinical data may be used to infer 
drug effects at comparable levels of inhibition in humans.  Naproxen’s prescriber 
information provides data on the incidence of gastro-intestinal side effects varying between 
1 and 4% with increasing doses.  Despite comparable drug concentrations in rats receiving 
doses up to 40 mg/kg naproxen and in patients taking therapeutic doses, interspecies 
differences in the sensitivity to the effects of naproxen on TXB2 may explain the lower 
incidence of adverse events in humans as compared to the findings in rats.   
Clearly strategies are needed in the evaluation of long term safety and toxicity that increase 
full and impartial examination of existing data before generating new evidence using 
experimental protocols.  Understanding of the underlying pharmacokinetic-
pharmacodynamic (PKPD) relationships becomes therefore a pre-requisite to improve the 
methodological quality and minimise the consumption of animal and other resources within 
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experiments of questionable utility.  As stated by Perel et al. (2007), the failure of animal 
models to adequately represent chronic disease processes in humans may be one of the 
fundamental causes of the poor predictive value of preclinical data.  Yet, the authors seem 
to overlook the relevance of the underlying PKPD relationships to explain concordance or 
discrepancy between animal and clinical data.  In addition establishing the correlation 
between drug exposure and pharmacodynamics, another advantage of a biomarker-guided 
evaluation of safety is the possibility to make inferences about long term effects.  The 
implications of chronic treatment, expressed in terms of total daily dose or systemic 
concentrations may not be as sensitive to allow characterisation of risk. In our investigation 
with naproxen, one of the major concerns has been the potential for cardiovascular risk 
associated with the chronic use of COX inhibitors (Figure 3S).  More specifically, an issue that 
remains unanswered is how to best predict the implications of long term suppression of 
COX-2 activity. Evidence exists for the role of PGE2 and other prostanoids, which suggests 
their contribution to tissue healing and repair (109). Information on the levels of PGE2 
inhibition (instead of systemic concentrations or dose level) may facilitate the interpretation 
and translation of chronic safety data. 
 
Integrated design and analysis of safety pharmacology and toxicology protocols 
Several challenges exist to successfully translating the outcomes from animal research to 
humans in a clinical setting.  Despite the efforts to account for biological and genetic 
differences between species and strains in the interpretation of findings, these differences 
are often disregarded in the design of animal studies (Hooijmans et al., 2013).  In addition, 
the statistical methods used to analyse results are often questionable (Kilkenny et al., 2009).  
These failures have prompted to the use of systematic reviews to assess the predictive value 
of non-clinical experiments.  Yet these reviews have not provided a solution to the source 
problem, i.e., the rationale for evidence generation in safety pharmacology and toxicology.   
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There are a few additional limitations in the current investigation which have not been 
previously mentioned.  Some mechanisms of action may be too complex or poorly 
understood to be characterised by PKPD modelling of data arising from a general toxicity 
study, even if biomarkers have been collected.  Multiple downstream markers may present a 
significant confounder problem which cannot be avoided without additional data.  This 
cannot be easily addressed by the proposed analysis method and becomes a drug 
development issue.  Yet, the use of a parametric approach, and more specifically of 
hierarchical mixed-effects modelling, to inform experimental design and dose selection 
represents an important step in the advancement of translational toxicology, both from a 
biological and statistical perspective.  In this context, the design of the present study was not 
intended to replicate a full toxicology programme for a new chemical entity.  Our intent was 
to show how data obtained from different experimental protocols can be integrated to 
optimise the design of new experimental protocols as well as to characterise drug exposure 
and the underlying pharmacological effects in a strict quantitative manner.  In fact, we 
acknowledge that evaluation of the gastrointestinal effects without prior consideration of 
expected pharmacology and available assays would have been far less informative.   
Important lessons and recommendations can however be derived from our study which are 
applicable other compounds across a wide range of mechanisms of action.  First is the need 
to revisit the dose rationale for the evaluation of safety pharmacology and toxicity.  Whilst 
the concept of safety margin is appealing, it does not address the main issue one faces with 
regard to the therapeutic use of drugs, which is the understanding of the impact of sustained 
pharmacological effects associated with the primary target or receptor system on which the 
drug acts.  Currently, doses are selected in experimental protocols, which exceed by far the 
levels required to achieve maximum pharmacological effects and often even the levels 
required for maximum receptor binding.  Secondly, safety pharmacology and toxicity 
findings are analysed independently from existing data on the pharmacokinetics and 
pharmacodynamics of the compound of interest, making the interpretation of findings an 
empirical process.  Pharmacokinetic and pharmacokinetic-pharmacodynamic modelling 
provides a framework for data integration, enabling a distinction between drug- and system 
 240 
specific properties (Danhof et al., 2008).  Of relevance is the possibility to accurately 
characterise background adverse event rates as well as to establish correlations between 
primary and secondary adverse events. Lastly, the use of different measures of (systemic) 
exposure as a proxy for the underlying risk or hazard needs to be revisited.  Advancements in 
imaging, pathology, genetic and genomic research clearly show that overt symptoms and 
signs arise from drug action as well as from the pharmacological effects induced at cellular 
and tissue levels.  The availability of physiologically-based or semi-mechanistic 
pharmacokinetic and pharmacokinetic-pharmacodynamic models may provide a stronger 
basis for the assessment of risk in humans. In addition to gaining further understanding of 
possible nonlinearity in drug disposition, the possibility to estimating drug-specific 
parameters, such as the estimates of potency or IC80 values, offers measures of the 
pharmacological activity during the course of treatment, which cannot be intuitively derived 
from systemic exposure data, such as Cmax or AUC values.  
In summary, we have shown the benefits of implementing a model-based approach for the 
evaluation of the safety profile of naproxen after chronic administration.  Furthermore, our 
investigation illustrates how PKPD relationships can be used to translate pre-clinical findings 
taking into account interspecies differences in the underlying pharmacological effects.  
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TXB2 PGE2PK
Supplemental material         
Figure 1S: Population pharmacokinetics and pharmacokinetic-pharmacodynamic modelling of TXB2 and PGE2 inhibition by naproxen. For each biomarker, 
goodness-of-fit plots show observed vs. population predicted concentrations (upper left) and conditional weighted residuals vs. time (upper right). Mid and 
lower panels depict the NPDE summary, including QQ plot and histogram of the normalised discrepancy between observed and predicted values. X denotes 
the independent variable, i.e., time.  Samples are clustered around 0, 1, 2, and 4 weeks. 
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Supplemental material 
Figure 2S. Predictive check for derived measures of exposure, as determined by non-compartmental 
analysis. Observed values (triangles and dotted line) are shown to occur within the 95% prediction 
intervals. Solid line depicts the predicted median, whereas shaded region indicates the 2.5th and 
97.5th percentiles. Note that predicted and observed estimates obtained by non-compartmental 









Figure 3S: Schematic representation of COX-2 selectivity with incidence of cardiovascular (CV) and 
gastrointestinal (GI) risk. Increasing degrees of selectivity for COX-2 are associated with augmented 
CV risk, whereas increasing degrees of selectivity for COX-1 are associated with augmented GI risk. 
The relative size of the circles indicates the variation in sample sizes among the trials. The average 
selectivity for each drug is presented ranging from drugs that are highly selective for inhibition of 
COX-2 (e.g., etoricoxib) to those that are more selective for COX-1 (e.g., naproxen). Given the 
interindividual variability in response to these drugs, selectivity is a continuous variable at the 
individual level. ETORIOVER, VIGOR, MEDAL, TARGET and CLASS refer to the overview of Phase II and 
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Abstract 
Despite increasing relevance of the use of biomarkers as predictors of drug effects, 
traditional toxicology protocols continue to rely on the experimental evidence of the link 
between adverse events (AEs) in animals and estimates of systemic drug exposure (e.g., 
Cmax and AUC). Furthermore, biomarkers may facilitate the translation of findings from 
animals to humans. Thus, combined with a model-based approach, biomarker data has the 
potential to predict long term pharmacodynamic effects arising from prolonged drug 
exposure. Here, we use naproxen as a paradigm drug to explore the feasibility of a 
biomarker-guided approach for the prediction of long term AEs in humans. An experimental 
toxicology protocol was set up for the evaluation of effects of naproxen in rats, in which four 
doses were tested (7.5, 15, 40 and 80mg/kg). In addition to AE monitoring and histology, 
sparse blood sampling for the assessment of exposure, thromboxane B2 and prostaglandin 
E2 were also collected. Nonlinear mixed effects modelling was used to analyse the data and 
identify covariate factors on the incidence and severity of AEs. Modelling results show that 
besides drug exposure, maximum PGE2 inhibition and treatment duration are also predictors 
of GI ulceration.  Although PGE2 levels were clearly linked to the incidence rates, it appears 
that ulceration severity is better predicted by measures of drug exposure. These results 
show that the use of a model-based approach provides the opportunity to integrate 
pharmacokinetics, pharmacodynamics and toxicity data, enabling optimisation of the design, 




A key purpose of preclinical general toxicity and safety pharmacology studies is to support 
the safe dose selection in humans. In particular, the need to understand the risks associated 
with long term drug exposure falls within the remit of these two disciplines.  Preclinical 
toxicity data consists of a mixture of acute, mid-term and chronic toxicity data, however, 
identification of long term risks often happens in Phase IV post marketing surveillance.  
Earlier identification of potential risks would enable the use of evidence-based risk 
mitigation strategies.  However, understanding of time-dependent physiological changes 
arising from repeated exposure to a drug is required to identify and assess risks associated 
with long term use of medicinal products. Such an objective may be hampered by the use of 
empirical experimental protocols, as they render the extrapolation of findings across species 
and across molecules rather difficult, preventing accurate translation of the pharmacological 
properties to man (Bai et al. 2013, Della Pasqua, 2013). Among other things, differences in 
sensitivity and target organ specificity continue to represent drawbacks for most clinical 
pathology parameters traditionally used for monitoring organ integrity both during 
preclinical toxicological assessment and clinical safety testing (Connelly et al., 1991). Clearly, 
efforts are required to ensure the availability of tissue- and mechanism-specific data for 
accurate interpretation of acute and long term safety findings. Over the last few years, 
several novel toxicity biomarkers have emerged as sensitive tools for detection, monitoring, 
quantification and prediction of safety and toxicity (O’Brien, 2008, Xie et al., 2013). 
Nevertheless, little attention has been given to the possibility of evaluating safety and 
toxicity using a mechanism-based approach whereby adverse events are assessed taking into 
account the underlying pharmacokinetic-pharmacodynamic (PKPD) properties of the 
molecule (McGonigle et al., 2013). In this context biomarkers can be of great relevance for 
drug discovery and development as they offer the possibility to discriminate between acute 
and chronic term treatment effects. 
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In the current investigation we show therefore how pharmacokinetic-pharmacodynamic 
(PKPD) modelling can be used to unravel the relationship between chronic drug exposure, 
pharmacodynamic effects and overt symptoms and signs. The concept is illustrated by the 
correlation between naproxen concentrations, inhibition of prostaglandin E2 (PGE2) and 
thromboxane B2 (TXB2) and gastric ulceration in rats. Non-selective NSAIDs, such as 
naproxen, act by blocking cyclo-oxygenase (COX), which catalyses the rate-limiting step in 
the formation of prostanoids from arachidonic acid (Chakraborti et al., 2010). Continuous 
COX-1 inhibition following prolonged administration of non-selective COX inhibitors is known 
to induce gastrointestinal adverse effects, especially ulceration and haemorrhagic bleeding. 
Unfortunately, at present the dose selection of COX inhibitors disregards whether maximum, 
long-lasting blockade of either enzyme systems is strictly required for anti-inflammatory, 
analgesic response and how its pharmacology relates the observed adverse events (Huntjens 
et al., 2006). These considerations become essential when evaluating the side effects 
associated with long term use of COX inhibitors, which include gastric and cardiac adverse 
events. From a pharmacological perspective, various investigations have shown that both 
COX-1 and COX-2 mRNA and protein are either constitutive or inducible in specific areas of 
the stomach of animals and humans (Morita, 2002, Coruzzi et al., 2007) (Figure 1). Hence, it 
can be anticipated that some balance between the activity of either isoform may be required 
to ensure normal physiological function.  On the other hand, COX-1-deficient mice show no 
evidence of spontaneous gastric injury despite the absence of COX-1-derived prostaglandins 
(Langenbach et al., 1999). Yet, the administration of NSAIDs-induced gastric damage can be 
invariably related to COX-2 inhibition (Loftin et al., 2002, Wallace, 2008, Takeuchi, 2012). In a 
previous investigation, we have shown how these safety biomarkers can be used in 
conjunction with general toxicity protocols to predict the safety window in humans using an 
empirically derived safety threshold; the no-observed adverse- effect level (NOAEL) (Sahota 
et al., 2014).  The NOAEL approach has many statistical and experimental limitations which 
have been documented elsewhere (Dorato et al.,2005, Sahota et al., 2014). Most 
importantly, by dichotomising the exposure-risk relationship using a threshold, the NOAEL 
approach precludes quantitative risk assessment. Here we demonstrate that the availability 
of a mechanism-based PKPD model together with the application of probabilistic modelling 
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to the adverse event data not only provides a quantitative rationale for determining 
effective and safe dosages following chronic treatment in humans, it also enables effective 
data integration, offering a stronger basis for extrapolating pre-clinical findings into humans 
(Rohatagi et al., 2007).  Moreover, predictive modelling enables testing of different 
parameterisations of biomarker response and drug exposure to enable exploration of causal 
factors driving risk.  This is ultimately provides a flexible evidence-based framework for risk 




Figure 1:  (Upper panel) Diagrammatic presentation of ulcer healing and factors affecting ulcer 
healing. In the intact mucosa, cyclooxygenase 1 (COX-1) is the predominant COX isoform in the 
gastrointestinal tract. In contrast, during wound healing, expression of cyclooxygenase 2 (COX-2), 
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rather than COX-1, is strongly increased in the repair zone. (Lower panel) Gastric effects of non-
selective and COX-2 selective NSAIDs in normal or damaged gastric mucosa. The different effects of 
non-selective or selective COX-2 inhibition are explained by differences in COX-2 tissue expression 
(printed with permission from Halter et al., 2001, Coruzzi et al., 2007) 
In contrast to traditional safety extrapolation methods such as allometric scaling, which 
relies primarily on the estimation of safe exposures based on the human equivalent dose 
(HED), a mechanism-based approach can account for the variability in drug elimination or 
differences with respect to physiological, biochemical (e.g., expression of drug metabolizing 
enzymes), and other time-variant factors (e.g., disease).  These time-variant factors may 
become more important as clinical trials move from acute to chronic interventions in 
patients (in Phase II and III).  
In spite of known interspecies differences exist in GI-related morbidity, we hypothesise that 
the characterisation of the relationship between markers of COX inhibition and adverse 
events enables the prediction of safety windows for chronic treatment with selective and 
non-selective COX inhibitors.  In fact, various studies provide further evidence of a 
multistage pathogenic mechanism for NSAID enteropathy by which the topical action of 
NSAIDs may initiate mucosal damage, which is then converted to macroscopic damage by 
the concomitant inhibition of COX, with decreased mucosal prostaglandins, presumably 
because of their effect on the microvasculature (Fornai et al., 2014).   
Methods 
 
The present investigation is based on a previously published general toxicity study in rats by 
Sahota et al. (2014), with the non-selective COX inhibitor naproxen.  Detailed description of 
the study design, strain of rats, sample collection and analysis and PKPD modelling details 
can be found in Sahota et al. (2014). 
 
Summary of study design: Three different treatment durations were investigated (1 week, 2 
weeks and 4 weeks).  Rats were given daily doses of naproxen by oral gavage.  There were 
four cohorts per treatment duration receiving 0, 15, 40 and 80 mg/kg/day doses.  Satellite 
 255 
animals received identical doses to toxicology groups and were used for plasma drug 
concentration (PK) and biomarker (PD) data measures, TXB2 and PGE2. A optimised 
composite sampling scheme was used and sampling too place on days 1, 7, 14 and 28.  
Details regarding sample analysis can be found in Sahota et al. (2014).  Endpoints in 
toxicology groups included adverse events, including GI histology and terminal PK and PD 
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Figure 2 : Schematic representation of general toxicity study.  
 
Histology: Histological evaluation of the stomach was performed to establish a correlation 
between acute and long term adverse events.  After euthanasia, stomachs were removed 
immediately and were cut open along the greater curvature and washed with warm saline.  
The inner surface was photographed to allow the measurement of the area covered by 
hemorrhagic ulceration. The area of ulceration was determined under a dissecting 
microscope.  Gastric ulceration was measured as percentage stomach surface area affected 
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by ulceration the software Image J version 1.43 (Abramoff et al., 2004) was used for 
calculating ulcer area and total stomach surface area.  The person who performed the 
ulceration measurement was blinded as to animal ID and treatment group. 
PKPD model: The PK and PD data of naproxen were assessed by nonlinear mixed effects 
modelling, as implemented in NONMEM version 7.2.0.  The pharmacokinetics of naproxen in 
plasma were best described by a one-compartment model with first order absorption, first 
order elimination and nonlinear dose-dependent bioavailability.  Weight was included as a 
significant covariate on clearance and volume of distribution.  The PK/PD models for both 
biomarkers, PGE2 and TXB2 were characterised by direct sigmoid IMAX models.  Parameter 
values, precision estimates and goodness of fit diagnostics are described in Sahota et al. (in 
press). 
Data analysis 
Final model parameters describing the gastric ulceration incidence and percentage gastric 
area affected were performed via the numerical integration routine ADVAN13 in NONMEM 
7.2.0 using FOCE with Laplacian estimation.  Convergence was determined by successful 
minimisation and covariance step.  All fitting procedures were performed on a computer 
(AMD-Athlon XP-M 3000+) running under Windows XP with a FORTRAN compiler (Compaq 
Visual Fortran, version 6.1).  Data processing, management and graphical display were 
performed in R (R Development Core Team, 2012).  Model diagnostics and validation were 
performed according to graphical and statistical criteria.  Goodness-of-fit plots, including 
observed (OBS) versus individual prediction (IPRED), OBS versus population prediction 
(PRED), conditional weighted residuals (CWRES) versus time and CWRES versus OBS were 
used for diagnostic purposes (104).  
Given the purpose of the study in discriminating between acute and long term effects of 
naproxen, different parameterisations were considered for describing drug effects during 
the course of treatment.  Model-based exposure and biomarker levels from the final PKPD 
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model were calculated for each individual animal using post-hoc empirical Bayes estimates 
(using MAXEVAL=0).  Details of the calculation methods are described in Table 1.   
 
 
Table 1: Calculation of biomarker response and exposure variables. Individual predicted naproxen 
concentrations and biomarker levels are denoted by () and g(), respectively. 
Parameter name Symbol Calculation 
Area under drug concentration vs. time profile AUC   !!"#  
Area above biomarker concentration vs. time 
profile 
AOC g(0) −  g !!"#  
Time under threshold (80% inhibition) TUT  1l01n.l01(;) !;  
Cumulative area under drug concentration vs. 
time profile 
CAUC   !;  
Cumulative area over biomarker concentration 
vs. time profile 
CAOC g(0) −  g !;  
Maximum drug concentration over 24 hour 
period 
CMAX max	('(():  − 24 < ( < .) 
Maximum biomarker inhibition over 24 hour 
period 






Ulceration model: Since each histological examination was performed once per 
animal, no between-subject variability could be estimated.  All random effects are 
therefore accounted for with the residual variability structure.  Nevertheless, both 
the incidence and severity of ulceration were considered during modelling.  
Incidence was modelled as the probability of occurrence of ulceration, q, at the 
time of sacrifice, , and severity was modelled as 
DC45|,,, the % gastric surface 
area affected,  when ulceration is observable at the time of assessment . 
A logit transformation was used to describe the incidence of stomach ulcers.  The general 
equation describing the incidence of ulcers is given by: 
 
          
(q, = 1) = rst(uvw∑ u~∗0yz,{,~~ )Lwrst(uvw∑ u~∗0yz,{,~~ )    (equation 5) 
 
where  P(Ui,j) represents the probability of the presence of ulceration in individual i at time   .  COVi,j,k is the Kth covariate value for individual i and time . L  is a parameter governing 
the baseline logit probability and θ k is the coefficient of the K
th covariate relationship. 
For technical reasons, the severity of ulceration, i.e., percentage gastric surface area affected 
was log-transformed.  The basic model did not include any covariates on response.  Two 
fixed effect model parameters were used, L and .  
 
(q, = 1) = rst(uv)Lwrst(uv)   (equation 6) 
 PER,, =  0, F	q, = 0, F	q, = 1  (equation 7) 
 logPER,, = logPER,, + ε, (equation 8) 
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where  PERobs,i,j and PERpred,i,j represent observed and predicted percentage ulceration, 
respectively, in individual i at time .  εi,j is the random effect describing residual variability 
with mean 0 and estimated standard deviation. 
Covariates: To explore the relationship between drug exposure, biomarkers and adverse 
events over the course of treatment, different secondary pharmacokinetic and 
pharmacodynamic parameters expressing systemic exposure and pharmacological activity 
were explored as covariates on the logistic model parameters using the stepwise covariate 
method (SCM) in PsN (107).  Potential influential factors on the incidence of ulcers included 
body weight, age.  Time measured in days (DAY) was also tested used as a covariate as 
surrogate for time-dependent effects such as healing, tolerance or other mechanisms 
influencing ulceration incidence and/or severity. For the percentage gastric area affected, 
PER, the specification of the covariate relationship was based on the diagnostic plots of the 
basic model.  Linear, exponential and hyperbolic (sigmoid Emax) functions were considered 
during covariate model building.  A hockey-stick function was also tested to describe toxicity 
only manifesting above a threshold exposure/biomarker level. The linear relationship was 
characterised by: 
 PER,, =  0, F	q, = 0L +	ytr ∗ (N −= FG?(N)) , F	q, = 1 
where  is population prediction and 695 is the slope of relationship between parameter 
and (centred) covariate 
The exponential relationship was similarly characterised by: 
 PER,, =  0, F	q, = 0L ∗ expytr ∗ (N −= FG?(N)) , F	q, = 1 
 
Since data were sparse and maximum effect may not have been reached, maximum effect 
was fixed to 100% during the evaluation of the sigmoid Emax function.   
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 PER,, =  0, F	q, = 0 ∗ L;;∗0yz0yzw0yz , F	q, = 1 
where γ is an estimated Hill coefficient. 
Covariate relationships were centred by the median value of the covariate so that in this 
case PER,, = , as in the basic model. 
 N; = (L;;"u)85|:(0yz)u  
The hockey stick function was implemented according to the following function: 
PER,, =  L, F	q, = 0	and	COV < 	e£¤r£L +	ytr ∗ (N − e£¤r£) , F	q, = 1	and	COV ≥ 	e£¤r£  
where e£¤r£ is the threshold value of the covariate where toxicity begins. 
Covariates were incorporated into the model by stepwise forward inclusion.  A significance 
level of p<0.01 was used for inclusion, which represented a drop of least 6.63 units in the 
objective function for each additional parameter.  A final evaluation of the statistical 
significance of all factors identified during the previous step was performed by subtracting 
each covariate individually (backward elimination).  The final structural model (i.e., fixed 
effects model) included only those covariates whose subtraction resulted in a decrease of at 
least 6.63 units in the objective function (p<0.01).  Finally, to investigate model uncertainty a 
bootstrap SCM was performed to estimate covariate inclusion probabilities. 
 
Model validation: The performance of the ulceration models were assessed by numerical 
and visual predictive checks.  To that purpose, 1000 data sets were simulated with the final 
model parameter estimates.  The mean and the 95 % confidence intervals were calculated 
for the incidence and percentage gastric area affected.  Validation procedures also included 
normalised prediction distribution errors (NPDE), which are based on the assumption that 
 261 
the normalised (de-correlated) prediction distribution errors (discrepancies) are normally 
distributed (Comets et al., 2008).  One hundred datasets were simulated using the final 




In total, 80 histological examinations were performed on ontoxicology group animals.  These 
revealed gastric ulceration in all dose levels; therefore no NOAEL could be obtained for any 
of the treatment durations (Figure 3).  All animals receiving 80 mg/kg in the 1 week cohorts 
suffered from moderate weight loss.  The animals in this cohort were immediately sacrificed, 
and due to ethical reasons this dose level was discontinued.  Different dose levels of 
naproxen were considered for the two-week and one-month cohorts, which received lower 
doses (7.5, 15, and 40mg/kg).  Histological examination and terminal blood samples were 
performed on these animals.  No other adverse events were reported. 
Logistic models for gastric ulcerations  
Empirical analysis of this data revealed some peculiarities in data where there was no 
significant dose-response until week 4.  In fact, the data revealed a possible negative dose-
response relationship before week 4.  Moreover, the incidence of ulcers was much lower in 
the week 4 cohort than in shorter treatment durations. Furthermore, exploratory evaluation 
of the relationship between naproxen exposure and biomarker levels instead of dose did not 
provide further evidence of an apparent relationship.  Physiologically, interpreting such data 
is difficult.  However, it is plausible that the ulcerative effect is acute and diminishes with 
sustained long term exposure. After an initial attempt to describe the data without the use 
of covariates, a clear model misspecification was observed.  As shown in Figure 4, the 
apparent negative dose-toxicity relationship for week 1 and week 2 was not replicated by 













Figure 3. Plots of the observed ulcer incidence (left) and severity (right).  Dots in the left plot show observed percentage of 
total animals in each cohort manifesting GI toxicity. Ulcer severity is measured as % of stomach area affected by ulceration. 
Given the time-dependent effect on the accuracy of this measure, the uncertainty (shaded area) of the regression line is also 
shown together with the data. 
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Stepwise model building combined with bootstrap methods showed a possible negative 
correlation between the incidence of ulceration and treatment duration, indicating an acute 
effect dissipating over time (see Figure 5).  By contrast, upon incorporation of this time-
dependent effect into the final model, the overall fit improved (Figure 6). CMAX and AUC 
were shown not be the primary drivers of toxicity, although these parameters may be 
indirectly correlated with risk.  
Our attempt to establish a relationship between drug exposure/ biomarker levels and 
adverse events revealed clear differences in the sensitivity of explanatory variables used to 
describe the incidence of ulcers and ulceration severity.  Out of tested relationships, the 
maximum inhibition of PGE2 was the best predictor of adverse event incidence, with the 
bootstrap SCM showing low model uncertainty.  On the other hand, cumulative TXB2 
inhibition was found to be the best explanatory variable for the severity of ulceration (Figure 
7).  Other physiologically plausible explanatory factors, such as maximum PGE2 inhibition or 
DAY (treatment duration) were found to be fraught with significant model uncertainty.  The 
model parameters for the final model are summarised in Table 2 and figure 5. 
Table 2: Logistic  model parameters. SE = standard error.  
Relationship Description Parameter value SE 
LOGIT Typical value: 
Logit (
(q, = 1)) -0.226 0.305 
LOGIT – IMAXPGE Covariate: 
Logit (additive) 
0.042 64.8% 
LOGIT – DAY Covariate: 
Logit (additive) 
-0.066 0.022 
PER Typical value:  
% gastric area affected 
0.21% 17.2% 
PER – CAUCTXB Covariate: Hockey stick Threshold= 94.3% 




















Figure 4: Plots of the observed and predicted ulcer incidence (left) and severity (right).  Dots in the left plot show observed percentage of total 
animals in each cohort manifesting GI toxicity. Ulcer  severity is measured as % of stomach area affected by ulceration. The shaded area is depicts 
the 95% uncertainty in population prediction of the model (dotted lines depict the 50th percentile). The model is unable to describe the apparent 
negative dose-response trend observed after short treatment durations (i.e., 1 and 2 weeks), indicating that time-independent, long-lasting or 
irreversible processes may appear only after long term treatment. 
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Figure 5: Model specification uncertainty. Results of boostrap SCM.   Bars indicate model selection 
probability as determined by the bootstrap SCM ordered from most to least probable.  Only top 5 
most probable displayed.  A wider, flatter distribution reflects high model specification uncertainty, 
i.e., two or more different models may be indistinguishable.  The overlaid table in the insert shows 
















Figure 6: Visual predictive checks. Left panel depicts the prediction distribution for the incidence of ulcers, whereas the solid line indicates the 
observed percentage of total animals manifesting GI toxicity. Right panel shows ulceration severity against predicted normalised 
exposure for different variables of interest (AUC= area under the concentration vs. time curve; AOC= area above biomarker concentration vs. 
time profile; CAUC= cumulative area under the concentration vs. time curve; CAOC= cumulative area over biomarker concentration vs. time 
profile; CMAX = maximum drug concentration over the period of 24h; CMIN= maximum biomarker inhibition over the period of 24h). The shaded 




Figure 7: Differences in the sensitivity of explanatory variables describing the relationship between drug exposure/ biomarker levels and adverse 
events, as determined by the incidence of ulcers and ulceration severity.  Dashed lines represented median profile of simulated values using the 
final model, whereas shaded represents the 95% prediction intervals.  AUC= area under the concentration vs. time curve; AOC= area above 
biomarker concentration vs. time profile; CAUC= cumulative area under the concentration vs. time curve; CAOC= cumulative area over biomarker 
concentration vs. time profile; CMAX = maximum drug concentration over the period of 24h; CMIN= maximum biomarker inhibition over the 
period of 24h; IMAX= maximum biomarker inhibition; TOT= time over threshold (i.e., 80% biomarker inhibition); PGE = prostaglandin E2; TXB= 
thromboxane E2). See text for details on the units of the independent variables (x-axis). Based on statistical criteria, it appears that maximum 
inhibition of PGE2 was the best predictor of adverse event incidence. On the other hand, cumulative TXB2 inhibition was found to be the best 




Current practices in toxicology and safety pharmacology rely on the concept of thresholds of 
drug exposure (e.g., NOAEL) as a proxy for the risk of adverse events, which are treated in a 
mechanism- and time-independent manner.  The disadvantage of such an approach is that 
long term toxicity can become conflated with acute toxicity, which in turn could be mitigated 
or related to entirely different physiological mechanisms (Blantz, 1996, Dom et al., 2012).  
Another hurdle to overcome in the assessment of risk is that general toxicity studies are not 
designed to characterise the relationship between drug exposure and toxicity, but rather to 
explore the boundary between therapeutic and toxic exposures.  As such, data can be 
uninformative with respect to understanding the causal factors and underlying mechanisms 
associated with unwanted pharmacological effects.  Clearly, these inefficiencies in 
experimental protocol design also violate the principle of the 3 Rs (reduction, refinement 
and replacement) and ultimately contribute to biased conclusions about the long term 
benefit-risk ratio of an intervention (Balls, 1994).  By contrast, the use of a model-based 
approach provides the opportunity to integrate safety and toxicity data and assess in a 
strictly quantitative manner the contribution of influential factors, namely drug exposure 
and biomarkers of pharmacological activity to potential adverse events (Danhof et al., 2005, 
Danhof et al., 2008, Bai et al., 2013).  
 
Mechanism-based analysis of long-term safety and toxicology data  
From a methodological perspective, general toxicology studies represent a challenge for 
model-based analysis techniques since sparse pharmacokinetic data, which are often 
derived from satellite animals, need to be linked to adverse event data, which are also 
typically sparse.  In addition, lack of individual exposure profiles often prevents further 
evaluation of the role of relevant physiological or pathophysiological measures, such as 
biochemistry, haematology or biomarker data as influential covariates on treatment 
outcome. Typical experimental protocols in toxicology research yield therefore less 
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informative datasets, as compared to studies aimed at the characterisation of PKPD 
relationships, which are now commonly used in early drug development (Knight, 2007).  In 
fact, the impact of such limitations has been highlighted in a separate investigation, where 
focus is given to the statistical aspects of protocol optimisation and to the use of nonlinear 
mixed effects modelling of safety data (Sahota et al., unpublished results).  Among other 
things, we have identified important design requirements for ensuring accuracy and 
precision of parameter estimates for safety thresholds. 
An important aspect our analysis was to show that without major modification to existing 
general toxicity protocols, it is possible to explore and eventually elucidate the causal 
relationship between drug administration, exposure and the incidence and severity of 
adverse events associated with chronic therapy.  In addition to the integrated analysis of 
pharmacokinetic, pharmacodynamic and toxicity data, here we have shown that the lack of 
NOAEL in the present study (due the presence of adverse events at all tested dosing levels) 
has not prevented us from further characterising the exposure-adverse event relationships.  
Yet, the proposed modifications to the study protocol were designed not to prevent existing 
empirical analysis methods, including the estimation of non-compartmental parameters 
such as composite AUCs.  The main modifications consisted in the additional collection of 
biomarker data from animals and the choice for treating histological observations as a 
continuous data type.  The incorporation of biomarkers into the assessment of long term 
toxicity enables us to further understand time dependencies and nonlinearities in down-
stream effects related to the primary pharmacological target (Huntjens et al., 2010).  Here 
we have characterised COX-1 (TXB assay) and COX-2 (PGE assay) activity given their role in 
maintaining the homeostasis and integrity of the gastric mucosa (Jackson et al., 2000).  As 
shown in Sahota et al. (2014), considerable inhibition of both isoforms occurs at all 
experimental dose levels.  
 
PKPD relationships as translational factor for the evaluation of risk in humans.  
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Characterisation of the relationship between chronic exposure and the incidence and 
severity of adverse events is a critical but not sufficient requirement to predict safety and 
toxicity in humans. PKPD models need to be parameterised in such a way that it is possible 
to discriminate between drug-specific and system-specific parameters.  Understanding of 
pharmacokinetic differences in conjunction with detailed information on potential system 
specific differences, such as varying metabolic capacity, are sine qua non conditions to 
translate and accurately interpret safety findings (Zuideveld et al., 2007, Chain and Dubois et 
al., 2013).  Even when estimation of such parameters may be impractical, inferences can be 
made about their magnitude.  Undoubtedly, a mechanism-based approach is likely to yield 
more reliable predictions than the currently accepted use of empirical cover or safety margin 
which disregard any possible pharmacological basis for both observed and unobserved 
adverse events.  
Specifically with regard to naproxen-induced ulceration, our results need to be interpreted 
with caution.  First, it should be noted that formal extrapolation of our findings requires 
further information on system-specific properties, including potential differences in gastric 
mucosa susceptibility to ulceration and expression and activity of isozymes during 
maintenance and repair processes.  Rats appear to be more susceptible to GI toxicity than 
humans and show gender specific differences in ulceration, so any prediction without 
correcting for such differences is therefore likely to overestimate risk (Urushidani et al., 
1978, Lanza et al., 1979).  In addition, from a methodological perspective, the use of non-
linear mixed effects modelling as a tool to characterise the determinants of drug effects and 
concurrently explain variability, imposes a different approach to statistical inference and 
interpretation of experimental results.  Here we have shown that multiple models, with 
different explanatory variables meet the statistical criteria used for fitting procedures.  
These apparently conflicting findings can be interpreted as model uncertainty due to design 
or even imprecision in parameter estimation.  On the other hand, these same results can 
also be considered hypotheses generating, i.e., they shed light into the possible or even 
plausible combination of mechanisms underpinning the causal path(s) between drug 
exposure and toxicity.  This latter aspect is essential for extrapolating data from animals to 
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humans.  In fact, a study performed by Huntjens et al. (Huntjens et al., 2006). The authors 
conclude that the main determinant of the primary anti-inflammatory, analgesic effect is the 
degree of target engagement at the tested dose ranges, as defined by the inhibition e of 
PGE2 and TXB2.  
It is known that inhibition of both isoforms is required for GI toxicity.  Hence, despite our 
attempt to identify a single biomarker as explanatory variable or covariate on the incidence 
of ulceration is likely a result of the interaction between them (White, 2004).  However, our 
model was unable to estimate interaction terms. Given that selective COX-2 inhibitors cause 
less GI toxicity than non-selective inhibitors (Brzozowski et al., 2001, Rostom et al., 2007), 
this limitation could be overcome by incorporation of toxicity data from compounds with 
high selectivity for COX-2.  Accounting for this interaction will allow prospective prediction of 
new compounds with varying selectivity for COX-1 and COX-2.  Such integration could be 
achieved either within a Bayesian framework through the use of informative prior 
distributions, or through simultaneous analysis of the aggregated dataset.  Ultimately, such 
an analysis may shed light on the optimum degree of selectivity to be obtained for the 
selection of future compounds with a superior risk-benefit profile.  Moreover, we anticipate 
the possibility to extend the approach for the evaluation of NSAID-induced cardiovascular 
effects (McGettigan et al., 2006, Schneeweiss et al., 2006, Fitzgerald, 2007).  A 
comprehensive risk management strategy prior to market authorisation is now in place for 
the development of new selective and non-selective COX-inhibitors, which is aimed at the 
detection of late onset cardiovascular events associated with long term use of a compound 
(Solomon et al., 2004; Motsko et al., 2006).  As such, these adverse drug reactions are not 
likely to be observed pre-clinically in a traditional chronic toxicity protocol.  Efforts are 
required to predict the implications of continuous target engagement, instead of simply 





The findings of this study demonstrate the feasibility and potential benefits of proposed 
model-based approach for the evaluation of chronic safety pharmacology and toxicity. 
However, it should be noted that the accuracy, precision and validity of the method still 
relies on the experimental data, which is maximised in terms of its informative value. The 
adverse events we have assessed in this study were relatively frequent.  Characterisation of 
rare or low frequency events may still be difficult, particularly if one cannot make use of 
historical data (e.g., unprecedented mechanism) or make inferences about class effects.  
The quantification of model uncertainty is not currently routine practice in traditional PKPD 
analyses.  The present work has shown that even for relatively frequent adverse events, 
model uncertainty can be significant and therefore one should quantify it.  This likely arises 
from the fact that toxicity studies are generally designed to find safety windows and not to 
explore the entire exposure-risk profile.  We also acknowledge that the absence of 
ulcerations in vehicle treated animals and the lack of additional cohort with lower exposure 
levels may represent a weakness in our investigation.  True baseline rates for ulceration 
could not be factored into the analysis, nor was it possible to accurately establish the 
adverse event rates at lower doses. 
In summary, identification of long term adverse events often arises in Phase IV post 
marketing surveillance.  Our investigation has shown how a model-based approach can be 
used to support early identification of long term adverse events, enabling further integration 
and translation of pre-clinical data.  Our results also illustrate the importance of quantitative 
methods for further understanding of the mechanisms of toxicity.  Moreover, the availability 
of PKPD relationships may allows us to make inferences about untested doses and dosing 
regimens, providing an opportunity for risk mitigation, independently from available 
experimental data.   
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Pharmacology-based assessment of toxicity: towards quantitative 
risk prediction in humans  
 
Undoubtedly, the main objective of toxicology studies during the course of drug discovery 
and development is to support scientists, clinicians and regulators in establishing the likely 
risks posed to humans and more specifically to patients. Challenges exist not only when 
interpreting the results and making extrapolations to predict risk, but also at the planning 
and design stage, including the choice of most relevant species, choice of the doses to be 
investigated and duration of treatment.   
Despite the requirement for extrapolations and more quantitative measures of what 
represents safe exposure, limited attention has been given to the role of alternative 
methodologies that have emerged in pharmacological sciences. Over the last decades, most 
of the empirical evidence generated as part of general toxicity package in drug development 
has been treated in a descriptive manner.  Yet, numerous statistical modelling tools have 
been developed over that same period that have substantially improved our understanding 
of human exposure, pharmacokinetics, pharmacodynamics and disease processes (32-35).  
Opportunities exist for toxicology to transition from a qualitative science to a discipline 
capable of quantitatively describing relevant biological and pharmacological processes that 
determine the exposure-effect relationships in animals and in humans. However, there are 
multiple methodological obstacles to overcome before efficient and early prediction of 
chronic toxicity of new chemical and biological entities becomes routine practice in 
pharmaceutical R&D. First of all, the application of quantitative modelling concepts to 
toxicology imposes the need for an integrative approach in that the evaluation of toxicity 
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and adverse events become part of continuum that encompasses primary and secondary 
pharmacology as start point (5,6).  
 
Integration of quantitative tools within experimental design, data collection, analysis and 
interpretation has become more important than ever in pharmacology research. Evidence so 
far supports the use of such tools to 1) optimise experimental protocols, 2) refining and 
reducing the burden and number animals required and most importantly 3) translating drug 
effects from animals to humans.   
The scientific and regulatory communities should acknowledge that most toxicity tests, as 
currently designed, provide only a qualitative estimate of the hazard associated with 
supratherapeutic exposure (7). This is clearly not the most important question that needs to 
be addressed from a clinical perspective. The safety and toxicity profile of a medicinal 
product needs to include an assessment of the risk at therapeutic levels, especially in chronic 
disease conditions (8).  Yet, data produced using current testing guidelines are not always 
suitable for robust mathematical exposure–response modelling. As stated at the beginning 
of this thesis, we recognise therefore that adequate data integration and optimised 
protocols are required before quantitative modelling can be applied as mainstream tool for 
the analysis and interpretation of toxicity and adverse events.  
The research performed in this thesis is therefore focused on a number of issues that need 
to be considered during the course of drug discovery and development to ensure more 
efficient use of the data generated in safety pharmacology and toxicology protocols. We 
have attempted to address four questions that can be considered enablers for the 
implementation of a systems approach for the characterisation of physiological and 
pharmacological responses induced by chronic exposure to a drug. 
In Chapter 1 we reviewed mainstream safety assessment practices in drug development and 
the consequences of empirical evidence generation.  Based on historical examples we 
identified methodological flaws in the current paradigm and categorised issues relative to 
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the scientific rationale as a hierarchical tree describing the decision making process.  From a 
theoretical perspective, different facets of the same problem were discussed, which relate 
to four seminal areas of scientific research: 1. optimisation, 2. translation, 3. analytical 
construct and 4. decision criteria.  The implications of each of these points for the 
implementation of model-based methods were addressed separately. We showed that 
errors in the prediction of safety may arise due to the use of empirical safety thresholds, 
which are used as a proxy or surrogate for toxicity or undesirable effects. Published data 
make it clear that instead of pursuing a more mechanistic approach, empirical methods 
continue to be used. To cope with inaccuracy and poor precision, safety factors, also known 
as uncertainty factors, have been incorporated on the top of empirical thresholds.  Their 
application in drug development has become widespread and is detailed within the 
regulatory guidelines.  Based on historical examples, we have shown some important 
challenges for the early characterisation of the safety profile of a new molecule and discuss 
how model-based methodologies can be applied for better design and analysis of 
experimental protocols. An initial conclusion can be drawn in support of the efforts 
presented throughout the thesis, in that current practices fail to support decision making on 
multiple levels.   
A shift in paradigm was then proposed to ensure that pharmacological concepts are 
incorporated into the evaluation of safety and toxicity. In chapter 2, we presented the 
conceptual and methodological aspects that underpin the work presented in the subsequent 
chapters of this thesis. Our goal was to explore the feasibility of pharmacologically based 
quantitative toxicology assessment and risk prediction in humans and, where possible, to 
compare the performance of this approach to traditional safety assessment approaches. We 
have also highlighted an important difference in the objective of current experimental 
protocols, which are aimed at confirming safety rather than characterising the range of 
toxicity. Four important questions were highlighted which define the scientific framework 
presented in the subsequent chapters, which can be defined as opportunities for 
optimisation and knowledge integration. We set a constraint that existing experimental 
protocols would be viewed as a starting point, and any proposals to deviate from these 
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protocols would be minimal.  Although similarities exist between efficacy and toxicology 
assessment from a pharmacological point of view, here we proposed an investigational plan 
to determine the methodological requirements of toxicological data analysis.  Furthermore, 
we set an often forgotten objective in non-clinical research, i.e., the ethical duty to refine, 
reduce and replace the use of animals in experimental protocols (9).  The investigational 
plan of the thesis was detailed and divided into two distinct sections (sections 2 and 3), in 
which the development of methodology is followed by a case study with real data. 
  
Conceptual framework 
In Section II, the advantages and limitations of a model-based approach were evaluated.  
Conceptually, we have demonstrated how factors such as within- and between-subject 
variability or uncertainty in estimation can be accounted for when descriptive statistics are 
replaced by pharmacokinetic and pharmacokinetic-pharmacodynamic parameters. Using 
simulations to replicate experimental protocols we have illustrated how different measures 
of exposure can be obtained which may be physiologically more relevant for the 
characterisation of delayed or late onset adverse events. Particular focus was given to the 
feasibility of assessing long term risk from shorter duration studies.  In addition, we have 
identified alternative options for the design and analysis of preclinical general toxicology 
protocols. 
Initially, focus was given to the use of non-linear mixed-effect (NLME) modelling as a data 
analysis tool for the evaluation of toxicokinetic experiments and parametric estimation of 
safety thresholds. In Chapter 3 we simulated toxicokinetic data from satellite treatment 
groups in general toxicity protocols using three hypothetical drugs, with distinctly different 
pharmacokinetic properties.  Analysis of the simulated datasets with traditional non-
compartmental analysis and NLME models allowed us to measure the performance of both 
methodologies and compare them in terms of bias and precision.  The main source of the 
bias in the parameters of interest was found to be intrinsic to the non-compartmental 
method, especially when looking at the estimation of Cmax. Our results also revealed the 
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typical point estimates of parameters derived from empirical methods to describe drug 
exposure give an undue measure of certainty, allowing for the propagation of uncertainty 
from estimation to uncertainty in safety thresholds such as NOAEL. As demonstrated by the 
simulations, this issue could be circumvented by model-based methods, which enable the 
assessment of uncertainty associated with a variety of causes such as uninformative study 
design, large variability and/or unknown covariates. The use of hypothetical drugs with 
different pharmacokinetic properties also allowed us to illustrate how obtaining a 
pharmacokinetic model provides opportunities for different parameterisations or metrics of 
drug exposure, as for example, the estimation of cumulative AUC to describe irreversible or 
chronic toxicity, including predictions beyond the study duration. This entails an increase in 
the quality of the decision-making process and ultimately in the interpretation of the 
estimated safety thresholds. 
Since experimental protocols for the evaluation of general toxicity are not optimised for 
model-based analysis, and more specifically for population pharmacokinetic modelling, an 
important question to be addressed is whether they can  be optimised to ensure a reduction 
in the number of animals required, whilst still providing sufficient estimation precision for 
measures of exposure, which are often secondary pharmacokinetic parameters, such as AUC 
and Cmax.  In contrast to existing optimality software and algorithms, which support 
optimisation of experimental design with respect to primary parameter precision, in Chapter 
4 we show that secondary parameters can be optimised without the resource-intensive 
procedures imposed by D-optimality.  Our approach instead consisted of FIM evaluations 
followed by calculation of the expected secondary parameter precision.  Both of these 
procedures were found to be computationally inexpensive. Most importantly, our results 
highlight the impact of optimal protocol design on parameter estimation. The proposed 
method for optimisation of sampling time and group size indicates that a reduction of 
approximately 30% in the number of animals can be obtained for composite sampling 
designs without significant loss of precision in the estimates of interest. This improvement 
was found to be independent of differences in drug disposition, as assessed by the different 
profiles derived for the hypothetical compounds. Our analysis also suggests that for 
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composite methods sample size does not determine the precision of the pharmacokinetic 
parameters of interest. Rather, it is the sampling scheme and dose levels which matter. 
Interestingly, we have observed that the precision of the secondary parameters remains 
unaffected even when some of the primary pharmacokinetic parameters are poorly 
estimated.   
Whereas the use of model-based estimates for the assessment of safety thresholds may be 
perceived as complicated, this approach was shown to be unbiased and predictive, allowing 
for the incorporation of the physiological factors underlying the pharmacokinetic properties 
of the drug under investigation, such as metabolic saturation. Moreover, our simulation 
scenarios provided evidence of the feasibility to integrate prior information, including data 
from other experiments. 
Still within the scope of protocol optimisation, in Chapter 5 we explored the implications of 
introducing biomarkers into the evaluation of a drug’s safety toxicity profile. Here we 
emphasised the fact that accurate prediction of long term adverse events and toxicity may 
require one to identify not only the exposure at which the effects are observed, but also 
biomarkers of pharmacological activity. In contrast to traditional protocols, which imply a 
direct relationship between observed systemic exposure and adverse events, we have 
proposed the collection of biomarkers at the scheduled pharmacokinetic sampling points to 
facilitate the characterisation of pharmacokinetic-pharmacodynamic relationships. Our 
evaluation also compared the analysis of biomarker data based on standard non-
compartmental methods. We simulated toxicokinetic and biomarker data from satellite 
groups using a variety of hypothetical drugs. The analysis of the simulated data showed that 
the true underlying model was often unidentifiable particularly in scenarios with delayed PD 
effects (hysteresis). However, in all scenarios, model approximations could be made which 
led to satisfactory performance in predicting biomarker levels.   We believe, therefore, that 
greater awareness is required about the limitations of current experimental protocols, 
particularly in a period in which long-term safety have become a major clinical and 
regulatory concern.  To mitigate such effects we recommend careful consideration of model 
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uncertainty. Our analysis showed that model selection criteria should be guided not only by 
ability to describe data but also by assessing the physiological relevance of model 
assumptions.  When model development ends in multiple competing models performing 
similarly with respect to model selection criteria, clear reporting of such model uncertainty is 
necessary.  In any case, model averaging should be discouraged when predictions arising 
from different model differ significantly.  Finally, parameter uncertainty should be 
incorporated when performing simulations or using the model to make predictions. 
Our goal with Chapter 6 was to investigate the feasibility of integrating the aforementioned 
mechanistic PKPD models with adverse event data for model-based toxicology assessment.  
Similar in silico methods used in chapters 3 and 5 were used to simulate drug induced and 
background adverse events according to three different pharmacological mechanisms 
(direct, indirect, and irreversible binding).  We focused on rare and chronic adverse drug 
reactions to provide the largest methodological challenge, including reversible and 
irreversible drug effects. To ensure real-life conditions, assumptions were made with regard 
to situations 1) in which drug-induced and background adverse events are indistinguishable 
from each other, 2) the time interval elapsed between onset and diagnosis was large and 
symptoms can be detected only once per animal during histological examination and 3) the 
adverse event can be treated as binary data.  Our results showed that estimation of safety 
thresholds, as determined by the NOAEL, was highly biased and imprecise.  Moreover, in two 
out of three scenarios where the effects of safe and effective hypothetical compounds were 
simulated, we found that strict use of the NOAEL as go/no-go criteria would lead to a more 
than 50% probability of concluding that the compound is unsafe and consequently leading to 
wrongful termination of the development program. Upon investigating the feasibility of 
model-based analysis, we found that we required two important components for successful 
quantification of rare drug-induced effects: a) the availability of prior information on 
background adverse events and b) MCMC-based estimation algorithms.  Regarding the first 
requirement, we showed that without prior information, adverse drug reactions are 
confounded with background incidence rates, preventing parameter identifiability. We 
found that an aggregated historical placebo data was sufficient to resolve this confounding. 
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On the other hand, when evaluating the performance of available parameter estimation 
methods, we found that maximum likelihood algorithms are unstable and unreliable.  By 
contrast, MCMC-based estimation provided stable and accurate measures of parameter 
uncertainty.  The use of the BIC as a model comparison and averaging criteria showed 
consistently high model specification uncertainty. Our results highlighted that traditional 
model selection and averaging techniques based on the penalizing models for complexity 
were not appropriate as they heavily weighted models featuring no drug effect. Finally, it 
should be noted that missed adverse events were also easily quantified using the proposed 
strategies.  Differently, from the empirical approach to treating missing events as absent, the 
use of MCMC methods provided evidence of the parameter distribution, enabling 
imputation of the events, even if they have not been observed. 
In summary, the conceptual framework presented throughout this section  provides 
evidence regarding the feasibility and relevance of  a model-based approach for the, 
evaluation of safety pharmacology and toxicology profile of new molecules prior to their 
progression into humans. It has become clear that current methods in preclinical toxicology 
do not support the integration of pharmacokinetic and pharmacodynamic data as basis for 
predicting safe exposure in humans. By contrast, a model-based approach represents a 
viable tool for characterising PKPD relationships, including estimates of parameter and 
model uncertainty.  A benefit this strategy lends to decision-making is that clinical judgment 
can be applied to consider the entire relationship between drug exposure and adverse 
event, rather than a point estimate or threshold. 
In the third part of the thesis (Section III) we attempted to illustrate the implementation of 
experimental protocols that meet the requirements for model-based analysis. Given the 
continuous debate regarding the benefit-risk balance of chronic treatment with non-
steroidal anti-inflammatory drugs, naproxen was used as a paradigm compound to evaluate 
the known acute and chronic toxicities. Whilst the lack of selectivity of naproxen and the 
evidence for distinct mechanisms underpinning acute effects (such as bleeding and 
ulceration) and long term effects (such as renal and cardiovascular damage) have evolved 
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over the years and might not have been understood at time of the development of the 
compound, our  investigation made it quite didactic in that it demonstrates how human 
safety and toxicity may require characterisation of drug effects at exposure levels 
corresponding to the therapeutic doses. Furthermore, by considering the requirements for a 
suitable experimental protocol, we also took the opportunity to identify practical challenges 
and difficulties that one may face for the prospective use of the methodology.   
 
Practical application 
Using a typical toxicology protocol in rats, in Chapter 7 we have explored how two 
biomarkers, namely thromboxane (TXB2) and prostaglandin (PGE2), can be used in 
conjunction with drug exposure data to evaluate short, moderate and long-term treatment 
effect. It was assumed that gastrointestinal bleeding is due continuous COX-1 inhibition, 
whereas ulceration results primarily from the suppression of COX-2.  Pharmacokinetic and 
biomarker data were integrated with data from historical protocols and published literature 
to ensure characterisation of drug properties at putative therapeutic levels. We found that 
the pharmacokinetics were best described a one-compartmental model with first-order 
absorption.  A nonlinear relationship between dose and bioavailability was included into the 
model which led to a less than proportional increase in exposure with respect to dose.  
Toxicity findings showed gastric ulceration at all tested dosing levels (7.5, 15, 40 and 80 
mg/kg) meaning that no NOAEL could be established. Despite the lack of a safety threshold, 
we have demonstrated that experimental data can be used to characterise the underlying 
PKPD relationships for both TXB2 and PGE2, which were best described by direct inhibition 
models.  Estimation of all parameters was precise and models performed well in diagnostics 
and predictive checks, confirming the feasibility claims of chapters 3 and 5.  In addition, our 
results emphasised the role of construct validity to account for the potential impact of 
interspecies differences in the underlying exposure-response relationships.  As indicated by 
the level of biomarker inhibition observed at the selected doses, inferences from the 
preclinical data can be made to predict drug effects at comparable levels of inhibition in 
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humans. In fact, we found that the PKPD relationship was within 10-fold range of published 
human values, raising questions about differences in the sensitivity of rats to the cyclo-
oxygenase inhibition.     
Whereas the use of a parametric approach and more specifically of hierarchical mixed-
effects modelling to inform experimental design and dose selection represents an important 
step in the advancement of translational toxicology, both from a biological and statistical 
perspective, we have also identified a few limitations that are worth mentioning.  Some 
mechanisms of action may be too complex or poorly understood to be characterised by 
PKPD modelling of data arising from a general toxicity study, even if biomarkers are 
collected. Multiple downstream markers may present a significant confounder problem 
which cannot be avoided without additional data. This cannot be easily addressed by the 
proposed analysis method and becomes a drug development issue.  
Our feasibility evaluation was complemented in Chapter 8 by further integrating the 
histological data obtained at completion of treatment to the observed biomarker effects.  In 
this investigation we showed how the pharmacokinetic-pharmacodynamic (PKPD) model 
obtained in the previous chapter can be incorporated into a formal analysis to describe 
adverse event incidence and severity. The adverse events (gastric ulceration) were 
quantified as continuous measures of ulcerative area.  Ulceration incidence (binary) and 
severity (severity) were modelled as two separate variables or endpoints of interest.  The 
final model parameters describing the incidence of adverse events showed that ulceration 
was an acute effect driven primarily by maximum inhibition of PGE2 levels corresponding to 
maximum blockade of COX-2.  The implications of model uncertainty highlighted in chapter 6 
prompted us to combine model selection criteria with bootstrap methodology to obtain 
model uncertainty estimates.  We found that there was minimal model uncertainty with 
regard to the characterisation of ulceration incidence but high specification uncertainty 
when describing ulceration severity.  Despite such high uncertainty, cumulative suppression 
of TXB2 levels, assumed to result from to long term blockade of constitutive COX-1 could be 
identified as an influential covariate of ulceration severity. In summary, our investigation has 
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shown how a model-based approach can be used to support early identification of long term 
adverse events, enabling further integration and translation of pre-clinical data. Our results 
also illustrated how the availability of PKPD relationships may allows us to make inferences 
about untested doses and dosing regimens, providing an opportunity for risk mitigation, 
independently from available experimental data.   
From a methodological perspective, the findings arising from this experimental protocol 
demonstrated the feasibility and potential benefits of proposed model-based approach for 
the evaluation of chronic safety pharmacology and toxicity. However, it should be noted that 
the accuracy, precision and validity of the method still relies on the experimental data. The 
adverse events we have assessed in this study were relatively frequent. Characterisation of 
rare or low frequency events may still be difficult, particularly if one cannot make use of 
historical data (e.g., unprecedented mechanism) or make inferences about class effects. We 
also acknowledge that the absence of ulcerations in vehicle treated animals and the lack of 
additional cohort with lower exposure levels may represent a weakness in our investigation. 
True baseline rates for ulceration could not be factored into the analysis, nor was it possible 
to accurately establish the adverse event rates at lower doses. 
 
Practical recommendations for safety assessment 
 
Given the challenges and limitations for the characterisation of exposure-effect relationships 
using data arising from typical experimental protocols, we have compiled a list of points to 
consider regarding methodological and practical issues, including recommendations for 
further protocol optimisation which may facilitate the implementation of model-based 
techniques in safety pharmacology and  toxicology research. 
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• Sampling scheme and dose selection to be used in the safety pharmacology and 
toxicology protocols need to take into account the underlying mechanism or mode of action 
associated with the primary pharmacological target or receptor system. It is imperative to 
ensure that different levels of target engagement (i.e., receptor occupancy) within and 
beyond the expected therapeutic exposure are included. 
• Study protocols should be analysed in an integrated manner to ensure accurate 
conclusions are drawn about the safety and toxicity profile of the compound. This implies 
the combination of data arising from all experimental protocols where pharmacokinetic and 
biomarker data are collected. 
•  Integration of historical data as priors (describing parameter distributions) may be 
required to reduce the degree of uncertainty associated with models predictions across the 
exposure-response curve describing the adverse event or toxicity. 
• Better, continuous inference metrics (e.g., EC10, cumulative biomarker levels and 
other derived parameters from the underlying PKPD relationship), are required to 
extrapolate findings from toxicological dose levels to clinically relevant therapeutic exposure 
ranges. Safety thresholds are conservative and biased. 
• Optimisation of study design should be performed on parameters of interest (i.e. 
AUC< Cmax) rather than primary model parameters.  Standard optimality algorithms (e.g. D-
optimality) are not suitable for that purpose, as current software programs maximise the 
overall expected parameter precision within design constraints (10).  Acceptability criteria 
for precision of parameters of interest should be defined in advance and evaluated within 
the design space taking into account feasibility aspects. Selected designs should be 
parsimonious in that further reduction does not produce a sufficient design. 
• The impact of prior model and parameter uncertainty should be investigated during 
the study design phase (e.g., by simulation) to ensure uncertainty is factored accordingly 
into the expected study outcomes. 
• Lack of model identifiability represents a risk for PKPD analyses based on standard 
experimental toxicology and safety pharmacology protocols. Therefore, to ensure model and 
parameter identifiability, simulation re-estimation (SSE), bootstrapping and sensitivity 
 294 
analysis with respect to initial estimates are essential steps to be considered throughout 
model development and validation (11, 12). 
• Maximum likelihood methodology is insufficient to model rare adverse events.  The 
use of a Monte Carlo-Markov Chain algorithm is required for stability and accurate 
parameter uncertainty estimation (13). 
• Model uncertainty is a likely outcome of adverse event modelling.  Model uncertainty 
should therefore be accounted for and quantified e.g. using the bootstrap covariate method.  
Final model predictions should also be displayed along with prediction intervals to account 
for parameter uncertainty (14-16). 
• Traditional model selection and averaging criteria which penalise for model 
complexity (e.g. BIC and AIC) are inappropriate when modelling rare adverse event data as 
models without drug effects are overweighed.  A conservative approach to model selection 
should instead be guided by pharmacological plausibility and data fitting metrics without 
penalisation (e.g. -2 log likelihood). 
Future perspectives 
 
The methodological issues identified through simulation scenarios and the lessons learned 
from the integrated experimental protocol developed for naproxen have highlighted the 
limitations of current practice in the evaluation of the safety profile of new chemical entities. 
More specifically, our findings reveal that inferences about safe exposure as well as the risk 
associated with long term use of a compound cannot be achieved by scattered empirical 
experimentation. A framework is required that enables integration, in a parametric manner, 
of experimental data and theoretical knowledge.  As shown in figure 1, such a framework 
would encompass multidimensional data, allowing for the incorporation of not only in vivo, 











Figure 1:  Integration of in vitro and in vivo data as input for in silico models. A model’s ability to 
predict toxicity in humans is used as reference for further refinement of the model as well as of the 
experimental design (modified with permission from 17). 
 
In order for computational models to be used to predict long term safety and toxicity in 
humans, methods are required that incorporate the mechanisms associated with primary 
and known secondary targets. In addition, general parameterisations also need be 
considered to describe drug action beyond the receptor or target level, including broader 
concepts, such as inappropriate cell signalling, mutagenesis and carcinogenesis (17). The 
emerging field of systems pharmacology could hold promise in this respect by providing a 
systematic framework which accounts for all relevant processes from target-drug interaction 
at the biophase to downstream cellular and organ level processes (110).  In fact, one of the 
first examples of the approach for the characterisation of general toxicity is the case of 
vitamin D, which has been used to establish target tissues for 1,25-(OH)2 vitamin D3 (19). 
Systems pharmacology makes evident that the actions of most of the target tissues are 
unrelated to systemic calcium regulation and are instead related to the regulation of 
endocrine and exocrine secretion, cell proliferation and cell differentiation.  It can be easily 
seen that many, if not all, target tissues of the vitamin D system will be activated in patients 
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treated with a vitamin D-related compound – whether taken against osteoporosis, tumour 
growth or any other single condition. However, physiologic dosing of vitamin D does not 
cause hypercalcemia – hypercalcemia is related to overdosing only (19, 20). 
More recent developments have allowed for a more quantitative characterisation of system 
and drug behaviour in vivo. Quantitative systems pharmacology represents a convergence of 
systems biology and pharmacology, combining computational and experimental methods to 
elucidate and predict disease progression and drug effects. The approach does not only take 
into account the underlying pharmacokinetic-pharmacodynamic relationships, but also 
potentially multiple components of the biological systems leading to changes in biological or 
disease state. This feature is particularly relevant, both from a clinical and methodological 
perspective,  for the parameterisation of long term adverse events, which may originate 
from a perturbation of homeostatic mechanisms, from cellular changes or cell injury (21). In 
contrast to empirical and probabilistic models, in systems pharmacology one can introduce 
both mechanistic and physiological elements as parameters for the characterisation of 
acute, delayed or late safety signals, which in turn can be correlated with global clinical 
measures, such as morbidity (figure 2). In conjunction with physiologically-based 
pharmacokinetic (PBPK) models, systems pharmacology can provide the basis for 
determining the impact of observed variations in physiological and biochemical factors, as 
well as discriminate pharmacokinetic from pharmacodynamic or biological variability.  
Instead of compartments defined solely by experimental kinetic data, compartments in a 
PBPK model are based on realistic organ and tissue groups, with weights and blood flows 
obtained from the literature. Moreover, instead of compartmental rate constants 
determined solely by fitting data, actual physicochemical and biochemical properties of the 
compound can often be used to define parameters in the model.  In particular, a properly 
validated PBPK model can be used to perform the high-to-low dose, dose-route, and 
interspecies extrapolations necessary for estimating human risk on the basis of experimental 











Figure 2. Dose-exposure-response paradigm for toxic effects, relating observed response as 
consequence of perturbations of the normal control processes in the cell. Low doses are largely 
without functional consequences; intermediate doses activate adaptive stress responses with 
attendant homeostatic controls; and high-enough exposures lead to overt toxicity (reprinted with 
permission from 22). 
 
One example of modelling incorporating systems pharmacology, which can be deemed 
relevant for the evaluation of target-mediated efficacy and safety, regards the effects of 
steroids. The work developed by Ramakrishnan and collaborators shows how experimental 
data, including transcription and gene mediated effects can be parameterised to describe 
the binding of steroidal drugs to the cytosolic glucocorticoid receptor and subsequent 
translocation of the complex into the nucleus where it binds as a dimer to the glucocorticoid 
responsive element (GRE) in the DNA (23) (Figure 3). This leads to the enhanced or repressed 
expression of numerous genes. At the same time, binding of the activated steroid-receptor 
complex to the GRE results in reduced levels of receptor mRNA. This further leads to 
decrease in the free receptor density in the cytosol. The concept nicely illustrates how long 
term use of corticosteroids may lead to suppression of normal physiological function at 










Figure 3 – Schematic representation of the cellular/molecular mechanism of steroid action in the 
hepatocyte. The thick open and solid arrows indicate induction and repression of gene transcription 
(reprinted with permission from 23) 
 
Whilst there are relatively few examples specific to safety pharmacology and toxicology, 
Berger et al. have recently shown how a systems pharmacology approach can be used to 
characterise and predict QT prolongation (111). Their work shows that the QT prolonging 
effects of multiple drugs targeting very different indications could be estimated with a 
network analysis approach. They were also able to account for multiple off-target binding 
sites for each drug showing that target related and off-target effects could be assessed 
within the same framework.  It should be noted that the model was Boolean in nature, 
which implies the need for further refinement for quantitative toxicological predictions. 
Another interesting application has been shown by Timchalk et al., who illustrate the 
development of a model-based approach to describe the pharmacodynamics of 
cholinesterase inhibiting compounds (25). Their model accounts for the synthesis and loss 
rates of the enzyme in vivo, enabling prediction of the brain synthesis.  
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Still in the realm of systems pharmacology, attention should be given to the contribution of 
mechanism-based models describing biomarkers as predictors of drug response, even when 
the underlying toxicological mechanisms are poorly understood. Increasing emphasis has 
been given by academic researchers and regulators on the relevance of biomarker selection 
and early risk prediction (112-114). In fact, the use of biomarkers to predict liver and kidney 
toxicity has been the subject of numerous public-private initiatives. Unfortunately, little has 
been done to integrate biomarkers as covariates or into PKPD models. In principle, one could 
consider the prediction of acute and chronic toxicity by parameterising biomarker response 
in a similar manner to what creatinine clearance currently represents in renal impairment. 
In addition to the development of more physiological, mechanism-base models, another 
avenue for future extension of the proposed methodology in this thesis lies in risk-benefit 
analysis.  There are numerous examples of risk-benefit assessment in the published 
literature in which pharmacological and physiological models have been applied. Yassen et 
al. (2008) performed an analysis on buprenorphine and fentanyl to assess risk benefit for 
antinociceptive and respiratory depressant effects (115). The development of a population 
PKPD model enabled both effects to be probabilistically modelled as a function of the 
predicted biophase concentrations.  By constructing a clearly defined utility function, they 
were able to obtain therapeutic indices consistent with known literature at the time. The 
most difficult hurdle to overcome with the acceptance of utility functions is in demonstrating 
construct validity.  Ultimately, it should function as a mathematical description of the 
subjective risk-benefit criteria held by patients and physicians.  Methods to assess the 
degree of construct validity however are not currently well established and widespread 
acceptance of utility functions to define therapeutic windows is still lacking. When utility 
functions are too subjective, overlaying exposure-benefit and exposure-risk relationships will 
possibly aid in the selection of safe and efficacious doses. 
The advantages of quantitative models in toxicology are unquestionable, as they facilitate 
the characterisation of exposure, biomarkers, and pharmacodynamics both at organ, tissue 
and cellular levels. However, a model can only be validated for its predictive performance for 
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some aspects/ modules, but not for other due to the difficulty in obtaining experimental 
measures (e.g., free concentration in a given organ). Yet, the primary advantage of a 
biologically based model is the possibility to make predictions of variables that cannot be 
easily accessed with the available methodologies or that are impossible to measure in an 
intact biological system using current technologies.   
Efforts must therefore be made to define the endpoints as well as the purpose of the 
biological model even before its development.  In this context, one last aspect that deserves 
further attention is the need to replace uncertainty factors by a more formal, systematic 
measure of the lack of construct validity or discrepancy between experimental conditions 
and the expected therapeutic use of a drug. The predictive performance of a model must 
include the uncertainty about the model itself (e.g., identifiability) and about the 
translational gap (e.g., differences between species or experimental conditions). A central 
premise of toxicology has been that adverse effect are examined on the basis of higher 
doses and then extrapolated to lower doses. There is enough evidence showing that 
responses occurring a lower exposure may not be predicted from higher doses when 
homeostatic regulation (e.g., oscillatory, antagonistic balance) is involved (7,31). Dose and 
time considerations in the development and use of a drug are important for assessing 
actions and side effects, as well as predictions of safety and toxicity. We believe that lack of 
observance of this axiom will probably be the main source of uncertainty in any integrative 
approach, such as proposed throughout this thesis. This point has been raised by the Swiss-
German physician, Theophrastus of Hohenheim in 1538, who stated that all things are 
poison and nothing is without poison: only the dose makes a thing not to be poison (20). 





Figure 4 – Statement by the Swiss-German physician, Theophrastus of Hohenheim (Paracelsus). What 
is not a poison? All things are poison and nothing is without poison. Only the dose makes a thing not 
to be poison (reprinted with permission from 20). 
 
Given the increased relevance of evidence synthesis as the basis for decision-making within 
regulatory and clinical practice, we anticipate that some of the meta-analytical elements 
presented across the various simulation scenarios will become embedded into daily practice 
in safety pharmacology and toxicology. Irrespective of the degree of understanding of the 
mechanisms of toxicity, a model-based approach appears to outperform standard methods 
for the prediction of the safe drug exposure of novel molecules in early drug development, 
especially those events that show low frequency or have delayed onset. Despite the narrow 
scope of the scenarios and limitations intrinsic to the selected experimental protocols 
presented in this thesis, our findings raise a new, potentially even more important question 
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Nederlandse Samenvatting (Synopsis in Dutch)  
 
De toxiciteit en veiligheid van nieuwe geneesmiddelen wordt voornamelijk bestudeerd in 
proefdier modellen. De resultaten verkregen met deze modellen worden vervolgens 
geëxtrapoleerd om bijwerkingen in de mens te voorspellen. Bij dit onderzoek richt men zich 
vooral op lever en nierschade, schade aan het oog, immuno- en genotocixiteit alsmede aan 
carcinogeniteit. Daarbij wordt slechts beperkt aandacht besteed aan de analyse van de 
relatie tussen de blootstelling (in termen van het beloop van de geneesmidelconcentratie in 
het lichaam) en de toxiciteit. Zelfs in het geval dat resultaten van het veiligheidsonderzoek 
bruikbaar zijn voor een dergelijke analyse, is het uitvoeren van dit type experimenten 
tijdrovend en zijn extrapolaties van dier naar de mens vaak niet robuust, accuraat en/of 
precies. Een aantal van deze beperkingen is blijven bestaan ondanks het feit dat 
toxicokinetiek wordt beschouwd als een essentieel onderdeel van de beoordeling van de 
veiligheid van nieuwe farmaca. 
In dit proefschrift laten we zien  dat het mogelijk is om kennis uit farmacologische 
experimenten te combineren met specifieke informatie uit in vitro test systemen en 
computer modellen om zowel de werkzaamheid als de veiligheid in vivo te voorspellen. 
Daarbij is het ook mogelijk om verstoringen in vitro te bestuderen die de oorzaak zijn van 
bijwerkingen van een geneesmiddel of die daaraan een bijdrage leveren. Dit heeft als 
belangrijk extra voordeel dat de focus van traditionele toxicologie studies, waar risico’s van 
een hoge dosis van een stof  in vivo bestudeerd worden, vervangen kunnen worden door 
experimentele protocollen  waarin de de veiligheid van geneesmiddelen wordt bestudeerd 
bij een klinisch relevante blootstelling. 
Op dit moment zijn er methodologische en conceptuele ontwikkelingen  voor het 
bestuderen van de veiligheid en de toxiciteit van nieuwe farmaca, waardoor  de risico’s van 
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het gebruik bij de therapeutische toepassing efficiënter kunnen worden gekarakteriseerd. 
Helaas worden deze methoden nog niet vaak toegepast om bij de registratie van nieuwe 
geneesmiddelen, belangrijke vragen op het gebied van de veiligheid en toxiciteit te 
beantwoorden. De betekenis van kwantitatieve concepten is eerder aangetoond oa. voor de 
structuur-werkingsrelaties, als basis voor het voorspellen van de toxiciteit van een 
chemische verbinding onder bepaalde omstandigheden. Op basis daarvan kan men 
uitspraken doen over de mogelijke effecten van een behandeling zelfs wanneer de 
blootstelling in de mens erg laag is en toxicokinetische gegevens niet gemakkelijk verkregen 
kunnen worden. 
Door het ontbreken van een sterke farmacologische basis voor de experimentele protocollen 
heeft de implementatie van een modelmatige benadering voor het karakteriseren van de 
veiligheids- en toxiciteitsprofiel van een nieuw geneesmiddel nooit op grote schaal 
plaatsgevonden. Daardoor is de analyse van de relatie tussen blootstelling en effect nog 
steeds niet het primaire doel van de desbetreffende protocollen. Men gaat ervan uit dat 
veiligheid gekarakteriseerd kan worden door een veiligheidsdrempel. Ook het concept van 
op fysiologie-gebaseerde farmacokinetische (PBPK) modellering voor het voorspellen van de 
blootstelling  wordt nog niet veel toegepast en wanneer het wordt toegepast is dit 
voornamelijk op het terrein van milieu-toxicologische vraagstukken en in mindere mate voor 
de ontwikkeling van geneesmiddelen. 
Methoden die veiligheid en de toxicologische effecten van geneesmiddelen in de mens 
kunnen voorspellen of op basis waarvan een vertaling vanuit in vivo diermodellen of in-vitro 
modellen naar de mens kan worden gemaakt, zijn van erg groot belang. Er is een grote vraag 
naar de ontwikkeling van deze methoden, ongeacht de huidige richtlijen voor toxicologisch 
onderzoek of de urgentie voor verandering van de eisen die gesteld worden door de 
registratie autoriteiten. Om dit te kunnen bewerkstelligen is er meer nodig dan de 
ontwikkeling nieuwe experimentele protocollen en technologieën. Een integrale benadering 
waar efficiënt gebruik wordt gemaakt van de beschikbare informatie en de toepassing van 
farmacokinetische-farmacodynamische modellering kan van grote betekenis zijn. Hierbij is 
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het essentieel dat ook bijwerkingen die op lange termijn optreden en zeldzame bijwerkingen 
bestudeerd kunnen worden, omdat die nog steeds een belangrijke oorzaak zijn van het falen 
van nieuwe medicijnen. Daarnaast ontbreekt er ook een geïntegreerde benadering  om de 
juiste eindpunten te kiezen om zo de risico’s die het gebruik van het geneesmiddel met zich 
meebrengt nauwkeurig en precies te kunnen beoordelen.  
De huidige toxiciteit testen zijn voornamelijk bedoeld om de gevaren van het gebruik van 
een geneesmiddel op supraherapeutisch niveau te kunnen bestuderen. De data die wordt 
gegenereerd op basis van de bestaande richtlijnen is daardoor niet altijd geschikt om de 
relatie tussen blootstelling en effect vast te stellen. Noch om deze relatie op basis van 
wiskundige modellen te kunnen karakteriseren. Om de relatie tussen blootstelling en 
respons te bestuderen zou er eerst aan enkele voorwaarden moeten worden voldaan.  Ten 
eerste, zouden verschillende doses moeten worden toegediend, waardoor een breed bereik 
kan worden verkregen in termen van blootstelling niveaus en respons. Daarbij moet men 
ook de samenhang tussen de primaire en secondaire farmacologische mechanismen en de 
gewenste en ongewenste effecten proberen te identificeren.  
Het onderzoek dat is beschreven in dit proefschrift heeft betrekking op een aantal 
onderdelen in het proces van de ontwikkeling van nieuwe geneesmiddelen, die overwogen 
dienen te worden om dit efficiënter te laten verlopen. De nadruk ligt bij het efficiënt gebruik 
van data die worden verkregen bij het veiligheids- en toxiciteitsonderzoek. Vier 
onderzoeksvragen vormen de basis van het werk zoals gepresenteerd in de volgende 
hoofdstukken: 
1. Kunnen experimentele protocollen voor veiligheids- en toxiciteitsevaluaties worden 
geoptimaliseerd om de relaties tussen farmacokinetiek en farmacodynamiek te 
karakteriseren? 
2. Kan het gebruik van meta-analytische methoden gebaseerd op niet-lineair gemengde 
effecten modellen bijdragen aan een verhooging van de nauwkeurigheid en precisie van 
veiligheidsdrempels in vergelijking met de methoden die thans worden toegepast?  
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3. Kan een op mechanisme gebaseerd model worden gebruikt om de veilige blootstelling aan 
een geneesmiddel nauwkeuriger te definiëren, waardoor vertraagde (lange termijn) of 
zeldzame bijwerkingen voorspeld en voorkomen kunnen worden? 
4. Kunnen biomarkers gecombineerd met farmacokinetische data bijdragen aan het 
vastellen van  de veilige blootstelling bij langdurig gebruik van een geneesmiddel?   
Het proefschrift heeft betrekking op de hierboven benoemde onderzoeksvragen zowel van 
conceptueel als van praktisch oogpunt. 
Sectie I: Algemene inleiding 
In Hoofdstuk 1 wordt een overzicht gepresenteerd van de gangbare veiligheid toetsen en 
methoden die worden toegepast bij de ontwikkeling van nieuwe geneesmiddelen. Hierbij 
wordt er aandacht besteed aan de gevolgen van het genereren van empirisch bewijs. 
Vervolgens worden methodologische beperkingen voor het vastellen van de relatie tussen 
blootstelling en ongewenste effecten (bijwerkingen) geïdentificeerd op basis van 
voorbeelden. Tevens wordt een hiërarchische beslisboom ontwikkeld die het 
beslissingsproces weergeeft en de daarbij behorende experimentele data samenvat. Vanuit 
een theoretisch perspectief worden verschillende facetten van hetzelfde vraagstuk 
besproken, die gerelateerd kunnen worden aan vier aspecten van wetenschappelijk 
onderzoek, te weten: 1. optimalisatie 2. vertaling 3. analyse en 4. beslissingscriteria. De 
relevantie van deze punten voor de implementatie van experimentele protocollen en voor 
de schatting en interpretatie van parameters die de veiligheid en toxiciteit van een 
geneesmiddel beschrijven wordt apart besproken.  We hebben laten zien dat foutieve 
voorspellingen van veiligheid kunnen ontstaan door gebruik te maken van empirische 
veiligheidsdrempelwaarden, indien die beschouwd worden als voorspellend  voor toxiciteit 
of ongewenste effecten. Om rekening te kunnen houden met slechte precisie en vertekende 
nauwkeurigheid van deze methodes worden in de praktijk veiligheidsfactoren (ook wel 
bekend als onzekerheidsfactoren) geïmplementeerd bovenop de empirische criteria. We 
laten ook zien dat ondanks bovengenoemde beperkingen het gebruik van een 
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veiligheidsdrempel binnen de ontwikkeling van geneesmiddelen breed geaccepteerd is en 
gedetailleerd wordt beschreven in de richtlijnen van registratie autoriteiten.  
Op basis van historische voorbeelden hebben wij een aantal belangrijke uitdagingen 
geïdentificeerd om het karakteriseren van een veiligheids profiel van een nieuw molecuul in 
een vroeg stadium mogelijk te maken.  Voor de toepassing van farmacologische concepten 
in het onderzoek naar de veiligheid en de toxiciteit van nieuwe geneesmiddelen werd een 
nieuw paradigma voorgesteld.  
In Hoofdstuk 2 presenteren wij de conceptuele en methodologische aspecten die op de 
daaropvolgende hoofstukken worden uitgewerkt. Het doel van het onderzoek was om de 
uitvoerbaarheid van op farmacologische concepten gebaseerde analyse van toxicologische 
gegevens het risico van een behandeling in de mens te voorspellen, en waar mogelijk de 
uitkomsten te vergelijken met die verkregen met traditionele veiligheidstoetsen en 
methoden.  Daarbij komt een fundamenteel verschil in het doel van de veiligheidsevaluatie 
aan de orde. Het doel van de nieuwe benadering is om de veiligheid van een nieuw 
geneesmiddel bij normaal gebruik vast te stellen. Dat is een belangrijk verschil met de 
huidige praktijk die erop gericht is om vast te stellen dat een bepaalde toxische limiet niet 
wordt overschreden. Vier belangrijke vragen die het wetenschappelijke raamwerk vormen 
van het onderzoek, worden in de hieropvolgende hoofdstukken besproken, tegen de 
achtergrond van de mogelijkheden voor optimalisatie en integratie van kennis. De in de 
praktijk gehanteerde experimentele protocollen vormden daarbij het uitgangspunt. Hoewel 
er, vanuit een farmacologische perspectief,  overeenkomsten bestaan tussen de toetsing van 
de  werkzaamheid enerzijds en toetsing  van de toxiciteit anderzijds stellen wij uitsluitend 
een onderzoeksplan voor de analyse van toxicologische data voor. Verder hebben wij een 
vaak vergeten aspect van het pre-klinisch onderzoek gedefinïeerd: het ethische belang van 
het verfijnen, reduceren en vervangen van experimenten met proefdieren.  
Sectie II: Conceptueel kader 
De voordelen en beperkingen van een modelmatige benadering voor veiligheids- en 
toxiciteitsonderzoek werden geëvalueerd in Sectie II. Binnen een conceptueel kader laten 
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we zien hoe er rekening kan worden gehouden met de variabiliteit binnen en tussen 
patiënten en met de onzekerheid in de respons (bijwerkingen) door gebruik te maken van 
farmacokinetische en farmacokinetisch-farmacodynamische modellering in plaats van 
beschrijvende statistische methoden. Op basis van simulaties van experimentele protocollen 
wordt aangetoond hoe waarden van de blootstelling kunnen worden verkregen die 
fysiologisch relevant zijn voor het karakteriseren van vertraagde of late bijwerkingen. De 
nadruk lag hier vooral op de uitvoerbaarheid van het voorspellen van lange termijn 
bijwerkingen gebruik makend van de gegevens uit een studie met een korte duur. Verder 
wordt er een alternatieve manier beschreven om pre-klinische algemene toxicologische 
protocollen te ontwerpen en analyseren.  
In eerste instantie werd er gefocused op niet-lineair gemengde effecten modellen als een 
data analyse methode voor de evaluatie van toxicokinetische gegevens en het vaststelllen 
van (parametrische) veiligheidsdrempels. In hoofdstuk 3 werd voor drie hypothetische 
geneesmiddelen, met verschillende farmacokinetische eigenschappen, toxicokinetische data 
gesimuleerd voor dieren in de satellietgroepen van een algemene toxiciteitsstudie. Deze 
analyse maakte het mogelijk om de juistheid en nauwkeurigheid van zowel de 
veiligheidsdrempels als de secondaire farmacokinetische parameters zoals de opervlakte 
onder de concentratie vs. tijd curve (AUC) te vergelijken en de beperkingen van de 
traditionele niet-compartmentele analyse methode aan te tonen, ten opzichte van de  
resultaten die verkregen zijn op basis van populatie farmacokinetische modellen. De 
grootste foutmarges in de geschatte farmacokinetische parameters bleken intrinsiek 
verbonden te zijn met de niet-compartmentele analyse methode, vooral als de maximale 
concentratie (Cmax) geschat moeten worden. Deze resultaten laten ook zien dat de typische 
puntschatter afgeleid van empirische methoden om medicijn blootstelling te beschrijven een 
te grote mate van onzekerheid bevatten, die ongeïdentificeerd blijft. Dit onderstreept het 
belang van de toepassing van benaderingen voor het vaststellen van de onzekerheid in 
veiligheidsdrempels zoals de drempel voor het niet-ongewenst effect (no adverse effect 
level), oftewel de NOAEL. Met de simulaties werd aangetoond dat dit fenomeen kan worden 
omzeild door gebruikt te maken van modelmatige methoden, die de onzekerheid 
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parametrisch beschrijven ongeacht of deze als gevolg van een ongeschikt protocolontwerp, 
een grote biologische variabiliteit en/of onbekende covariaten voorkomt. De analyse op 
basis van de drie hypothetische geneesmiddelen heeft ook aangetoond hoe een 
farmacokinetisch model mogelijkheden biedt om de blootstelling op verschillende manieren 
parametrisch af te leiden. Een voorbeeld daarvan is de  cumulatieve opervlak onder de 
concentratie vs. tijd curve (CAUC) bij de beschrijving van toxiciteit na langdurige 
behandeling, die ook gebruikt kan worden om voorspellingen te maken buiten de studie 
duur. Dit draagt bij aan een toename in kwaliteit van het beslissingsproces en uiteindelijk in 
de klinische interpretatie van de veiligheidsdrempels. 
Data uit in de praktijk gehanteerde experimentele protocollen voor de evaluatie van 
algemene toxiciteit zijn niet geoptimaliseerd voor de analyse met behulp van modelmatige 
methoden, inclusief populatie farmacokinetisch modellen. De vraag is of protocollen zo 
kunnen worden geoptimaliseerd dat een vermindering van het aantal benodigde 
proefdieren kan worden bereikt zonder dat dit gepaard gaat met een verlies van de juistheid 
en de nauwkeurigheid van  farmacokinetische parameters (zoals AUC en Cmax). Anders dan 
door gebuik te maken van bestaande optimalisatie software en algoritmes, waar de 
optimalisatie van het experimenteel ontwerp wordt bereikt op basis van de  precisie van de 
primaire parameters, wordt in Hoofdstuk 4 een methode voorgesteld die het mogelijk maakt 
om secundaire parameters te optimaliseren. Onze benadering bestond uit evaluaties van de 
Fisher informatiematrix gevolgd door berekeningen van verwachte juistheid of 
betrouwbaarheid van de secundaire parameter, zonder de nadelen van intensieve 
procedures zoals D-optimality. De resultaten laten zien dat de opzet van de studie, inclusief 
de keuze van de doses en het aantal monsters, grote invloed heeft op de juistheid van de 
parameter schattingen. De voorgestelde methode om de tijdstippen voor het nemen van 
bloedmonsters en de groepsgrootte te optimaliseren kan leiden tot een afname van het 
benodigde aantal proefdieren (ongeveer 30%) zonder verlies van de juistheid van de 
parameters die relevant zijn voor het karakteriseren van de veiligheidsdrempels.  Deze 
verbetering was onafhankelijk van de verschillen in de farmacokinetiek sche profielen, zoals 
bestuudeerd op basis van de drie hypothetische geneesmiddelen. Tevens suggereert onze 
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analyse dat de juistheid van de farmacokinetische parameters niet door de groepsomvang 
wordt beïnvloedt maar dat het juist de tijdstippen van bloedafname en de toegediende 
doses zijn, die dit bepalen. Daarnaast laten deze resultaten zien dat de betrouwbaarheid van 
de secundaire parameters niet beïnvloed wordt als een aantal primaire parameters met 
onvoldoende nauwkeurigheid geschat wordt. 
Hoewel het gebruik van een modelmatige benadering voor de evaluatie van de 
veiligheidsdrempels als gecompliceerd wordt gezien bleek onze methode juist te beschikken 
over een goed voorspellend vermogen zonder veel fouten of problemen met de 
identificeerbaarheid van het model en de daarbij behorende parameters. Verder laten we 
zien hoe bestaande kennis, inclusief data van andere experimenten, op een formele manier 
opgenomen kan worden tijdens de analyse en intrepretatie van de resultaten.  De 
mogelijkheid om zgn. ‘priors’ te gebruiken voor het schatten van parameters in een model 
biedt vele kansen om oa. fysiologische factoren, die ten grondslag liggen aan 
farmacokinetische eigenschappen, mechanistisch te bestuderen. Men zou bijvoorbeeld de 
invloed van de verzadiging van metaboliserende enzymen kunnen evalueren, ongeacht de 
doses die gebruikt zijn tijdens een experiment. 
Hoofdstuk 5  heeft betrekking op  het gebruik van biomarkers in de evaluatie van de 
veiligheid en toxiciteit van nieuwe geneesmiddelen. Hier ligt de nadruk op het feit dat voor 
een nauwkeurige voorspelling van de veiligheid en toxiciteit na langdurig gebruik van een 
geneesmiddel, biomarkers belangrijke informatie kunnen opleveren voor het voorkomen 
van een bijwerking. In tegenstelling tot traditionele protocollen, die een directe relatie 
tussen de blootstelling en de bijwerking veronderstellen, hebben wij het voorgesteld om het 
nemen van bloedmonsters voor de bepaling van de farmacokinetiek te combineren met de 
bepaling van biomarkers. Het uiteindelijk doel van zo’n aanpak is het ontrafelen van de  vaak 
vertraagde of indirecte relatie tussen de farmacokinetiek in plasma en de bijwerkingen of 
ongewenste effecten. Om de voordelen van een modelmatige aanpak te kunnen aantonen 
werden farmacokinetische en biomarker data gesimuleerd voor een aantal hypothetische 
geneesmiddelen met  verschillende PKPD relaties. Nog eens proberen we de voordelen en 
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nadelen van de voorgestelde benadering te vergelijken met een analyse van de data op basis 
van een standaard niet-compartmentele methode. De analyse van de gesimuleerde data laat 
zien dat, op basis van gegevens verkregen met een traditioneel monsterafname schema,  het 
echte onderliggende PKPD model vaak niet identificeerbaar is. Dat is in het bijzonder het 
geval wanneer er sprake is van een complexe PKPD relatie (o.m. door het optreden van 
hysterese). Niettemin werden in alle gevallen bevredigende resultaten verkregen met 
betrekking tot de geschatte biomarker concentraties. Wij zijn daarom van mening dat men 
zich meer bewust moet zijn van de beperkingen die de huidige experimentele protocollen 
met zich mee brengen. Dit is vooral van belang omdat de veiligheid van geneesmiddelen na 
langdurig gebruik steeds meer een prominente rol krijgt binnen de ontwikkeling en toelating 
van nieuwe medicijnen. Om de gevolgen van zo’n vertekening te beperken benadrukken wij 
de behoefte aan methoden die de mate van onzekerheid bepalen en daardoor modellen en 
voorspellingen betrouwbaarder kunnen maken.  
Een andere bevinding van onze analyse is dat de criteria voor de selectie van parameters 
tijdens het ontwikkelen van een model niet alleen aan statistische eisen moeten voldoen 
maar ook de mogelijkheid moeten bieden om de fysiologische relevantie van bepaalde 
aannames te kunnen beoordelen. Duidelijke rapportage van alle modellen is van belang 
wanneer de ontwikkeling van het hierarchische model eindigt in een verzameling van 
modellen met vergelijkbare selectie criteria.  
Het doel van het onderzoek dat in Hoofdstuk 6 is beschreven was om de uitvoerbaarheid te 
evalueren van de integratie van  mechanistische PKPD modellen met toxicologische 
gegevens uit standaard experimentele protocollen. Rekening houdende met de achtergrond 
incidentie van verschijnselen en fysiologische veranderingen die op lange termijn voorkomen 
en vaak met bijwerkingen kunnen worden verwisseld, werden vergelijkbare in silico 
methoden zoals eerder beschreven in hoofdstukken 3 en 5 toegepast om door 
geneesmiddelen  geïnduceerde bijwerkingen te simuleren voor drie verschillende 
farmacologische mechanismen (directe werking, indirecte werking en irreversibele binding). 
Wij hebben ons hierbij geconcentreerd op zeldzame en chronische bijwerkingen die pas na 
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langdurige inname van een geneesmiddel ontstaan, inclusief het onderscheid tussen 
reversibele en irreversibele effecten, om de grootste methodologische uitdaging aan te 
gaan. Om er zeker van te zijn dat realistische condities werden gecreëerd zijn  verschillende 
scenario’s getoetst, namelijk: 1) de door het geneesmiddel geïnduceerde bijwerking en het 
achtergrond fysiologische verschijnsel waren niet van elkaar te onderscheiden. 2) het 
tijdsinterval tussen het begin van de behandeling en de diagnose was groot en de 
symptomen konden per proefdier maar een keer worden vastgesteld  op basis van 
histologisch onderzoek (na afloop van het experiment). 3) de bijwerking kon beschreven 
worden als binaire respons. Onze resultaten lieten zien dat veiligheidsdrempels, zoals 
vastgesteld door de NOAEL, onbetrouwbaar en onnauwkeurig zijn. In twee van de drie 
scenario’s, waar het effect van veiligheid en effectiviteit van de hypothetische 
geneesmiddelen was gesimuleerd, vonden wij dat het rigoureus toepassen van de NOAEL als 
beslissingscriterium zou leiden tot een foutieve classificatie in 50% van de gevallen. Dit zou 
vervolgens leiden tot een onterechte beeïndiging van de ontwikkeling van het geneesmiddel. 
Tijdens het vastellen van de haalbaarheid van de toepassing van modelmatige methoden 
voor de analyse van toxicologische gegevens hebben wij twee belangrijke componenten 
geïdentificeerd, die essentieel zijn voor de voorspelling van de geïnduceerde effecten: a) de 
beschikbaarheid van onafhankelijke informatie over achtergrond verschijnselen en 
verandering die meegeteld kunnen worden als bijwerkingen  en b) het gebruik van Markov 
keten Monte Carlo (MCMC)-gebaseerde algorithmen. Zo hebben wij laten zien dat  
historische placebo data doeltreffend genoeg is om achtergrond verschijnselen en andere 
fysiologische veranaderingen te kunnen onderscheiden van de onderliggende 
farmacologische effecten en bijwerkingen. Aan de andere kant, toen de prestatie van 
statistische methoden geëvalueerd werd, vonden wij dat modellen die gebaseerd zijn op het 
‘maximum waarschijnlijkheid’kriterium onstabiel en onbetrouwbaar zijn. Daarentegen, 
bleken de MCMC-gebasseerde resultaten stabieler en nauwkeuriger, inclusief  het schatten 
van de model- en parameteronzekerheid. Door gebruik te maken van het Bayes informatie 
criterium, oftewel BIC, om modellen te vergelijken konden wij de hoge mate van model 
onzekerheid blootleggen. Onze resultaten tonen aan dat traditionele technieken die gebruikt 
worden voor de selectie van een model en de daarbij behorende parameter verdelingen niet 
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geschikt waren om modellen met een zekere mate van complexiteit te identificeren. Het 
dient verder gezegd te worden dat gemiste bijwerkingen ook gemakkelijk gekwantificeerd 
konden worden middels de voorgestelde modelmatige aanpak. Door MCMC methoden toe 
te passen was het mogelijk om verschijnselen en bijwerkingen te beschrijven zelfs als deze 
niet waren waargenomen tijdens het experiment. 
Het conceptuele raamwerk gepresenteerd in deze sectie van het proefcshrift draagt het 
bewijs aan voor de uitvoerbaarheid van een modelmatige benadering voor de evaluatie van 
de veiligheid en toxiciteit van nieuwe moleculen voordat ze in de mens worden getest. De 
integratie van farmacokinetische en farmacodynamische data als basis voor het voorspellen 
van de veilige blootstelling in de mens vereist enkele belangrijke voorwaarden waaraan de 
huidige methoden voor pre-klinische toxicologisch onderzoek niet voldoen. Een 
modelmatige benadering is daarvoor de geschikte oplossing. In plaats van het vastellen van 
de correlatie tussen één enkele waarde en de geschatte veiligheidsdrempel, biedt deze 
strategie het voordeel dat het klinische oordeel over de kans op toxiciteit wordt gebaseerd 
op de gehele relatie tussen blootstelling en bijwerkingen.  
In het derde deel van dit proefschrift (Sectie III) hebben wij geprobeerd de implementatie 
van experimentele protocollen die voldoen aan de eisen van modelmatige dataanalyse 
methoden te illustreren op basis experimentele studies. Vanwege de lopende discussies over 
de risico’s en de baten omtrent de chronische behandeling met niet-steroïdale 
ontstekingsremmers hebben wij naproxen gebruikt als voorbeeldstof om de bekende acute 
en chronische toxiciteit van deze klasse geneesmiddelen te evalueren. Gedurende de 
afgelopen jaren en tijdens de ontwikkeling van naproxen was men niet op de hoogte van het 
gebrek aan de selectiviteit van werking. Daarnaast ontbrak ook het bewijs voor de 
mechanismen, die de effecten na acuut gebruik (zoals bloedingen en maagzweren) en 
langdurige behandeling (zoals renale en cardiovasculaire schade) onderschrijven. 
Desalnietemin, laat onze analyse zien dat kennis over de farmacokinetiek en de blootstelling 
aan naproxen die bereikt wordt na de toediening van therapeutische doses van belang zijn 
voor het karakteriseren van het veiligheids- en toxiciteitsprofiel. Verder hebben wij ook 
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praktische uitdagingen geïdentificeerd, die men tegenkomt bij het gebruik van nieuwe 
experimentele protocollen.  
Sectie III: Toepassing in de praktijk 
In Hoofdstuk 7 wordt een typisch toxicologie protocol gebruikt om de effecten van acute, 
middellange en langdurige behandeling aan naproxen te bestuderen. Naast het 
karakteriseren van de blootstelling in plasma worden twee biomarkers gemeten, namelijk 
thromboxane (TXB2) en prostaglandin (PGE2). Er werd vanuit gegaan dat gastro-intestinale 
bloedingen veroorzaakt werden door continue remming van cyclo-oxygenase 1 (COX-1), 
terwijl zweren voornamelijk door de inhibitie van cyclo-oxygenase 2 (COX-2) onstaan. 
Farmacokinetische en biomarker data werden geïntegreerd met  gegevens uit de literatuur 
om de vermeende therapeutische effecten te correleren met zowel de blootstelling als de 
veranderingen in de biomarkers thromboxane en prostaglandin. De farmacokinetiek van 
naproxen werd het best beschreven met een een-compartiment model met eerste-orde 
absorptie. Er werd een niet-lineaire relatie vastgesteld tussen de dosis en biologische 
beschikbaarheid, die ertoe leidde dat de toename van de  blootstelling in plasma minder dan 
proportinieel was met toenemende doses van naproxen. In tegenstelling tot eerdere 
bevindingen werd zweer vorming in de maag gezien bij alle doses (7.5, 15, 40, 80 mg/kg), 
waardoor geen NOAEL vastgesteld kon worden. Desalniettemin, hebben wij aangetoond dat 
de beschikbare experimentele data gebruikt kan worden om de onderliggende PKPD relaties 
for TXB2 en PGE2 te karakteriseren. Door middel van  inibitiemodellen hebben we de 
dalende bloedspiegels van zowel thromboxane als prostaglandin kunnen correleren met 
naproxen concentraties.  Er waren geen problemen met de identificeerbaarheid van de 
modellen en de schatting van parameters was precies, overeenkomend met de resultaten 
van hoofdstukken 3 en 5. Daarnaast toonden onze resultaten aan, dat farmacokinetische-
pharmacodynamische relaties het mogelijk maken om potentiele verschillen tussen 
diersoorten te onderscheiden en desnoods daarvoor te corrigeren. De bijwerkingen van 
naproxen in de mens kunnen worden voorspeld op basis van pre-klinische data mits 
rekening wordt gehouden met de onderliggende blootstelling-effect relaties. Eigenlijk 
hebben wij gevonden dat bij de rat de PKPD relaties ongeveer tienvoud afwijken van de 
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waardes die verkregen zijn voor de mens. Hierdoor ontstaat de vraag over de vertaling naar 
de mens en de geschiktheid van de zogenoemde “meest gevoelige species” bij toxicologisch 
onderzoek als de gevoeligheid van ratten voor cyclo-oxygenase inhibitie  aanzienlijk verschilt 
van de mens. 
De toepassing van een parametrische aanpak en meer specifiek, van niet-lineair gemengde 
effecten modellen om experimenten te ontwerpen en de keuze voor een dosis te kunnen 
onderbouwen kan  een belangrijke stap zijn voor translationeel toxicologisch onderzoek  
vanuit zowel het biologisch als statistisch perspectief. Tegelijkertijd hebben wij ook een 
aantal beprekingen kunnen vaststellen. De werkingsmechanismen van sommige 
geneesmiddelen zijn niet voldoende onderzocht of begrepen om op een parametrische 
manier vertaald te kunnen worden in een PKPD model, zelfs als biomarkers beschikbaar zijn. 
Daarnaast is het beschrijven van effecten die via meerdere pathways tot stand komen 
buitengewoon moeilijk. Zo’n situatie kan een significant probleem blootleggen dat niet 
voorkomen kan worden zonder extra experimentele data. 
De uitvoerbaarheid en geschiktheid van een modelmatige benadering voor het bestuderen 
van het veiligheids- en toxiciteitsprofiel van een geneesmiddel is in hoofdstuk 8 aangevuld 
door histologische data te integreren met de PKPD relaties die op het voorafgaande 
hoofdstuk zijn beschreven. Hier lieten wij zien dat het mogelijk is om farmacokinetische-
farmacodynamische modellen,  die de relatie tussen blootstelling en het effect of biomarkers 
beschrijven, te koppelen aan de analyse van de frequentie en intensiteit van bijwerkingen.  
In dit experiment werd de ernst van een zweer gecorreleerd met het oppervlak daarvan en 
als een continue variabele uitgedrukt. Daarnaast werd de  frequentie van maagzweren als 
een discrete variabele geanalyseerd. De modelparameter die de frequentie van bijwerkingen 
beschreef wijst aan dat zweer vorming na toediening van naproxen een acuut effect  is  dat 
gepaard gaat met de maximale inhibitie van PGE2, welke een maat is van de blokkade van 
COX-2. Gegeven de implicaties van model onzekerheid, zoals beschreven in hoofdstuk 6, zijn 
we gedwongen geweest om bootstrap methodes te gebruiken om zo de onzekerheid te 
kunnen schatten. De onzekerheid met betrekking tot de karakterisatie van de frequentie van 
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zweren was aanzienlijk lager dan wanneer de ernstigtheid van zweren werd beschreven. 
Ondanks de hoge mate van onzekerheid  hebben we kunnen vaststellen dat het oppervlak 
van maagzweren het gevolg is van cumulatieve remming van TXB2. Samengevat, ons 
onderzoek laat zien hoe een modelmatige  benadering gebruikt kan worden om 
bijwerkingen die zowel na acute als langdurige behandeling voorkomen, vroeg te kunnen 
identificeren en zo pre-klinische data als basis te kunnen gebruiken voor de vertaling van het 
veiligheids en toxiciteitsprofiel naar de mens. Verder illustreren onze resultaten ook hoe 
PKPD relaties het mogelijk maken om conclusies te trekken over doses and dosis schema’s 
die niet experimenteel geëvalueerd zijn.  
Vanuit een methodologisch oogpunt hebben de bevindingen van dit onderzoeksprotocol de 
haalbaarheid en voordelen van een modelmatige benadering  voor de evaluatie van  
chronische veiligheid en toxiciteit  onderschreven. Hierbij dient echter de kanttekening te 
worden gemaakt, dat precisie, nauwkeurigheid en validiteit van de voorgestelde methoden 
nog altijd afhankelijk zijn van de experimentele data. In deze studie waren de bijwerkingen 
die wij beschreven hebben relatief frequent. Het karakteriseren van effecten die met lage 
frequentie voorkomen kan aanzienlijk moeilijker zijn, vooral als historische data ontbreken 
of waaruit ook maar enige gevolgtrekking gemaakt kan worden met betrekking tot klasse 
effecten. Wij erkennen ook dat de afwezigheid van zweer vorming in de controlegroep en 
het gebrek aan een cohort met lagere blootstelling een zwak punt in ons onderzoek is. 
Daardoor kon de echte basislijn voor het onstaan van maagzweren niet worden vastgesteld. 
Als gevolg daarvan was het ook niet mogelijk om de frequentie van bijwerkingen bij lagere 
dosissen nauwkeurig te voorspellen. 
Sectie IV: Conclusies, aanbevelingen en perspectieven 
Een overzicht van de resultaten en conclusies zoals beschreven in de verschillende 
hoofdstukken is samengevat in Hoofdstuk 9. Het meest belangrijk is dat aanbevelingen 
verstrekt zijn voor de analyse van veiligheids en toxicologie protocollen met behulp van 
farmacologisch gebaseerde kwantitatieve methoden. Hier hebben wij de antwoorden op de 
initiele vragen zoals beschreven aan het begin van dit proefschrift samengevat. Er is een lijst 
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is samengesteld van punten, die overwogen dienen te worden, gezien de uitdagingen en 
beperkingen die men tegenkomt bij het kakrakteriseren  van relatie tussen blootstelling en 
effect wanneer er gebruik gemaakt wordt van traditionele toxicologische 
onderzoeksprotocollen. Deze lijst bevat aanbevelingen met betrekking tot methodologische 
en praktische aspecten die die ertoe leiden dat modelmatige data analyse technieken, 
toegepast kunnen worden bij veiligheids en toxicologisch onderzoek.  
Noemenswaardig is de rol van het primaire (farmacologische) werkingsmechanisme en de 
daarbij betrokken receptorsystemen, die  overwogen dienen te worden bij de keuze van de 
dosis en bij het vaststellen van het benodigde tijdschema voor monster afname. Daarnaast 
kan het gebruik van historische data (die de distributie van parameters kan bescrijven) van 
belang zijn om de onzekerheid omtrent de relatie tussen blootstelling en bijwerkingen of 
toxiciteit te reduceren.  Vanuit een statistisch oogpunt, kan het gebrek aan model en 
parameter identificeerbaarheid  een risico zijn voor de interpretatie van resultatent uit een 
PKPD analyse. Daarom zijn techknieken zoals simulaties, bootstrap en gevoeligheidsanalyse  
essentieel om zowel de betrouwbaarheid als de nauwkeurigheid van de voorspelingen te 
kunnen waarborgen. Tenslotte, benadrukken wij de relevantie van de zogenoemde selectie 
criteria op de identificeerbaarheid van een model. Onze bevindingen wijzen er op dat 
traditionele criteria, die gebruikt worden om de complexiteit van een model beoordelen 
zoals  BIC en AIC, ongeschikt zijn voor het modelleren van effecten die met lage of zeer lage 
frequentie voorkomen. Daarom stellen wij voor om farmacologische plausibiliteit naast 
minder conservatieve statistische criteria toe te passen bij de selectie van een PKPD model. 
Het hoofdstuk wordt afgerond met een beknopte discussie over de ontwikkelingen op het 
terrein van PKPD modellering en hoe de methodologische problemen die wij geïdentificeerd 
hebben verholpen kunnen worden. Onze bevindingen onthullen dat gevolgtrekkingen over 
de zogenoemde “veilige blootstelling” en de daarop geassocieerde risico’s niet geschat of 
voorspeld kunnen worden op basis van losse empirische experimenten waarin uitsluitend 
het effect van supratherapeutische concentraties is bestudeerd. Het gebruik van een 
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computationeel modelmatig raamwerk is onvermijdelijk als men  data en kennis over het 
lotgeval en de farmacologische eigenschappen van een stof tracht te integreren. 
Om het lange termijn veiligheids en toxiciteitsprofiel van een geneesmiddel in mensen te 
kunnen voorspellen zijn methodes nodig die de werkingsmechanismen geassocieerd met 
zowel primaire als secundaire receptorsystemen verbinden. Verder moet er rekening 
worden gehouden met de factoren die deel uitmaken van het biologische systeem na de 
receptor. Daarbij zal kwantitatieve systeem farmacologie een belangrijk rol kunnen spelen. 
Dit vakgebid vertegenwoordigd de integratie van systeem biologie en farmacologie waar 
computationele en experimentele methoden gecombineerd kunnen worden om de 
progressie van ziekten en effecten van geneesmiddelen te bestuderen en/of voorspellen.  
Deze aanpak is met name relevant, zowel vanuit klinisch als methodologisch perspectief, 
voor de parameterisatie van lange termijn bijwerkingen, die hun oorsprong vinden in de 
pertubatie van homeostatische mechanismen, door cellulaire veranderingen of bij weefsel 
en cel schade.  
Naast het ontwikkelen van meer fysiologisch en mechanistisch-gebasseerde modellen dient 
ook de toekomstige uitbreiding van de risico-baten analyse zoals voorgesteld in dit 
proefschrift overwogen te worden. Er zijn verschillende voorbeelden gepubliceerd van risico-
baten analyses waarin gebruik wordt gemaakt van PKPD modellen. Het is aannemelijk dat de 
integratie van deze methoden tot een veel betrouwbaarder raamwerk kan leiden, dat 
vervolgens gebruikt zou kunnen worden ter beoordeling van nieuwe en bestaande 
geneesmiddelen,  alsmede het optimale gebruikt ervan. Bij de evaluatie van het veiligheids 
en toxiciteitsprofiel van een geneesmiddel dienen de dosis en de tijd als bepalende factoren 
te worden overwogen. Dit punt werd aangehaald al in 1538 door de Zwits-Duitse arts, 
Theophrastus of Hohenheim, die stelde dat alles giftig is en dat niets niet giftig is: alleen de 
dosis maakt iets niet giftig. 
Ter conclusie: ondanks het gebrek aan een breed scala van scenario’s en beprekingen die 
intrinsiek verbonden zijn aan het selecteren van experimentele protocollen zoals 
gepresenteerd in dit proefschrift, werpen onze bevindingen een nieuwe, wellicht 
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belangrijkere vraag op met betrekking tot de ethische basis voor het gebruik van proefdieren 
bij empirische experimentele protocollen, met als rechtvaardiging dat daarmee de veiligheid 
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